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chapter 1
General introduction 
lymphomas: subtypes, incidence, survival and prevalence
Lymphomas are defined by an abnormal proliferation of malignant B or T lymphocytes. Two 
major groups can be distinguished, i.e. Hodgkin Lymphoma (HL) and non-Hodgkin lymphomas 
(NHL). HL is named after Thomas Hodgkin, who first described abnormalities in the lymph system 
in 18321. NHLs are a diverse group of more than fifty lymphomas that include any type except 
HL2, whereby the most common types are diffuse large B-cell lymphoma (DLBCL), follicular 
lymphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The 
latter types of lymphoma are categorized as indolent, incurable but with a good prognosis even 
without treatment, whereas the former are/or become aggressive, causing rapid deterioration 
and death if untreated2, 3. However, most patients with aggressive lymphomas respond well 
to treatment and are curable2, 3. The prognosis depends on the disease stage and the correct 
classification of the disease, which is established after examination of a biopsy by a pathologist.
Incidence and age of onset are quite different for HL and NHL. The annual incidence of HL is 1 
in 37,000, with approximately 400 new diagnoses in the Netherlands4, 5,600 in Europe5 and 
8,500 in the US6. Onset occurs most frequently between the ages of 20 and 35 years. With 
respect to NHL, the annual incidence is 1 in 5,000, with approximately 3,500 new diagnoses in 
the Netherlands4, 58,000 in Europe5 and 65,000 in the US6. The disease occurs predominantly 
in individuals aged over 45 years.
Advances in lymphoma treatment have led to longer survival, also in the south of the 
Netherlands7-9.  To date, more than 80% of patients diagnosed with HL are expected to be 
disease-free at five years or more after diagnosis4, 6. The overall 5-year relative survival rate for 
patients with NHL (2003-2009) is 50-82%6, 8. The statistics vary, depending on the NHL type, 
stage of disease at diagnosis, treatment, and age of the patient. The 5-year relative survival of 
patients with HL, and indolent and aggressive NHL in the Netherlands (2006-2011) is displayed 
in Figure 1.
Additionally, the conditional 5-year relative survival, survival estimated for patients who have 
already survived a certain period of time, improves strongly for patients with aggressive NHL in 
the first year after diagnosis from 48% at diagnosis to 68% at 1 year after diagnosis. After the first 
year, the 5-year relative survival improves gradually to 93% after 16 years10. For indolent NHL, 
the conditional 5-year relative survival improves slightly with each additional year survived up 
to 91% after 16 years10. The increase in survival results in more patients who have or ever had 
lymphoma. A worldwide estimate shows around 1,021,400 men and women to be still alive in 
2008, up to five years after their lymphoma diagnosis11. In the Netherlands, the twenty-year 
prevalence of HL, with 3,400 patients in the year 1990, is expected to increase to approximately 
6,300 patients in 2020 and from 6,400 to approximately 32,000 patients with NHL (Figure 2)4. 
Instead of the term ‘cancer patients’, ‘cancer survivors’ is increasingly being used, especially in 
the US. The definition of cancer survivors include all living persons who ever received a diagnosis 
of cancer12 and is often used by researchers and cancer patient organizations. However, clinicians 





























Note. Source: Netherlands Cancer Registry
that cannot be cured. Therefore, both the terms cancer patients and cancer survivors are being 
used interchangeably in this thesis.
health-related quality of life and patient reported outcomes
Since cancer patients survive longer, health-related quality of life (HRQoL) and other patient 
reported outcomes (PROs) are more and more recognized to be important13, 14. Particularly 
because many survivors continue to face physical and psychosocial problems after completion 
of primary treatment15. HRQoL is a multidimensional construct that covers patients’ perceptions 
of his or her physical, emotional, social and cognitive functions and disease and/or treatment 
related symptoms and represents patients’ subjective experience with cancer. In the past decade 
a growing number of studies have documented the high prevalence of short-term effects (e.g. 
hair loss, pain, nausea and vomiting, anemia), long-term effects (e.g. fatigue, pain, memory 
problems and sexual dysfunction) and late effects (e.g. second malignancies, cardiovascular 
disease and osteoporosis) of cancer treatment12, 16-18. Research also shows that many survivors 
experience a deteriorated HRQoL, fear of recurrence, high levels of anxiety and depression, 
employment, insurance and financial problems and relationship difficulties12, 19. This knowledge 
has been primarily gained from survivorship studies that focused on survivors of common types 























































































Note. Source: Netherlands Cancer Registry
Figure 1. Five-year relative survival for patients with Hodgkin and indolent and aggressive non-
Hodgkin lymphoma in the Netherlands (2006-2010). 
Figure 2. Twenty-year prevalence of Hodgkin and non-Hodgkin lymphoma in the Netherlands on 
1990, 2000, 2010 and the prognosis for 2020.
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rationale for this thesis
Up to now, the number of studies focusing on (long-term) HRQoL and disease and treatment-
related symptoms of patients with lymphoma is limited. Since increasing numbers of 
lymphoma patients undergo (ever) changing treatment regimens, a careful evaluation of 
survival improvements, as well as potential side effects of treatment, and (long-term) HRQoL 
is required. Besides evaluating these effects of (targeted) therapies in RCTs, population-based 
observational studies are needed to study the effects of these therapies in patients treated in 
daily practice including elderly and patients with comorbid diseases. Studying long-term effects 
of different treatments provides information on the medical and psychosocial needs of patients 
and its determinants. This information will help to evaluate the functional effectiveness of the 
treatment and help clinicians to inform cancer patients and survivors about the potential late 
effects from the specific treatment they receive(d). It can also give direction to the recognition 
of problems and surveillance of those survivors who are at high risk for late consequences of 
cancer treatment.
Most studies among lymphoma survivors that have been performed up to now focused on 
biological endpoints such as second malignancies and cardiovascular disease, predominantly 
among Hodgkin lymphoma survivors17, 18, 21-24. The studies that did focus on the HRQoL of lymphoma 
patients commonly had a cross-sectional design, studied HRQoL as part of a randomized clinical 
trial or studied HRQoL among NHL patients in general25-48. Although these studies provide a 
good overview of the HRQoL of patients at a certain point in time, the course of HRQoL and 
the persistence of symptoms over time remains unknown, elderly patients and patients with 
comorbidities are underrepresented, or the HRQoL of different types of NHL is not examined. 
Studies focusing on populations including elderly and patients with comorbid conditions are 
of critical importance as comorbidity and age probably affect the HRQoL of patients and thus 
influences treatment decision making49-51. Furthermore, HRQoL studies among different types 
of NHL are important as prognosis, treatment modalities, and age of onset differ. 
aims and hypotheses 
Studies have shown that treatment and cancer itself can impact on the HRQoL of patients with 
solid tumors. Based on this knowledge, I developed a conceptual model with the perceived 
associations between clinical factors (such as treatment and lymphoma type) and socio-
demographic factors (such as age, educational level and nationality) with HRQoL (Figure 3). It 
is expected that active treatments such as chemo- and immunotherapy impact more on the 
HRQoL of patients compared to patients following a watchful waiting approach. Furthermore, 
it was hypothesized that several other clinical and socio-demographic factors may impact on 
the HRQoL of patients and that patients reporting disease and or treatment related symptoms 
or anxiety and depressive symptoms may experience a worse HRQoL.
In Chapter 2, the scientific literature regarding the impact of clinical (including treatment) and 
socio-demographic characteristics on HRQoL of HL and NHL patients was reviewed. Also the 
methodological strengths and limitations of the included studies were examined in this chapter. 
It appeared that mainly the evaluation of HRQoL following treatment among patients with 
subtypes of NHL was lacking. Therefore, the impact of targeted therapies on the HRQoL of 
patients for major types of NHL, i.e. DLBCL, FL and CLL/SLL, were studied in Chapter 3, 4 and 5 
respectively. In these chapters, we investigated if patients who received immunochemotherapy 
with more short-term toxicities would report a lower HRQoL compared to patients treated with 
treatments with less short-term toxicities or patients under active surveillance. We furthermore 
compared the HRQoL scores of patients with those of an age- and sex-matched normative 
population to investigate the impact of cancer and its treatment beyond the natural aging 
process and the impact of comorbidities.
Besides studying the impact of treatment and lymphoma itself on the HRQoL of patients I 
also evaluated the relation between disease and/or treatment related symptoms and anxiety 
and depressive symptoms and HRQoL (Figure 3). As many cancer patients with solid tumors 
report anxiety, depressive symptoms, and fatigue, I wanted to investigate the prevalence and 
Figure 3. Conceptual model: associations between patient, tumor, treatment and hospital factors 
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longitudinal course of anxiety and depressive symptoms among HL and DLBCL patients (Chapter 
6) and the prevalence of persistent fatigue among NHL, both DLBCL and FL patients (Chapter 7). 
Furthermore, patient information has proved to be an essential component of cancer care 
and rehabilitation52 and providing adequate information to cancer patients can reduce the 
psychological burden and improve patients HRQoL and their satisfaction with care53, 54. We 
therefore investigated the level of perceived information provision and satisfaction with this 
information among patients with lymphoma or multiple myeloma in Chapter 8. 
Cultural differences may affect the perception of the impact of cancer on HRQoL55, 56 and attitudes 
towards health practice and illness may also be defined by culture57. To better understand the 
commonality of psychosocial problems between cultures, it is important to examine cross-
national differences58. Therefore, we performed a cross-national study between Dutch and 
American (from North Carolina) NHL patients with respect to the positive and negative changes 
following cancer in Chapter 9.
At last, the main findings of this thesis will be discussed and implications for future research 
and clinical practice will be outlined in Chapter 10. 
methods: population-based registries
To perform these studies, a longitudinal population-based survey among HL and NHL survivors 
registered with the Eindhoven Cancer Registry (ECR) was set up. Data collection regarding 
HRQoL and other patient reported outcomes was done in PROFILES and detailed treatment data 
was obtained from PHAROS. All studies were conducted at the Comprehensive Cancer Center 
South (IKZ), the program owner of the ECR, which is part of Comprehensive Cancer Center the 
Netherlands (IKNL) since January 1st 2014.
Eindhoven Cancer Registry
The Eindhoven cancer registry (ECR) started in 1955, whereby data on all new cancer patients are 
collected directly form pathology reports and medical records. Since 1989, the population-based 
ECR is part of a program for nationwide cancer registration (Netherlands Cancer registry) and 
now hosts 2.4 million inhabitants, being referred to 10 general hospitals at 16 locations and is 
served by 6 regional pathology laboratories, 2 large radiotherapy institutes, and 1 neurosurgical 
center (Figure 4). The clinical data available from the ECR included date of diagnosis, tumor 
grade, histology, Ann Arbor stage59, primary treatment, and patients background characteristics, 
including gender, date of birth, comorbidity and postcode.
PROFILES
PROFILES (Patient Reported Outcomes Following Initial treatment and Long term Evaluation of 
Survivorship) is a registry for the study of the physical and psychosocial impact of cancer and 
its treatment from a dynamic, growing population-based cohort of both short and long-term 
cancer survivors15. PROFILES is a tool that enables data collection management; from inviting 
patients to participation in studies, to collecting patient-reported outcome data via web-based 
or mailed questionnaires and linking these data to clinical data from the ECR.  
Normative population  
HRQoL and other patient reported outcome data were also collected from a normative 
population of 2,040 individuals from the general Dutch population (CentER panel). This cohort 
is considered representative for the Dutch-speaking population in the Netherlands60. Based 
upon this normative population age- and sex-matched selections were made for the specific 
lymphoma samples. Comparison with an age- and sex-matched normative population provides 
information about the impact of cancer beyond the natural aging process and the impact of 
comorbidities.
PHAROS
PHAROS (Population-based Haematological Registry for Observational Studies) aims to 
contribute to the study of the effectiveness of targeted therapies for patients with hematological 
malignancies in a population-based setting61. Part of the effectiveness is the impact of these 
therapies on side effects and HRQoL among lymphoma patients. PHAROS is an extension of the 
Netherlands Cancer Registry and a collaboration between HOVON (Dutch Cooperative Group on 
Hemato-Oncology) iMTA (institute for Medical Technology Assessment) and IKNL. The PROFILES 
and ECR-data of patients on primary treatments were replenished with details on treatment 
from PHAROS. 
Figure 4. The current area of the Eindhoven Cancer Registry of the Comprehensive Cancer Centre 
Netherlands.
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Cancer survivors are at risk of experiencing adverse physical and psychosocial effects of their 
cancer and its treatment. Both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) 
survivors face problems that can affect their health-related quality of life (HRQoL). The authors 
systematically reviewed the literature on HRQoL among HL and NHL survivors. A PubMed and 
PsychINFO literature search for original articles published until May 2011 was performed. Twenty-
four articles, which met the predefined inclusion criteria, were subjected to a quality checklist. HL 
survivors showed the most problems in (role) physical, social and cognitive functioning, general 
health, fatigue and financial problems. In addition, HL survivors treated with a combination of 
therapies, with older age and female sex reported worse HRQoL. NHL survivors showed the 
most problems in physical functioning, appetite loss, vitality and financial problems. Having 
had chemotherapy was negatively associated with HRQoL but no differences in chemotherapy 
regimens were found. Furthermore, in NHL survivors not meeting public exercise guidelines 
HRQoL is low, but can be improved with more exercise. More research on the longitudinal 
comparison between HL and NHL survivors and healthy controls should be performed in order 
to better understand the long-term (side) effects of treatment on HRQoL and possibilities to 
alleviate these.
introduction
Treatment of cancer has improved considerably in the past decades resulting in more (long-term) 
survivors. A person diagnosed with cancer is defined a survivor from the moment of diagnosis 
through the balance of his or her life1. The number of cancer survivors in the United States (US) 
has increased steadily and is currently estimated to be 11.1 million2. The number of lymphoma 
survivors has relatively increased even more. On January 1, 2008, there were approximately 
167,000 Hodgkin’s lymphoma (HL) survivors, and approximately 454,000 non-Hodgkin’s 
lymphomas (NHL) survivors in the US2. In the Nordic European Countries (NEC: Denmark, Faroe 
Islands, Finland, Iceland, Norway, Sweden), there were approximately 10,500 HL survivors, and 
approximately 31,500 NHL survivors at the end of 20073. 
Although there are similarities between these subtypes of lymphoma, the incidence and age 
of onset are quite different. The annual incidence of HL is 1 in 35,000 in the US2 and 1 in 47,000 
in the NEC3, with approximately 8,500 new cases in the US2 and 558 new cases in the NEC3 
annually. Onset occurs most frequently between the ages of 20 and 35 years. Between 35 and 
50 years it occurs less often, especially in females, but from the age of 50 onward there is again 
a rise in incidence with age2. The lifetime prevalence of HL is one  in 4302. With respect to NHL, 
the annual incidence is one  in 5,000, with approximately 65,000 new cases in the US2 and 
73,000 new cases in the European Union (NEC numbers are unavailable)4. The disease occurs 
predominantly in individuals aged over 45 years and the lifetime prevalence of NHL is one  in 502.
Due to chemotherapy, radiotherapy, and stem cell transplantation, the survival of these patients 
has improved dramatically in the seventies and eighties, but has nowadays levelled off. In effect, 
most trials focus on maintaining the high level of cure, while reducing the long-term effects of 
treatment. To date, more than 80% of patients diagnosed with HL are expected to live free of 
disease for five years or more after diagnosis5. The overall 5-year survival rate for all types of 
NHL (1999-2005) is 50-60%. The statistics vary, depending on the cell type, stage of disease at 
diagnosis, treatment, and age of the patient5. 
As cancer survivors are living longer, they are at risk of experiencing adverse physical and 
psychosocial long-term effects of the fact they had cancer or of their treatment6-9. Especially 
the long-term HL and NHL survivors face specific problems, concerning mainly chronic medical 
as well as psychosocial complications that can affect their health-related quality of life (HRQoL). 
Fatigue, depression, marital disruption, and problems with infertility are frequently reported 
concerns by these survivors, not to mention problems with insurances and mortgages6, 8-11. 
Only recently, the focus of published papers has shifted from improvement of survival to HRQoL. 
In December 2009, a review concerning HRQoL in lymphoma survivors has been published12. 
This review described the HRQoL of both HL and NHL survivors combined, which may delude 
conclusions as differences in age of onset, treatment and overall survival time between HL and 
NHL greatly influences HRQoL. In addition, four prospective and two cross-sectional studies, 
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all published between 2004 and 2009, were not included in this review and especially these 
prospective studies contain important information. Furthermore, and most important, the 
review did not provide information about the clinical implications of its findings. Many studies 
base their conclusions on statistical significance, but clinical significance should also be studied 
for the representation of clinically important differences to patients. Our review will therefore 
distinguish itself by a separate discussion of both types of lymphoma, a more complete and 
update overview of studies, and by providing information about clinical significance of the 
findings. The aim of this systematic review was (1) to evaluate the quality of the included studies, 
(2) to identify the HRQoL domains and symptoms that are clinically relevant affected in HL and 
NHL survivors, (3) to evaluate the relation between treatment and HRQoL and (4) to evaluate 
potential differences in socio-demographic and clinical characteristics.
methods
Search strategy
The electronic databases of Pubmed and PsychINFO were searched to find all articles up to 
December 2010 using the terms ‘Hodgkin’s and ‘non-Hodgkin’s lymphoma’ in combination 
with: survivors, long-term, (health-related) quality of life, and HRQoL. The reference lists of all 
publications were checked to retrieve additional publications.
Selection criteria
Studies in English on HRQoL in HL and NHL adult survivors were included if they used a 
multidimensional HRQoL questionnaire. Studies that merely focused on one-dimensional 
aspects of HRQoL such as fatigue, anxiety, or depression were excluded from this review, because 
this is not consistent with the multidimensional concept of HRQoL (i.e. the existential influence 
of disease on physical, emotional, and social functioning). Also, studies that involved a variety 
of tumours including HL or NHL, focused on adult survivors of childhood cancer, and studies 
not published in peer-reviewed journals were excluded. Furthermore, the focus of the study 
had to be either one or more of the following; (1) comparison with a normative population, (2) 
studying the relation between treatment and HRQoL, (3) studying the relation between socio-
demographic or clinical characteristics and HRQoL. The search resulted in 270 hits. Based on titles 
and abstracts, 24 articles met our selection criteria and were included in this review (Figure 1).
Quality assessment
The methodological quality of the selected studies was assessed using a 12-item standardized 
checklist of predefined criteria which was a modified version of an established criteria list for 
systematic reviews (Table 1)13, 14. Each item of a study, which met our criteria, was assigned 
one point. If an item did not meet our criteria, was described insufficiently, or not at all, then 
zero points were assigned. The highest possible score was 12. Studies scoring ≥8 points were 
considered to be of ‘high quality’. Studies scoring <6 points or 6-8 points were rated respectively 
as low and moderate quality. 
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Criteria for clinically important difference
The following criteria were used to determine clinically important differences. For the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30), a score of ≥10 points difference on subscales reflects a clinical important difference 
9, 15-18. Concerning the SF-36, differences of ≥2 points for role physical functioning; ≥3 points 
for physical functioning, social functioning, bodily pain, general health, vitality, mental health 
and the component scales; ≥4 points for role emotional functioning are considered clinically 
meaningful19, 20. For the other questionnaires and some subscales Norman’s ‘rule of thumb’ was 
used whereby a ≈ 0.5 SD difference indicates a threshold of discriminating change in HRQoL 
scores of a chronic illness21.
results
Study characteristics
In total, 24 studies were included (14 HL9, 15, 16, 22-32 and 10 NHL11, 17, 33-40) all published between 
February 1994 and November 2010. Only one study was conducted outside the US and Europe40. 
Time since diagnosis ranged between circa two months and 44 years. The most frequently used 
questionnaires of HRQoL were the EORTC QLQ-C30 (10 studies)41 and the RAND Short Form-36 
Table 1. List of criteria for assessing the methodological quality of studies on health-related quality 
of life among Hodgkin’s and non-Hodgkin’s lymphoma.
Positive if with respect to:
Quality of life assessment
1. A validated (Health-related) Quality of Life questionnaire is used (e.g. SF36, EORTC-C30).
Study population
2. A description is included of at least two socio-demographic variables.
3. A description is present of at least two clinical variables of the described patient population 
(e.g. tumour stage at diagnosis).
4. Inclusion and/or exclusion criteria are described.
5. Participation rates for patient groups are described and are more than 60%.  
6. Information is given about the degree of selection of sample (information is given about 
the ratio respondents versus non-respondents).
Study design
7. The study size is consisting of at least 50 participants (arbitrarily chosen).
8. The data is prospectively gathered.
9. The process of data collection is described (e.g. interview or self-report).
Results
10. The results are compared between two groups or more (e.g., healthy population, groups 
with different treatment or age) and/or results are compared with at least two time points 
(e.g., longitudinally versus post-treatment).
11. Mean, median, standard deviations or percentages are reported for the most important 
outcome measures.
12. Statistical proof for the findings is reported.
(SF-36) (11 studies)42. Two studies used the Schedule for the Evaluation of Individual Quality 
of Life–Direct Weighting (SEIQoL-DW)43 and three studies used the Functional Assessment of 
Cancer Therapy-General (FACT-G)44.
With respect to HL, two studies had a prospective design and twelve studies had a cross-
sectional design. Of the 14 studies, ten cross-sectional studies compared HL survivors and the 
general population, two prospective and eight cross-sectional studies evaluated the relation 
with treatment, and two prospective and nine cross-sectional studies reported about potential 
differences in socio-demographic and clinical characteristics (Table 2). With respect to NHL, 
four studies had a prospective design and six studies had a cross-sectional design. Of the ten 
studies, two prospective and three cross-sectional studies compared NHL survivors and the 
general population, three prospective and two cross-sectional studies evaluated the relation 
with treatment, and nine studies reported about the potential differences in socio-demographic 
and clinical characteristics (Table 3). 
The evaluation of the methodological quality of the studies by the reviewers (SO, FM, LP) 
yielded the following results. On items 1, 5, 7, 8, 9, 11, and 12 there was disagreement once, 
and on items 2, 3, and 10 there was no disagreement. On items 4 and 6 (see Table 1), there 
was disagreement a couple of times, mostly due to differences in interpretation of the text. 
These were solved through discussion in a consensus meeting. The methodological quality of 
all included studies ranged from 8 to 12 points and was thus considered to be of high quality. 
General shortcomings concerned mainly the lack of information on non-respondents (n=11) and 
the lack of a prospective design (n=16).
Hodgkin’s lymphoma
HRQoL domains: HL survivors vs. normative samples 
Four cross-sectional studies found clinically important lower physical functioning scores for 
survivors compared to a normative population9, 26, 30, 32. No clinically important differences were 
found in six studies15, 22, 24, 27, 28, 31.
Five studies found that HL survivors had clinically important lower scores on social functioning 
compared to normative samples9, 15, 22, 24, 26. Three studies found no clinically important differences 
on social functioning27, 28, 30.
One study among 98 survivors that survived more than 8 years found that HL survivors had 
clinically important lower scores on emotional functioning compared to the normative sample 
22 while seven studies found no clinically important differences9, 15, 24, 26-28, 30.
Five studies found that HL survivors had clinically important lower scores on role physical 
functioning compared to the normative sample9, 22, 26, 27, 30. Three studies found no clinically 
important differences15, 24, 28.
No clinically important differences were found between HL survivors and normative samples 
with respect to Global health state (6 studies)15, 22, 24, 27, 28, 31.
Three cross-sectional studies found that HL survivors had clinically important lower scores on 
general health compared to the normative sample9, 26, 30 Two cross-sectional studies found no 
clinically important differences on general health28, 31.
No clinically important differences were found between HL survivors and normative samples 
regarding mental health scores (4 studies)9, 26, 28, 30.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Symptoms: HL survivors vs. normative samples 
Clinically important worse scores of HL survivors were reported on several symptoms: cognitive 
problems15, 22, 27, financial difficulties15, 22, 24, fatigue/vitality9, 15, 22 15, 22, dyspnea 22, 27 and insomnia15, 
22 were reported most often. Diarrhoea22 and pain26 were reported by one study each. Three 
studies found no clinically important differences between HL survivors and normative samples9, 
13, 30.
Treatment and HRQoL in HL survivors
One prospective study among 247 early stage HL survivors23, found clinically important lower 
scores on vitality among patients treated with a combination of radiotherapy and chemotherapy 
compared to patients treated with radiotherapy alone, but only in the first year after treatment. 
This effect was also found in a cross-sectional study among 126 HL survivors in Austria25. They 
reported that patients treated with a combination of radiotherapy and chemotherapy showed 
clinically important lower scores on physical functioning and clinically important higher scores 
on pain, fatigue and dyspnoea compared to patients who were treated with radiotherapy or 
chemotherapy alone. Two small cross-sectional studies also found clinical important higher 
scores on dyspnoea. One found that 26 patients treated with mantle field irradiation reported 
higher scores compared with patients treated without (n=16)29. The other study found that 37 
patients treated with high dose chemotherapy and stem cell transplantation reported higher 
scores compared with patients treated with conventional chemotherapy (n=61)22. Another 
prospective and four cross sectional studies found no effect of treatment on HRQoL9, 16, 24, 28, 32.
Socio-demographic and clinical characteristics in HL survivors
Three cross-sectional and one prospective study observed that older patients reported clinically 
important worse outcomes9, 16, 24, 27. Six studies reported contradicting differences in HRQoL 
according to gender 9, 15, 16, 24, 27, 29, three studies found clinically important worse scores for women 
9, 24, 27, one found only statistically worse scores for women16, one found worse scores for men29, 
and one found no differences15. Two cross-sectional studies reported that more advanced disease 
stage or recurrences were associated with reduced HRQoL, however no information about 
clinically important differences could be obtained15, 32. One study found remarkably that patients 
with stage IB-IIB scored significantly and clinically important lower on physical functioning and 
physical role limitations compared to patients with stage IA-IIA, IIIA-IVA, and IIIB-IVB9.
The impact of length of survival on HRQoL was reported in a cross-sectional study, showing 
that patients who had survived 10-15 years after diagnosis reported clinically important higher 
HRQoL scores than patients who had survived 5-9 years28.
Non-Hodgkin’s lymphoma
HRQoL domains: NHL survivors vs. normative samples 
In a prospective study among 95 Norwegians17, patients showed clinically important lower scores 
on physical functioning up till 5 months after start of therapy compared to the normative sample. 
However, 8 months after end of treatment the difference was no longer clinically relevant. A 
Dutch cross-sectional study among 294 survivors11, and an American cross-sectional study of 319 
survivors found no clinically important lower scores for survivors compared to the normative 
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sample on physical functioning33. A cross-sectional study of 761 survivors39 showed clinically 
important lower scores on the physical component scale. Another prospective study found 
statistically lower scores two years post-diagnosis, however no information about clinically 
important differences could be obtained37.
A prospective study17, exhibited clinically important lower scores on social functioning up till 6 
months after start of therapy compared to the reference population. However, 8 months after 
end of treatment the difference was no longer clinically relevant. Two years post-diagnosis 
another prospective study found statistically lower scores, however no information about 
clinically important differences could be obtained37. A cross-sectional study found no clinically 
important differences with respect to social functioning11.
A prospective study17 showed clinically important lower scores on role physical function 
compared to the general population and these scores remained clinically important lower until 
the end of the study (8 months). Another prospective study found statistically lower scores two 
years post-diagnosis, however no information about clinically important differences could be 
obtained37. However, a cross-sectional study found no clinically important differences regarding 
role physical function11.
Two prospective and a cross-sectional study did not find statistically or clinically important 
differences with respect to emotional functioning between NHL survivors and the normative 
populations11, 17, 37.
A prospective study17 exhibited clinically important lower scores on global health state up till 5 
months after start of therapy compared to the reference population. However, 8 months after 
end of treatment the difference was no longer clinically relevant. 
In addition, a cross-sectional study among 294 survivors showed clinically important lower 
scores on general health11. A prospective study found statistically lower scores two years post-
diagnosis, however no information about clinically important differences could be obtained37. 
Three cross-sectional studies did not find clinically important differences between NHL survivors 
and the reference population on mental health11, 33, 39. 
Symptoms: NHL survivors vs. normative samples 
A prospective study17 showed clinically important lower scores on appetite loss, constipation, 
fatigue and dyspnoea up till respectively 3 months for the first 2 symptoms and 5 months for 
the last 2 symptoms after start of therapy compared to the reference population. However, 8 
months after end of treatment the difference was no longer clinically relevant. Furthermore, 
they found that 9 months after the end of treatment until the end of the study, survivors had 
clinically more financial difficulties than the normative sample. A cross-sectional and prospective 
study found statistically lower scores for survivors on vitality28,37, clinically important differences 
were only found by the cross-sectional study28.
Treatment and HRQoL in NHL survivors
Three prospective studies showed no significantly different outcomes regarding HRQoL between 
patients treated with different chemotherapy regimens17, 34, 35. Two cross-sectional studies 
found that, compared to patients who did not receive chemotherapy, patients who did receive 
chemotherapy experienced clinically important worse overall health functioning36 and social 
well being11. 
Socio-demographic and clinical characteristics in NHL survivors
A prospective study did not found a relation between age and HRQoL outcome17. One cross-
sectional study11 found that older patients scored significantly lower on physical functioning 
than younger patients, however no information about clinically important differences could be 
obtained. Another cross-sectional study found clinical meaningful worse physical HRQoL scores 
for survivors who were older at study enrolment38.
Two prospective studies34, 35 found that survivors with progressive disease had clinically 
meaningful lower HRQoL than patients who were free of disease. Another prospective study 
found no relation between disease stage and HRQoL17. Two cross-sectional studies found 
statistically lower HRQoL score for survivors with active (relapsed) disease compared to disease 
free survivors36, 39, clinically important differences were found in one of them36.
The impact of length of survival was reported in a cross-sectional study11 showing that patients 
who had survived 10-15 years after diagnosis reported clinically important higher HRQoL scores 
than patients who had survived 5-9 years, but this was not observed by another study39 that 
compared short-term (2-5 years after diagnosis) and long-term (≥5 years after diagnosis) 
survivors.
Two prospective studies34, 35 investigated HRQoL in elderly patients in relation to the age-
adjusted International Prognostic Index which comprises 3 factors (performance status, 
lactate dehydrogenase, and stage)45. These studies found that patients with a low age-adjusted 
International Prognostic Index had a clinically meaningful better HRQoL than patients with a high 
age-adjusted International Prognostic Index. One prospective study found no relation between 
International Prognostic Index and HRQoL17.
Two cross-sectional studies found that survivors meeting public health exercise guidelines 
reported a clinical meaningfully better mental and physical health33, 40 than survivors not meeting 
these guidelines. Even more important, one of these studies33 found that there was a significant 
dose-response pattern in which more exercise resulted in better mental and physical health.
discussion
This systematic review summarized and evaluated the results of studies focusing on the HRQoL 
of HL and NHL survivors. It is a remarkable fact that the majority of these studies concerned HL 
and not NHL, certainly in view of the number of patients being treated (8,500 vs. 65,000), or 
the number of survivors (165,000 vs. 440,000)5. Another point is that the first included study 
on HRQoL in HL was published in 1994, whereas all included studies on HRQoL in NHL were 
published after 2004.
The quality scores of the included HL studies ranged from 8 till 12 points, which indicates a high 
methodological quality. The shortcomings of these studies were mainly the lack of a prospective 
design and lack of information on non-respondents. The HRQoL domains that were affected 
the most in these patients and represent clinically important differences to patients were 
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(role) physical, social and cognitive functioning, general health, fatigue and financial problems 
and fewer dyspnoea and insomnia. Clinically important differences in emotional functioning, 
diarrhoea and pain were reported once. No clinically important differences were found in the 
included studies for physical functioning and mental health. Based on the studies included in this 
review, HL survivors who received a combination of chemotherapy and radiotherapy23, 25, had 
worse scores on HRQoL domains. A clinically important higher score on dyspnoea was found by 
all therapies and this suggests that treatment in general results in problems29. However, most of 
the studies found no differences. In addition, HL survivors with older age and females reported 
worse outcomes. As expected, patients with a longer survival time reported better outcomes 
compared to those more recently diagnosed. 
With respect to the included NHL studies, it was not possible to divide the results section in 
aggressive and indolent lymphomas due to lack of information within most available studies. The 
quality scores of NHL studies ranged from 9 till 12 points, which indicates a high methodology 
quality. The shortcomings were mainly a lack of a prospective design. The HRQoL domains that 
were affected the most in NHL survivors and represent clinically important differences to patients 
were physical functioning, appetite loss, vitality and financial problems. Clinically important 
differences in social functioning, role physical functioning and global health were mentioned once 
up till 5 months after treatment but waned over time. When comparing different chemotherapy 
regimens, no differences were reported. Nevertheless, having had chemotherapy was associated 
with clinically important lower scores on social well being11 and overall health functioning36 as 
reported by two cross-sectional studies in (long-term) cancer survivors. Interestingly, the effect 
of exercise was studied in NHL patients, whereas this has not been investigated in HL survivors. 
NHL survivors that met public health exercise guidelines reported a clinically important better 
HRQoL than survivors that did not meet exercise guidelines33, 40, and even more important, more 
exercise resulted in a better mental and physical health33. Most studies showed worse HRQoL for 
survivors with aggressive disease or partial response, no response or progressive disease34-36, 39, 
and those with a high age adjusted Prognostic Index34, 35, which is well understandable. 
The criterion of clinically important differences is very important to specify those domains of 
HRQoL that are affected in survivors. Most of the included studies based their conclusions only 
on statistical significance. Sometimes differences between survivors and comparative groups 
were statistical significant, but not clinically important for patients. Therefore, researchers should 
always use a criterion for the interpretation of clinical relevance instead of only evaluating the 
statistical significance to really attribute to the care of patients. Of the 17 included studies that 
compared HRQoL between survivors and a normative population, only seven9, 15-17, 28, 32, 39 studies 
used a criterion to determine clinically relevant differences.
When comparing different studies, certainly in the field of HRQoL, there are many limitations. 
Seventeen of 22 included papers had a cross-sectional design9, 11, 15, 24-33, 39, 40. A limitation of this 
methodology is that it is not possible to draw causal relationships. In addition, these studies may 
have survivorship bias, because patients that do relatively worse will not participate as they are 
too ill or dead. A prospective design study provides better relevant answers about causality, for 
example the temporal direction between treatment and HRQoL, but only five studies had this 
design. Also the lack of information in some studies on non-respondents or possible bias makes 
it more difficult to determine the trustworthiness of a study. Future studies should therefore 
always try to collect data on non-respondents or discuss the possible risk of bias. Although 
there are inherent relationships between HRQoL dimensions, we discussed the dimensions 
separately to identify which specific dimensions are most affected. This does not mean that the 
unmentioned dimensions could not be affected. However, the underlying mechanisms between 
the relations in HRQoL dimensions and symptoms is understudied and not yet clear. Therefore 
studies focusing on symptom clustering are needed.
The different HRQoL questionnaires used, predominantly the EORTC QLQ-C30 (disease specific 
questionnaire) and the SF-36 (generic questionnaire) made it difficult to compare results, as the 
various scales do not exactly measure the same HRQoL dimensions. The questionnaires in the 
included studies were almost all generic or disease specific. Generic questionnaires are designed 
to measure health in general, and are therefore appropriate for a wide range of patient groups 
and also the general population, but are less sensitive to detect certain aspects of disease and 
treatment that are relevant to a specific patient group. The EORTC QLQ-C30 is a disease specific 
questionnaire, but consists of such questions that this questionnaire is also applicable to the 
general population46. In addition to these generic and disease specific questionnaires, lymphoma 
specific questionnaires should be used to detect, with more sensibility, side-effects and 
symptoms particularly relevant to HL and NHL survivors. However, cancer specific questionnaires 
are relatively new and underdeveloped and therefore used infrequently. Only two studies36, 39 
used a lymphoma specific questionnaire, the FACT-Lymphoma, which was developed in 200444. 
The American Cancer Society defines ‘long-term survivors’ as every person who is still alive 
five years after diagnosis47. Six studies, five HL15, 28, 30-32 and one NHL11, focused on patients who 
had survived more than five years. Only one recent study focused on the longitudinal HRQoL 
of HL survivors16. Especially these kind of studies are important in view of the growing number 
of survivors to identify as soon as possible negative long-term effects, certainly when taken in 
consideration the implementation of new treatments. 
If we compare the results of the eleven cross-sectional and two prospective studies among HL 
survivors, some cross-sectional studies are consistent with the prospective studies on points as 
comparison with the norm population, relation with received treatment and socio-demographic 
and clinical differences. However, if we compare the two prospective HL studies, one23 did find 
a relation with treatment while the other16 did not. With respect to NHL studies, again some 
of the cross-sectional studies (four) are consistent with the prospective ones. However, if we 
compare the three prospective studies, only consistent results concerning the absence of the 
relation with treatment on HRQoL were found17, 34, 35. 
In conclusion, the reviewed literature about the HRQoL of HL and NHL survivors reflects that 
several domains, even in long-term survivors, are affected. Overall, HL survivors experience 
the most problems in (role) physical, social and cognitive functioning, general health, fatigue 
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and financial problems. In addition, HL survivors with older age and female sex reported worse 
outcomes. NHL survivors experience the most problems in physical functioning, appetite loss, 
vitality and financial problems. However, these results are less clear as only a limited number 
of studies are performed among NHL survivors. Furthermore, importantly the HRQoL in NHL 
survivors not meeting public exercise guidelines is low, but can be improved with more exercise. 
More research on the longitudinal comparison between HL and NHL survivors and healthy 
controls should be performed. Lymphoma specific questionnaires should be further developed 
to better understand in detail the side-effects of treatment on HL and NHL survivors. 
references
1. US National Coalition for Cancer Survivorship. 
http://www.canceradvocacy.org/, accessed on 
December 28, 2009.
2. Howlader N, Noone AM, Krapcho M, et al. SEER 
Cancer Statistics Review, 1975-2008, National 
Cancer Institute. Bethesda, MD, http://seer.
cancer.gov/csr/1975_2008/, based on November 
2010 SEER data submission, posted to the SEER 
web site, 2011, accessed on May 10, 2011 
3. Engholm G, Ferlay J, Christensen N, et al. 
NORDCAN--Cancer Incidence, Mortality, 
Prevalence and Prediction in the Nordic 
Countries, Version 3.6. Association of the Nordic 
Cancer Registries. Danish Cancer Society (http://
www.ancr.nu).2010.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, 
Parkin DM. Estimates of worldwide burden of 
cancer in 2008: GLOBOCAN 2008. Int J Cancer. 
2010;127: 2893-2917.
5. National Cancer Institute. General information 
about adult non-Hodgkin’s lymphoma, 
http://www.cancer.gov.libproxy.lib.unc.edu/
cancertopics/pdq/treatment/adult-non-
Hodgkins, accessed on December 28, 2009.
6. Fobair P, Hoppe RT, Bloom J, Cox R, Varghese 
A, Spiegel D. Psychosocial problems among 
survivors of Hodgkin’s disease. J Clin Oncol. 
1986;4: 805-814.
7. Geffen DB, Blaustein A, Amir MC, Cohen Y. 
Post-traumatic stress disorder and quality of 
life in long-term survivors of Hodgkin’s disease 
and non-Hodgkin’s lymphoma in Israel. Leuk 
Lymphoma. 2003;44: 1925-1929.
8. Knobel H, Loge J, Brit Lund M, Forfang K, Nome 
O, Kaasa S. Late medical complications and 
fatigue in Hodgkin’s disease survivors. J Clin 
Oncol. 2001;19: 3226-3233.
9. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. 
Reduced health-related quality of life among 
Hodgkin’s disease survivors: a comparative 
study with general population norms. Ann Oncol. 
1999;10: 71-77.
10. Hess SL, Johannsdottir IM, Hamre H, Kiserud CE, 
Loge JH, Fossa SD. Adult survivors of childhood 
malignant lymphoma are not aware of their risk 
of late effects. Acta Oncol. 2011;50: 653-659.
11. Mols F, Aaronson NK, Vingerhoets AJ, et al. 
Quality of life among long-term non-Hodgkin 
lymphoma survivors: a population-based study. 
Cancer. 2007;109: 1659-1667.
12. Arden-Close E, Pacey A, Eiser C. Health-related 
quality of life in survivors of lymphoma: a 
systematic review and methodological critique. 
Leuk Lymphoma.51: 628-640.
13. Mols F, Vingerhoets AJ, Coebergh JW, van de 
Poll-Franse LV. Quality of life among long-term 
breast cancer survivors: a systematic review. Eur 
J Cancer. 2005;41: 2613-2619.
14. Den Oudsten BL, Van Heck GL, De Vries J. Quality 
of life and related concepts in Parkinson’s 
disease: a systematic review. Mov Disord. 
2007;22: 1528-1537.
15. Goodman KA, Riedel E, Serrano V, Gulati S, 
Moskowitz CH, Yahalom J. Long-term effects 
of high-dose chemotherapy and radiation for 
relapsed and refractory Hodgkin’s lymphoma. J 
Clin Oncol. 2008;26: 5240-5247.
16. Heutte N, Flechtner HH, Mounier N, et al. Quality 
of life after successful treatment of early-stage 
Hodgkin’s lymphoma: 10-year follow-up of the 
EORTC-GELA H8 randomised controlled trial. 
Lancet Oncol. 2009;10: 1160-1170.
17. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, 
Cavallin-Stahl E. Health-related quality of life and 
its potential prognostic implications in patients 
with aggressive lymphoma: a Nordic Lymphoma 
Group Trial. Med Oncol. 2001;18: 85-94.
18. Osoba D, Rodrigues G, Myles J, Zee B, Pater 
J. Interpreting the significance of changes in 
health-related quality-of-life scores. J Clin Oncol. 
1998;16: 139-144.
19.  Ware JE, Kosinski MA. SF-36 Physical and Mental 
Health Summary Scales: A Manual for Users of 
Version 1. 2nd Edition. Lincoln RI: QualityMetric 
Inc. 2001.
20. Ware JE, Kosinski MA, Dewey JE. How to score 
version 2 of the SF-36 health survey. Lincoln: 
Quality Metric Inc. 2000.
21. Norman GR, Sloan JA, Wyrwich KW. 
Interpretation of changes in health-related 
quality of life: the remarkable universality of 
half a standard deviation. Med Care. 2003;41: 
582-592.
22. Brandt J, Dietrich S, Meissner J, Neben K, 
Ho AD, Witzens-Harig M. Quality of life of 
long-term survivors with Hodgkin lymphoma 
after high-dose chemotherapy, autologous 
stem cell transplantation, and conventional 




23. Ganz PA, Moinpour CM, Pauler DK, et al. Health 
status and quality of life in patients with early-
stage Hodgkin’s disease treated on Southwest 
Oncology Group Study 9133. J Clin Oncol. 
2003;21: 3512-3519.
24. Gil-Fernandez J, Ramos C, Tamayo T, et al. 
Quality of life and psychological well-being 
in Spanish long-term survivors of Hodgkin’s 
disease: results of a controlled pilot study. Ann 
Hematol. 2003;82: 14-18.
25. Greil R, Holzner B, Kemmler G, et al. Retrospective 
assessment of quality of life and treatment 
outcome in patients with Hodgkin’s disease from 
1969 to 1994. Eur J Cancer. 1999;35: 698-706.
26. Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, 
Jacobsen AB, Loge JH. Quality of life in long-term 
Hodgkin’s disease survivors with chronic fatigue. 
Eur J Cancer. 2006;42: 327-333.
27. Joly F, Henry-Amar M, Arveux P, et al. Late 
psychosocial sequelae in Hodgkin’s disease 
survivors: a French population-based case-
control study. J Clin Oncol. 1996;14: 2444-2453.
28. Mols F, Vingerhoets AJ, Coebergh JW, et al. 
Better quality of life among 10-15 year survivors 
of Hodgkin’s lymphoma compared to 5-9 year 
survivors: a population-based study. Eur J 
Cancer. 2006;42: 2794-2801.
29. Norum J, Wist EA. Quality of life in survivors of 
Hodgkin’s disease. Qual Life Res. 1996;5: 367-
374.
30. van Tulder MW, Aaronson NK, Bruning PF. The 
quality of life of long-term survivors of Hodgkin’s 
disease. Ann Oncol. 1994;5: 153-158.
31. Wettergren L, Bjorkholm M, Axdorph U, Bowling 
A, Langius-Eklof A. Individual quality of life in 
long-term survivors of Hodgkin’s lymphoma--a 
comparative study. Qual Life Res. 2003;12: 545-
554.
32. Wettergren L, Bjorkholm M, Axdorph U, Langius-
Eklof A. Determinants of health-related quality 
of life in long-term survivors of Hodgkin’s 
lymphoma. Qual Life Res. 2004;13: 1369-1379.
33. Bellizzi KM, Rowland JH, Arora NK, Hamilton 
AS, Miller MF, Aziz NM. Physical activity and 
quality of life in adult survivors of non-Hodgkin’s 
lymphoma. J Clin Oncol. 2009;27: 960-966.
34. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de 
Groot C, Sonneveld P. Self-reported quality of life 
in elderly patients with aggressive non-Hodgkin’s 
lymphoma treated with CHOP chemotherapy. 
Eur J Haematol. 2005;75: 116-123.
35. Merli F, Bertini M, Luminari S, et al. Quality of life 
assessment in elderly patients with aggressive 
non-Hodgkin’s Lymphoma treated with 
anthracycline-containing regimens. Report of 
a prospective study by the Intergruppo Italiano 
Linfomi. Haematologica. 2004;89: 973-978.
36. Pettengell R, Donatti C, Hoskin P, et al. The 
impact of follicular lymphoma on health-related 
quality of life. Ann Oncol. 2008;19: 570-576.
37. Reeve BB, Potosky AL, Smith AW, et al. Impact 
of cancer on health-related quality of life of 
older Americans. J Natl Cancer Inst. 2009;101: 
860-868.
38. Smith SK, Crespi CM, Petersen L, Zimmerman 
S, Ganz PA. The impact of cancer and quality of 
life for post-treatment non-Hodgkin lymphoma 
survivors. Psychooncology. 2010;19: 1259-1267.
39. Smith SK, Zimmerman S, Williams CS, Zebrack 
BJ. Health status and quality of life among non-
Hodgkin lymphoma survivors. Cancer. 2009;115: 
3312-3323.
40. Vallance JK, Courneya KS, Jones LW, Reiman 
T. Differences in quality of life between non-
Hodgkin’s lymphoma survivors meeting and 
not meeting public health exercise guidelines. 
Psychooncology. 2005;14: 979-991.
41. Aaronson NK, Ahmedzai S, Bergman B, et al. 
The European Organization for Research and 
Treatment of Cancer QLQ-C30: a quality-of-life 
instrument for use in international clinical trials 
in oncology. J Natl Cancer Inst. 1993;85: 365-376.
42. Ware JE, Jr., Sherbourne CD. The MOS 36-item 
short-form health survey (SF-36). I. Conceptual 
framework and item selection. Med Care. 
1992;30: 473-483.
43. Browne JP, O’Boyle CA, McGee HM, McDonald 
NJ, Joyce CR. Development of a direct weighting 
procedure for quality of life domains. Qual Life 
Res. 1997;6: 301-309.
44. Cella DF, Tulsky DS, Gray G, et al. The 
Functional Assessment of Cancer Therapy scale: 
development and validation of the general 
measure. J Clin Oncol. 1993;11: 570-579.
45. Shipp M, Harrington D, Anderson J. A predictive 
model for aggressive non-Hodgkin’s lymphoma. 
The International Non-Hodgkin’s Lymphoma 
Prognostic Factors Project. N Engl J Med. 
1993;329: 987-994.
46. van de Poll-Franse LV, Mols F, Gundy CM, et al. 
Normative data for the EORTC QLQ-C30 and 
EORTC-sexuality items in the general Dutch 
population. Eur J Cancer. 2011;47: 667-675.
47. American cancer society. Cancer facts and 
figures-2009, Atlanta, GA: American Cancer 
Society 2009.
chapter 3
Health-related quality of life and persistent symptoms in relation to 
(R-)CHOP14, (R-)CHOP21 and other therapies among patients with diffuse 
large B-cell lymphoma: results of the population-based PHAROS-registry
S. Oerlemans, D.E. Issa, E.C. van den Broek, M.R. Nijziel, J.W.W. Coebergh, P.C. Huijgens, F. Mols, 
L.V. van de Poll-Franse
Annals of Hematology 2014; 93(10):1705-1714





The increasing number of longer living patients with diffuse large B-cell lymphoma (DLBCL) and 
serious side effects of treatment, urged us to study the health-related quality of life (HRQoL) 
and persistent (treatment-related) symptoms in unselected patients after different treatment 
modalities and compare HRQoL of patients with a normative population.
Methods 
The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with 
DLBCL from 2004-2010. The EORTC QLQ-C30 was completed twice, with a one-year interval. 
Detailed data on treatment were extracted from the Population-based HAematological Registry 
for Observational Studies. 
Results 
256 patients responded (84%, T1). Compared to patients treated with (R-)CHOP21, those who 
underwent (R-)CHOP14 more often reported tingling in hands and feet (27% versus 42%, p=0.02), 
fatigue (35% versus 46%, p=0.03) and reported a lower global health status/HRQoL. Mean HRQoL 
was statistically and clinically relevantly lower among DLBCL patients compared to a normative 
population (p<0.01). Persistent tingling in hands/feet was reported more often by older patients 
and patients treated with (R-)CHOP14 independently of the other characteristics. Furthermore, 
patients who reported symptoms exhibited significantly lower HRQoL compared to patients 
without symptoms/worries.
Conclusion 
Patients treated with (R-)CHOP14 reported more neuropathic symptoms, more fatigue and a 
lower HRQoL than patients treated with (R-)CHOP21. Alertness for persistent symptoms that 
occur during and after treatment of DLBCL patients is needed and may help to avoid lasting 
negative influence on their HRQoL.
introduction
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignancies and is the most common 
hematologic malignant neoplasm in adults. In the United States, there were approximately 
510,000 people alive who had a history of NHL on January 1, 20101, and the ten-year prevalence 
of aggressive NHL in the Netherlands, with 6,570 patients in the year 2009, is expected to 
increase to approximately 10,600 patients in 20202. Diffuse Large B-Cell Lymphoma (DLBCL) is 
the most common subtype, accounting for approximately 30-40% of NHL3, 4. 
Traditionally, treatment of DLBCL included the CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone) regimen5. With the addition of rituximab (R), response rates and overall survival 
have improved significantly, defining rituximab combined with CHOP (R-CHOP) as the new 
standard treatment for patients with DLBCL3, 6, 7 whereby CHOP every 14 days seemed superior 
to a 21-day schedule, with respect to overall survival8. However recently, two studies showed 
that overall survival in patients treated with R-CHOP14 was not superior to patients treated with 
R-CHOP219, 10. Patients with recurrent disease are treated with high-dose chemotherapy (HDCT) 
combined with autologous stem cell transplantation (ASCT). 
The increasing number of DLBCL patients that are being treated with changing treatment 
regimens requires careful evaluation not only of survival improvements, but also regarding 
potential side effects of treatment, and (long-term) health-related quality of life (HRQoL). 
HRQoL is a multidimensional construct that covers patients’ perceptions of his or her physical, 
emotional, social and cognitive functions and disease and/or treatment related symptoms and 
represents patients’ subjective experience with cancer. 
Up to now, some studies have investigated HRQoL among aggressive lymphoma patients11-13 and 
a few among DLBCL patients14, 15, however most studies were randomized clinical trials, or had a 
cross-sectional design. As a consequence, elderly patients and patients with comorbidities were 
underrepresented or HRQoL was only assessed at one time point. Furthermore, a comparison 
of (long-term) HRQoL between patients treated with (R-)CHOP14 or (R-)CHOP21 has never been 
made. 
The aims of the present study were therefore to (1) evaluate (long-term) HRQoL and symptoms/
worries of DLBCL patients on two time points in a population-based setting that includes 
these previously underrepresented patients and compare them with an age-and sex-matched 
normative population, (2) compare HRQoL and symptoms/worries between patients treated 
with (R-)CHOP14 or (R-)CHOP21 up to five years post-treatment, and (3) assess the prevalence 
of persistent symptoms/worries and identify associated clinical and/or socio-demographic 
characteristics. We hypothesized that HRQoL would be deteriorated in patients compared to 
the normative population. We furthermore hypothesized that patients treated with (R-)CHOP14 
would report a lower HRQoL and more symptoms than patients treated with (R-)CHOP21.





This study took place within the scope of the Population-based HAematological Registry for 
Observational Studies (PHAROS), an extension of the Netherlands Cancer Registry (NCR). 
The NCR was used to select all patients, who were diagnosed with DLBCL as defined by the 
International Classification of Diseases for Oncology-3 codes (ICD-O-3)16 between January 1, 
2004 and December 31, 2010 in an area covering approximately 40% of the Dutch population. 
The NCR-data of these patients (including date of diagnosis, morphology, gender, date of birth 
and stage) were replenished with details on treatment, adverse events and treatment outcomes 
from PHAROS. 
Additionally, a longitudinal population-based survey was set up among DLBCL patients registered 
with the Eindhoven Cancer Registry (ECR) which fills about 15% of NCR. The database with 
patients diagnosed between January 1, 2004 and December 31, 2010 was linked with the 
database of the Central Bureau for Genealogy to exclude patients who were deceased. HRQoL 
and symptoms were collected within PROFILES (Patient Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship). PROFILES is a registry for the study of 
the physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short and long-term cancer survivors17. 
Questionnaires were sent out in batches and this was done on three time points. In May 2009, 
patients diagnosed between January 2004 and January 2009 were included in the study and 
received the first questionnaire. In November 2009 and May 2011 patients newly diagnosed 
after the last inclusion date were subsequently invited to participate (T1) to include all patients 
up to December 31, 2010. Patients received the subsequent questionnaire (T2) one year after 
T1. Ethical approval for the study was obtained from a certified Medical Ethics Committee (of 
the Maxima Medical Centre in Veldhoven, The Netherlands; number 0734).
Study measures
The Dutch validated version of the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was used to assess HRQoL18. Answer 
categories range from one (not at all) to four (very much). After linear transformation, all scales 
and single item measures range in score from 0 to 100. A higher score on function scales and 
global health and quality of life scale implies a better HRQoL, whereas for symptoms a higher 
score refers to more symptoms18.
The Dutch version of the EORTC CLL-16 was used to assess disease and treatment-related specific 
symptoms and worries. This questionnaire was originally developed for patients with Chronic 
Lymphocytic Leukemia but is also applicable to lymphoma patients. The symptom tingling in 
hands/feet was added to this questionnaire, as it appeared from the literature and interactions 
with patients that this might be a prevalent symptom. Answer categories range from one (not 
at all) to four (very much).
Comorbidity at the time of survey was categorized according to the adapted Self-administered 
Comorbidity Questionnaire (SCQ)19. Patients’ marital status and educational level were also 
assessed in the questionnaire. Clinical data was obtained from the NCR and PHAROS.
If patients received more than one treatment line, the treatment category was based on the 
sum of treatments before completion of the questionnaire and were ordered from most to 
least expected impact on HRQoL. 1: autologous stem cell transplantation (ASCT), 2: high-dose 
chemotherapy (HDCT), 3: (R-)CHOP14, 4: (R-)CHOP21, 5: other chemotherapy (CT), radiotherapy 
(RT) or no therapy.
Normative population
The normative population was selected from a reference cohort of 2040 individuals from 
the general Dutch population (CentER panel). The set of questionnaires completed by this 
normative population in November 2011 included the EORTC QLQ-C30, SCQ and data on socio-
demographics. This cohort is considered representative for the Dutch-speaking population in 
the Netherlands20. Based upon this normative population an age- and sex-matched selection 
was made of 425 persons to compare HRQoL with the DLBCL patients. For matching, ten strata 
were formed using sex and age (5 categories). Within each stratum a maximum number of 
persons from the reference cohort were randomly matched according to the ‘strata frequency 
distribution’ of the patients. This resulted in 425 matched cancer-free panel members for 256 
patients.
Statistical analyses
Differences in socio-demographic and clinical characteristics between respondents and non-
respondents or patients with unverifiable addresses, between patients who completed one 
or two questionnaires, and between patients treated with (R-)CHOP14 or (R-)CHOP21 were 
compared with chi-square or t-tests, where appropriate. 
The mean QLQ-C30 scores from the DLBCL patients were compared with the mean scores of an 
age- and sex-matched Dutch normative population using independent sample t-tests.
Analyses of covariance (ANCOVA) were carried out to compare the mean QLQ-C30 scores and 
logistic regression analyses were used to compare the prevalence of CLL-16 symptoms and 
tingling in hands/feet between patients treated with (R-)CHOP14 or (R-)CHOP21 adjusted for 
age, number of comorbidities, time since treatment, and number of treatment cycles. Logistic 
regression analyses were also used to compare the prevalence of CLL-16 symptoms per time 
since treatment category stratified per treatment (i.e. (R-)CHOP14 or (R-)CHOP21), adjusted for 
age and number of comorbidities. Symptoms/worries were dichotomized as present (answer 
categories ‘a bit’, ‘quite a bit’ or ‘very much’) or not present (answer category ‘not at all’). 
Multivariate logistic regression analyses were constructed to investigate the independent 
association between socio-demographic and clinical variables and the five most frequently 
reported persistent symptoms/worries, and to assess the variance in the QLQ-C30 global health 
status/HRQoL scale explained by these symptoms/worries. Persistent symptoms/worries were 
defined by patients who had a specific symptom on both T1 and T2 and factors were a priori 
determined, including sex, age, number of comorbidities, time since diagnosis, stage, treatment 
and number of treatment cycles. Since we observed multi-collinearity between treatment and 
number of treatment cycles, we ran the analysis twice, once with treatment and once with 
number or treatment cycles. 
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Analyses of covariance (ANCOVA) were also carried out to compare the mean EORTC QLQ-C30 
global health status/HRQoL scale between patients with or without persistent symptoms/
worries adjusted for sex, age, number of comorbidities and time since diagnosis. Persistent 
symptoms were defined as symptoms present at both T1 and T2.
All statistical analyses were performed using SAS (version 9.3 for Windows; SAS Institute Inc., 
Cary, NC). P values of <0.05 were considered statistically significant. Clinically relevant differences 
were determined using the evidence-based guidelines for interpretation of the EORTC QLQ-C30 
between groups21. Patients were determined to be fatigued with an QLQ-C30 fatigue score >21.9 
(mean of age and sex matched normative population + small clinically important difference, 
i.e. 5 points).
results
Patients and normative population
Two hundred fifty-six DLBCL patients completed the first questionnaire (T1, 84% response rate; 
Figure 1) and subsequently, 130 patients completed the questionnaire again one year later (T2). 
The mean age at baseline survey completion was 63.5 years and 66% were male (Table 1). Mean 
time since diagnosis was 2.6 years and 93% of patients underwent one treatment line. (R-)
CHOP14 was received by 37% and (R-)CHOP21 by 50% of patients, the other 13% was treated with 
SCT, HDCT, other or no therapy. Two-third of patients reported one or more comorbid conditions, 
the most common were arthritis, back pain and hypertension. Patients treated with (R-)CHOP21 
were older, more often diagnosed with stage I, and had a longer time since diagnosis and time 
since treatment compared to patients treated with (R-)CHOP14.
With respect to the age- and sex matched normative population, mean age at baseline survey 
completion was 63.7 years and 66% was men. Almost two-third (66%) of respondents reported 
one or more comorbid conditions, the most common were hypertension and back pain. 
Quality of data
Non-response analysis
At baseline, non-respondents (N=48) and patients with unverifiable addresses (N=29) were 
more often female than respondents (60% and 66% versus 34%; p<0.01) and non-respondents 
were more often treated shorter than 12 months ago compared to respondents (48% versus 
27%; p=0.01). No statistically significant differences between these groups were observed for 
age, time since diagnosis, stage, treatment and number of treatment lines (data not shown).
Analysis between patients who completed one or more questionnaires
No statistically significant differences were observed between patients who completed one and 
patients who completed two questionnaires for QLQ-C30 global health and QoL score ( X =74.8 
versus X =72.9, p=0.47) or for sex, age, stage, (time since) treatment, comorbidities, marital 
status and educational level (data not shown).
 
 
933 patients diagnosed and registered with DLBCL 
between 1/1/2004 and 31/12/2010 and living in the 
region of ECR. 
 
647 patients remained of whom 333 were eligible i.e. 
older than 18 years at diagnosis and still alive at time of 
questionnaire mailing. 
 
Specialists’ from 18 hospital locations received an 
invitation letter to participate in the study. 
 
Addresses for the 333 eligible patients were checked 
for accuracy. 
 
304 patients received a questionnaire. 
 
256 patients returned a completed questionnaire 
(84%). 
Refusal of 2 general hospitals and 2 locations 
containing 260 patients in total. 
 
Exclusion of 26 patients (because of other 
medical problems) on advice of the specialists. 
 
29 unverifiable addresses (9%). 
 
48 patients did not complete the questionnaire 
(16%). 
 
Note. DLBCL=Diffuse Large B-Cell Lymphoma, ECR=Eindhoven Cancer Registry.
Figure 1. Flow chart of the data collection process.
HRQoL of DLBCL patients and the normative population
Compared to an age- and sex-matched normative population, responding DLBCL patients 
exhibited on average statistically significant and clinically relevant worse scores on QLQ-C30 
physical, role, cognitive and social functioning. DLBCL patients also reported more fatigue, 
dyspnea, sleeping problems, appetite loss, and financial problems compared to the matched 
norm (all p<0.05 and small clinically important differences; Figure 2).
HRQoL and symptoms/worries in relation to treatment
Patients treated with (R-)CHOP14 reported significantly more often tingling in hands and feet 
compared to patients treated with (R-)CHOP21 (42% versus 27%, p=0.02; adjusted for age, 
number of comorbidities, time since treatment and number of treatment cycles). Patients 
treated with (R-)CHOP14 also reported a statistically significant lower global health status/
quality of life compared to patients treated with (R-)CHOP21 (p=0.04; Table 2). Furthermore, 
significantly more patients with fatigue were identified in the (R-)CHOP14 group (46%) compared 
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Table 1. Clinical and socio-demographic characteristics of the total group of responding patients 




with HDCT ± 
ASCT, other CT, 













N (%) N (%) N (%) N (%) p-value
Gender 0.80
Male 169 (66) 26 (79) 60 (63) 83 (65)
Female 87 (34)   7 (21) 35 (37) 45 (35)
Age: mean (SD) 63.5 (13.4) 56.5 (15.1) 61.4 (13.2) 66.9 (12.0) <0.01
<55 years 58 (23) 12 (36) 26 (27) 20 (16)
55-65 year 70 (27) 12 (36) 27 (28) 31 (24)
66-75 year 87 (34)   7 (21) 34 (36) 46 (36)
75+ years 41 (16) 2 (6) 8 (8) 31 (24)
Years since diagnosis at time of 
questionnaire completion: mean 
(SD)
2.6 (1.3) 2.8 (1.5) 2.0 (1.1) 2.9 (1.2) <0.01
Months since treatment at time of 
questionnaire completion: median
21.0 24.0 16.3 29.2 <0.01
0-24 months since treatment 131 (51) 12 (36) 64 (67) 55  (43)
24+  months since treatment 112 (44) 11 (33) 29 (31) 72 (56)
Missing 13 (5) 10 (30) 2 (2) 1 (1)
Number of treatment lines 0.16
1st treatment line 228 (89) 14 (42) 91 (96) 123 (96)
Subsequent treatment line 17 (7)   8 (24) 4 (4)  5 (4)
Missing  11 (4) 11 (33) 0 (0)  0 (0)
Number of treatment cycles <0.01
< 6 cycles NA NA 12 (13) 35 (27)
≥ 6 cycles NA NA 82 (86) 92 (72)
Missing 1 (1) 1 (1)
Stage at diagnosis <0.01
I 85 (33) 15 (45) 15 (16) 55 (43)
II 60 (23)   6 (18) 21 (22) 33  (26)
III 56 (22)    6 (18) 31 (33) 19 (15)
IV 53 (21)   6 (18) 26 (27) 21 (16)
Missing 2 (1) 0 (0) 2 (2) 0 (0)
Self reported comorbidities 0.45
None 79 (31) 15 (45) 30 (32) 34 (27)
1 comorbidity 83 (32)   9 (27) 32 (34) 42 (33)
2 or more comorbidities 77 (30)   8 (24) 25 (26) 44 (34)
Missing 17 (7) 1 (3) 8 (8) 8 (6)
Marital Status 0.87
Partner 201 (79) 25 (76) 76 (80) 100  (78)
No partner   51 (20)   8 (24) 18 (19)   25 (20)
Missing   4 (2) 0 (0) 1 (1)   3 (2)
Education level$ 0.12
Low   41 (16) 2 (6) 14 (15) 25 (20)
Medium 151 (59) 19 (58) 53 (56) 79 (62)
High 60 (23) 11 (33) 27 (28) 22 (17)
Missing 4 (2) 1 (3) 1 (1) 2 (2)
Note. HDCT=High-Dose Chemotherapy, ASCT=Autologous Stem Cell Transplantation, CT=chemotherapy, 
RT=radiotherapy, (R-)CHOP=(Rituximab), cyclophosphamide, doxorubicin, vincristine, and prednisone. NA=Not 
Applicable. In the (R-)CHOP14 group, 2 patients were treated without rituximab and in the (R-)CHOP21 group 15 
patients were treated without rituximab. $Education levels included low = no/primary school; medium = lower 
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Note. *p<0.05; **p<0.05 and small clinically important differences 21; A higher score on functioning scores implies 
a better health-related quality of life, whereas a higher score on symptom scores refers to more symptoms. EORTC 
QLQ-C30= European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. 
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Figure 2. Differences on EORTC QLQ-C30 mean functioning, global quality of life and symptom scores 
between DLBCL patients (N=256) and an age- and sex-matched normative population (N=425) at T1.
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Table 2. Differences between DLBCL patients treated with (R-)CHOP14, (R-)CHOP21, ASCT, HDCT 












Patients treated with 
HDCT ± ASCT, other 
CT, RT or no therapy
N=33
EORTC CLL-16 N (%) N (%) p-value1 N (%)
Weight loss 18 (19) 16 (13) 0.29 3 (9)
Dry mouth 40 (42) 47 (38) 0.12 15 (47)
Bruises 8 (8) 9  (7) 0.86   4 (12)
Abdominal discomfort 31 (33) 40 (32) 0.94   8 (25)
Temperature up/down 14 (15) 16 (13) 0.91 2 (6)
Night sweats 27 (29) 44 (35) 0.58   8 (24)
Skin problems 37 (39) 55 (44) 0.66 15 (45)
Feeling ill or unwell 23 (24) 17 (13) 0.08   4 (12)
Feeling lethargic 33 (35) 39 (31) 0.08   8 (24)
Feeling slowed down 42 (44) 47 (37) 0.03 13 (39)
Limited in activities 32 (34) 37 (30) 0.15 12 (36)
Worried future health 55 (58) 60 (48) 0.05 20 (60)
Chest infections 14 (15) 19 (15) 0.17   9 (27)
Other infections 13 (14) 22 (17) 0.38 3 (9)
Repeated antibiotics 12 (13) 21 (17) 0.68   4 (12)
Worried about infections 22 (24) 27 (21) 0.62   9 (27)
Tingling hands/feet 40 (42) 34 (27) 0.02   9 (28)
EORTC QLQ-C30 Mean (SD) Mean (SD) p-value1 Mean (SD)
Physical Functioning 76.9 (22) 78.9 (21) 0.21 79.6 (23)
Role Functioning 75.1 (30) 79.4  (28) 0.16 73.2 (32)
Emotional Functioning 82.7 (19) 85.9 (19) 0.20 81.8 (22)
Cognitive Functioning 82.6 (23) 84.8 (20) 0.13 73.2 (28)
Social Functioning 80.7 (26) 84.4 (25) 0.21 77.3 (31)
Global health status/QoL 71.9 (22) 75.2 (19) 0.04 76.0 (18)
Fatigue 28.2 (27) 26.5 (26) 0.25 29.5 (27)
Nausea / Vomiting   5.6 (14)  4.1 (13) 0.55 2.5 (7)
Pain 18.4 (27) 14.4 (24) 0.22 14.1 (24)
Dyspnea 17.7 (28) 17.3 (26) 0.43 14.6 (22)
Insomnia 18.9 (29) 18.8 (29) 0.44 17.1 (22)
Appetite loss 13.0 (28) 8.6 (22) 0.19   1.0 (6)
Constipation   8.4 (23) 6.9 (19) 0.05   4.0 (14)
Diarrhea   7.4 (20) 5.6  (15) 0.13 2.0 (8)
Financial Problems 11.9 (22) 5.9 (17) 0.09 18.1 (32)
% Fatigued patients 46 % 35 % <0.01 44 %
Note. HDCT=High-Dose Chemotherapy, ASCT=Autologous Stem Cell Transplantation, CT=chemotherapy, 
RT=radiotherapy, (R-)CHOP=(Rituximab), cyclophosphamide, doxorubicin, vincristine, and prednisone. EORTC 
QLQ-C30= European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. 
DLBCL=Diffuse Large B-Cell Lymphoma; CLL-16=Chronic Lymphocytic Leukemia 16. 1p-value is adjusted for age, time 
since treatment, number of treatment cycles, and number of comorbidities.
EORTC CLL-16 Symptoms/worries were dichotomized as present (answer categories ‘a bit’, ‘quite a bit’ or ‘very 
much’) or not present (answer category ‘not at all’). Patients were fatigued if they had an EORTC QLQ-C30 fatigue 
score >23.1 (mean normative population + small clinically important difference, i.e. 5 points).
CHOP21 group (35%; p=0.03) and patients treated with (R)-CHOP14 also more often felt slowed 
down compared to patients treated with (R-) CHOP21 (44% versus 37%; p=0.03). No statistically 
significant differences were observed on the other HRQoL scales and symptoms. HRQoL scores 
and percentages of symptoms/worries of patients treated with HDCT, ASCT and other therapies 
are also displayed in Table 2, although numbers were too small to draw conclusions.
Prevalence of symptoms/worries
The most frequently reported symptoms/worries (by at least one-third of patients) on T1 were 
worry about future health (53%), skin problems (itching, dry skin; 42%), feeling slowed down 
(40%), dry mouth (40%), and tingling in hands and feet (33%). The prevalence of symptoms/
worries did not significantly differ per time since treatment category, except for skin problems 
which occurred more often among patients who received treatment more than three years ago 
(Figure 3). Furthermore, worry about future health and having a dry mouth seemed to occur 
more often among patients until one year after treatment.
Factors associated with persistent symptoms/worries and the relation with HRQoL
Of the patients who completed the questionnaire again one year later (N=130), persistent 
symptoms/worries were reported by 20-33% of patients. Multivariate logistic regression analyses 
showed that older patients and patients treated with (R-)CHOP14 more often had persistent 
tingling in hands and feet compared to patients treated with (R-)CHOP21 independently of the 
other characteristics. Persistent worry about future health and a persistent slowed down feeling 
was reported more often by patients with comorbid diseases (Table 3). Persistent skin problems 
more often occurred among patients diagnosed longer ago. Sex, disease stage and number of 
treatment cycles were not associated with any of the persistent symptoms/worries. Although, 
it seemed that, when studying the crude percentages, after the eighth cycle of (R-)CHOP14 
patients would report tingling in hands and feet more often compared to patients treated with 
less cycles (48% versus 32%) and for patients treated with (R-)CHOP21 the percentages were 
30% versus 25%.
Subsequently, patients who reported to be persistently slowed down, worrying about future 
health or having tingling hands or feet had statistically significantly and clinically relevant lower 
EORTC global health status/HRQoL compared to patients without these persistent symptoms/
worries (all p<0.01, data not shown).
discussion
HRQoL was lower among DLBCL patients compared to an age and sex-matched normative 
population, which confirms our hypothesis. Patients treated with (R-)CHOP14 reported tingling 
in hands and feet, fatigue, and slowed down feeling more often compared to patients treated 
with (R-)CHOP21. Patients treated with (R-)CHOP14 also reported a lower global health status/
quality of life compared to patients treated with (R-)CHOP21. The five most frequently reported 
symptoms/worries by at least one-third of patients were worry about future health, skin 
problems, feeling slowed down, having a dry mouth and having tingling in hands/feet. 





















Worry and symptoms 
0-1 year since treatment (N=66) 1-2 year since treatment (N=65)
2-3 year since treatment (N=53) 3-5 year since treatment (N=59)
* 
Note. *p<0.05; DLBCL=Diffuse Large B-Cell Lymphoma.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Subsequently, patients reporting one of these symptoms/worries exhibited significantly lower 
global health status/HRQoL compared to patients without these symptoms/worries.
Our results are in line with other studies comparing HRQoL between lymphoma patients and 
a normative population22-25, whereby physical functioning, appetite loss, fatigue and financial 
problems were most often affected. In the present study, also DLBCL patients treated >2 years 
ago were included, indicating that HRQoL is not only diminished at time of treatment but also 
thereafter.
Experiences of neuropathy among lymphoma patients were also observed by two other 
studies, although they did not compare patients treated with RCHOP14 versus RCHOP21. One 
small longitudinal study among 32 B-cell lymphoma patients treated with R-CHOP or R-CVP 
observed sensory neuropathy-associated symptoms among 84% and polyneuropathy among 
44% of patients26. The other longitudinal study observed a significant increase in peripheral 
neuropathy after the 6th cycle of CHOP compared to baseline11. We observed no statistically 
significant difference in tingling hands and feet according to number of treatment cycles. 
Although it seemed that, when studying the crude percentages, after the eighth cycle of (R-)
CHOP14 patients would report tingling in hands and feet more often compared to patients 
treated with less cycles. Further research should take this into account. An explanation for more 
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neuropathy complaints among patients treated with (R-)CHOP14 might be that these patients 
receive vincristine (whereby neuropathy is a known side-effect) in a quicker succession compared 
to patients treated with (R-)CHOP21. 
An explanation for the higher fatigue prevalence among the (R-)CHOP14 group compared to 
the (R-)CHOP21 group (47% versus 35%) is likely to be the higher toxicity and/or intensity of the 
(R-)CHOP14 treatment.
Patients who had comorbid diseases, were diagnosed longer ago, or were treated with (R-)CHOP14 
more often reported at least one persistent symptom. Subsequently, patients experiencing any of 
these symptoms/worries reported lower HRQoL compared to patients without these symptoms/
worries Therefore, these symptoms should be screened for and alleviated when possible to 
enhance patients HRQoL. 
The current study has some limitations: unfortunately, we did not have HRQoL and symptom 
scores of patients before treatment. Additionally, we could not compare HRQoL among patients 
treated in second line (HDCT or/and ASCT) due to small numbers and patients were enrolled 
in the study at different times since treatment and this time span was significantly different for 
patients treated with RCHOP14 versus RCHOP21. Although we controlled for time since treatment 
in the analysis, the variance in time since treatment between the two treatment groups remains 
an important point of concern. Furthermore, in the present study, neuropathy was only assessed 
with a single item. To better understand the prevalence and course of neuropathy, research with 
validated multi-item neuropathy questionnaires and/or nerve conduction tests is necessary. 
The strengths of our study are that we assessed HRQoL in a population-based setting that 
includes patients with comorbidities and elderly patients, resulting in a very representative 
group of DLBCL patients treated in daily practice. In addition, comparison with an age- and sex-
matched normative population provides important information about the impact of cancer and 
its treatment beyond the natural aging process and the impact of comorbidities. Furthermore, 
we assessed patients twice, which provides important information about the persistence of 
symptoms over time.
To our knowledge, this is the first study that compared HRQoL outcomes between patients 
treated with (R-)CHOP14 or (R-)CHOP21. Patients treated with (R-)CHOP14 more often reported 
tingling in hands and feet, were more often fatigued and had more often a slowed down feeling 
compared to patients treated with (R-)CHOP21. They furthermore reported a lower global health 
status/HRQoL. Based on these findings with respect to HRQoL, R-CHOP21 seems the preferred 
treatment in DLBCL patients. In addition, clinicians should be alert for symptoms that occur 
among DLBCL patients even long after diagnosis, as these symptoms have a negative influence 
on their HRQoL. 
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The increasing number of longer living patients with follicular lymphoma (FL) and serious side 
effects of treatment, urged us to study the health-related quality of life (HRQoL) and persistent 
(treatment-related) symptoms in unselected patients after different treatment modalities and 
compare HRQoL of patients with a normative population.
Methods 
The population-based Eindhoven cancer registry was used to select patients diagnosed with FL 
during 2004-2010. The European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a one-year interval. 
This questionnaire was also completed by a age-and sex-matched normative population (N=580). 
Detailed data on treatment were extracted from the cancer registry and Population-based 
HAematological Registry for Observational Studies (PHAROS).
Results 
Of the 181 patients who were invited, 148 responded (82%, T1). Patients treated with 
immunochemotherapy reported clinically relevant higher mean fatigue scores than those 
who underwent radiotherapy (p=0.02). No differences were observed on the other HRQoL 
scales between treatment groups. Mean HRQoL scores were worse for FL patients treated with 
immunochemotherapy compared to a normative population (p<0.01). A quarter to 50% of 
patients persistently reported to be slowed down, lethargic, or persistently worried about future 
health or was limited in social activities. Subsequently, patients reporting these symptoms/
worries had a lower global health status/HRQoL.
Conclusion 
Alertness for persistent symptoms that occur during and after treatment of FL patients is needed 
and may help to avoid lasting negative influence on their HRQoL.
introduction
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL), 
and represents 20-25% of all NHL with approximately 17,000 new diagnoses per year in the US 
and 850 in the Netherlands1, 2. Worldwide, it is estimated that there were approximately 770,000 
people alive in 2008, up to five years after their NHL diagnosis3. FL is often slowly growing and 
usually responds well to treatment, but is very hard to cure. There are several treatment options: 
radiotherapy (mostly stage I or early stage II), watchful waiting, or immunochemotherapy4, 5. 
Besides tumor control, the effect of therapy on (long-term) health-related quality of life (HRQoL) 
is of great importance for the individual patient. Up to now, several studies investigated HRQoL 
among patients with NHL in general or aggressive lymphoma6-14, however, research specifically 
focusing on FL patients is limited. This is important as different types of NHL have different 
prognosis and treatment modalities, which might affect patients HRQoL in different ways. Three 
cross-sectional studies investigating HRQoL among FL patients were identified15-17, whereby 
HRQoL was only assessed at one time point. Although this important research provides a 
good overview of the HRQoL of patients on a certain time point, the course of HRQoL and the 
persistence of symptoms over time remains unknown.
The aims of the present study were to 1) evaluate HRQoL and persistent symptoms/worries 
among unselected patients with FL after different treatment modalities in comparison with a 
normative population, 2) assess the prevalence of patients who report persistent symptoms/
worries over a one-year time span and assess their impact on global health/HRQoL. We 
hypothesized that HRQoL in patients would be inferior to a normative population and be lower 
when they underwent immunochemotherapy compared to patients treated with radiotherapy 
or patients under watchful waiting. We furthermore hypothesized that patients with persistent 




This study took place within the scope of the Population-based HAematological Registry for 
Observational Studies (PHAROS), an extension of the Netherlands Cancer Registry (NCR). 
The NCR was used to select all patients in an area covering approximately 40% of the Dutch 
population, who were diagnosed with FL as defined by the International Classification of Diseases 
for Oncology-3 codes (ICD-O-3) between January 1, 2004 and December 31, 201018. The NCR-data 
of these patients (including date of diagnosis, morphology, gender, date of birth and stage) were 
replenished with details on treatment, adverse events and treatment outcomes from PHAROS. 
Additionally, a longitudinal population-based survey was set up among FL patients registered 
with the Eindhoven Cancer Registry (ECR) which is part of NCR. The database with patients 
diagnosed between January 1, 2004 and December 31, 2010 was linked with the database of the 
Central Bureau for Genealogy to exclude patients who were deceased. HRQoL and symptoms 
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were collected within PROFILES (Patient Reported Outcomes Following Initial treatment and 
Long term Evaluation of Survivorship). PROFILES is a registry for the study of the physical and 
psychosocial impact of cancer and its treatment from a dynamic, growing population-based 
cohort of both short and long-term cancer survivors19. 
In May 2009, patients newly diagnosed between January 2004 and January 2009 were included 
in the study and received the first questionnaire. In November 2009 and May 2011 patients newly 
diagnosed after the last inclusion date were subsequently invited to participate (T1) to include 
all patients diagnosed up to December 31, 2010. Patients received the subsequent questionnaire 
(T2) one year after T1. Ethical approval for the study was obtained from a certified Medical Ethics 
Committee (of the Maxima Medical Centre in Veldhoven, The Netherlands; number 0734).
Study measures
The Dutch validated version of the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was used to assess HRQoL20. Answer 
categories range from one (not at all) to four (very much). After linear transformation, all scales 
and single item measures range in score from 0 to 100. A higher score on function scales and 
global health and quality of life scale implies a better HRQoL, whereas for symptoms a higher 
score refers to more symptoms20.
The Dutch version of the EORTC CLL-16 was used to assess disease and treatment-related 
specific symptoms and worries. This questionnaire, originally developed for patients with 
Chronic Lymphocytic Leukemia, was used in the absence of a true non-Hodgkin lymphoma 
questionnaire. After discussion with specialists treating both CLL and FL patients we decided to 
administer the questionnaire since most problems are both applicable for CLL and FL patients. 
Tingling in hands/feet was added to this questionnaire, as it appeared from the literature and 
from comments of patients on earlier questionnaires. Answer categories range from one (not 
at all) to four (very much).
Comorbidity at the time of survey was categorized according to the adapted Self-administered 
Comorbidity Questionnaire (SCQ)21. Patients’ marital status and educational level were also 
assessed in the questionnaire. Clinical data was obtained from the NCR and PHAROS.
Patients who received one treatment line or received the same treatment line twice were 
categorized according to their treatment. For patients who received two or more different 
treatment lines, the treatment category was based on the sum of treatments before completion 
of the questionnaire. Patients were categorized in the group of most expected impact on 
HRQoL: 1: (rituximab), cyclophosphamide, doxorubicin, vincristine, prednisone ((R-)CHOP), 2: 
(rituximab), cyclophosphamide, vincristine, prednisone ((R-)CVP) or (rituximab), chlorambucil 
((R-)chlorambucil),3: Radiotherapy. For example, if patients received (R-)CVP followed by (R-)
CHOP before completion of the questionnaire they were classified as (R-)CHOP.
Normative population
The normative population was selected from a reference cohort of 2040 individuals from 
the general Dutch population (CentER panel)22. The set of questionnaires completed by this 
normative population in November 2011 included the EORTC QLQ-C30, SCQ and data on socio-
demographics. This cohort is considered representative for the Dutch-speaking population in 
the Netherlands. From this normative population an age- and sex-matched selection was made 
of 580 persons to compare HRQoL with the FL patients. For matching, ten strata were formed 
using sex and age (5 categories). Within each stratum a maximum number of persons from the 
reference cohort were randomly matched according to the strata frequency distribution of the 
patients. This resulted in 580 matched cancer-free individuals for 148 patients.
Statistical analyses
Differences in socio-demographic and clinical characteristics between respondents and non-
respondents (never completed a questionnaire) or patients with unverifiable addresses on T1 
were assessed with a chi-square or t-test, where appropriate. Differences in socio-demographic 
and clinical characteristics between patients who completed one questionnaire or patients 
who completed two questionnaires on T1 were also assessed with a chi-square or t-test, where 
appropriate.
The mean EORTC QLQ-C30 scores from the FL patients were compared with an age- and sex-
matched Dutch normative population using independent sample t-tests.
Analyses of covariance (ANCOVA) were carried out to compare the mean EORTC QLQ-C30 scores; 
logistic regression analyses were used to compare the prevalence of EORTC CLL-16 symptoms 
and tingling in hands/feet between patients treated with different therapies adjusted for age and 
time since diagnosis. Logistic regression analyses were also used to compare the prevalence of 
EORTC CLL-16 symptoms per period since treatment. Symptoms/worries were dichotomized as 
present (answer categories ‘a bit’, ‘quite a bit’ or ‘very much’) or not present (answer category 
‘not at all’). 
Analyses of covariance (ANCOVA) were also carried out to compare the mean EORTC QLQ-C30 
global health status/HRQoL scale between patients with or without persistent symptoms/
worries adjusted for sex, age, number of comorbidities and time since diagnosis. Persistent 
symptoms were defined as symptoms present at both T1 and T2. Logistic regression analyses 
were used to evaluate if age, sex, comorbidity and time since diagnosis were associated with 
persistent symptoms.
Statistical analyses were performed using SAS (version 9.3 for Windows; SAS Institute Inc., Cary, 
NC). P values of <0.05 were considered statistically significant. The evidence-based guideline 
for interpretation of the EORTC QLQ-C30 was used to determine clinical relevant differences 
between groups. This guideline defines a minimum number of points that is required to detect 
a clinical relevant difference. These differences range for example from at least 3 points for the 
cognitive functioning scale and at least 5 points for the fatigue scale23. Patients were determined 
to be fatigued with an EORTC QLQ-C30 fatigue score >22.6 (i.e. mean of normative population 
+ minimal required difference of 5 points).
results
Patients and normative population 
One hundred forty eight FL patients completed the first questionnaire (T1, 82% response rate; 
Figure 1) and subsequently, 92 patients again one year later (T2, 50%). Mean age at T1 was 
59 years and 57% were male. Mean time since diagnosis was 2.6 years and 77% of patients 
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underwent one treatment line. (R-)CVP was received by 35%, (R-)CHOP by 25%, (R-)chlorambucil 
by 6%, and radiotherapy by 16% of patients. The other patients were under watchful waiting 
(13%) or received other or no treatment (5%). On T1, 140 patients (95%) were no longer receiving 
active treatment or maintenance therapy, and on T2 this was 93%. Two-third of patients reported 
one or more comorbid conditions, the most common being arthritis, back pain and hypertension. 
Patients who underwent radiotherapy were more often diagnosed with early stage disease 
compared to patients treated otherwise (Table 1).
With respect to the age- and sex-matched normative population, mean age was 59 years and 61% 
were men. Almost two-third (66%) of respondents reported one or more comorbid conditions, 
the most common were hypertension and back pain. 
Quality of data
Non-response analysis
At T1, no statistically significant differences were observed between respondents and non-
respondents (N=33) and between respondents and patients with unverifiable addresses (N=35) 





461 patients diagnosed and registered with FL between 
1/1/2004 and 31/12/2010 and living in the region of 
ECR. 
 
297 patients remained of which 216 were eligible i.e. 
older than 18 years at diagnosis and still alive at time of 
questionnaire mailing. 
 
Specialists’ from 18 hospital locations received an 
invitation letter to participate in the study. 
 
Addresses for the 216 eligible patients were checked 
for accuracy. 
 
181 patients received a questionnaire. 
 
148 patients returned a completed questionnaire 
(82%). 
Refusal of 2 general hospitals and 2 locations 
containing 111 patients. 
 
Exclusion of 53 patients (because of other 
medical problems) on advice of the specialists. 
 
35 unverifiable addresses. 
 
33 patients did not complete the questionnaire. 
 
Note. FL=Follicular Lymphoma, ECR=Eindhoven Cancer Registry.
Figure 1. Flow chart of the data collection process.



























N (%) N (%) N (%) N (%) N (%) p-value
Gender 0.92
Male 11 (58) 12 (52) 37 (61) 22 (59) 3 (38)
Female 8 (42) 11 (48) 24 (39) 15 (41) 5 (63)
Age (at time of survey) (mean±SD) 59 (13) 62 (12) 60 (12) 58 (14) 59 (15) 0.52
<45 years 2 (11) 2 (9) 14 (23) 7 (19) 3 (38)
45-60 years 7 (37) 7 (30) 13 (21) 12 (32) 1 (13)
61-75 years 8 (42) 11 (48) 23 (38) 14 (38) 2 (25)
75+ years 2 (11) 3 (13) 11 (18) 4 (11) 2 (25)
Time since diagnosis (mean±SD) 2.2 (1.1) 2.6 (1.2) 2.6 (1.3) 2.8 (1.3) 3.0 (1.3) 0.95
Time since treatment 0.13
0-1 year since treatment NA 2 (9) 21 (36) 12 (32) Missing
1-2 year since treatment NA 14 (61) 19 (32)   9 (24) Missing
2-3 year since treatment NA 1 (4) 7 (12)   5 (14) Missing
3-5 year since treatment NA   6 (26) 12 (20) 11 (30) Missing
Number of treatment lines 0.15
1st treatment line 19 (100) 19 (86) 43 (70) 26 (70) 6 (86)
Subsequent treatment line 0 (0)   3 (14) 18 (30) 11 (30) 1 (14)
Stage at diagnosis <0.01
I 1 (5) 17 (74) 2 (3) 4 (11) 2 (25)
II  5 (26) 3 (13) 10 (16) 6 (16) 1 (13)
III 7 (37) 2 (9) 17 (28) 6 (16) 4 (50)
IV 6 (32) 1 (4) 32 (52) 21 (57) 1 (13)
Selfreported comorbidities 0.92
No comorbidities 7 (37) 8 (36) 19 (33) 9 (27) 3 (43)
1 comorbidity 6 (32) 6 (27) 17 (30) 8 (24) 3 (43)
2 or more comorbidities 6 (32) 8 (36) 21 (37) 16 (48) 1 (14)
Marital Status 0.24
Partner 15 (79) 16 (73) 47 (77) 33 (92) 6 (75)
No partner 4 (21) 6 (27) 14 (23) 3 (8) 2 (25)
Education level$ 0.45
Low 4 (22) 5 (24) 5 (8) 3 (8) 0 (0)
Medium 10 (56) 11 (52) 40 (67) 24 (65) 4 (57)
High 4 (22) 5 (24) 15 (25) 10 (27) 3 (43)
Note. (R-)CVP=rituximab, cyclophosphamide, vincristine, prednisone; (R-)CHOP=rituximab, cyclophosphamide, 
doxorubicin, vincristine, prednisone; (R-)chlorambucil=rituximab, chlorambucil; NA=not applicable; $Education levels 
included low= no/primary school; medium= lower general secondary education/vocational training; or high= pre-
university education/ high vocational training/university.
Analysis between patients who completed one or more questionnaires
FL patients who completed two questionnaires had a significantly longer mean time since 
diagnosis at time of first enrollment than patients who completed only one questionnaire (2.8 
versus 2.3 years, p=0.04). Patients who completed two questionnaires also more often had a 
partner (85% versus 70%, p=0.02). No statistically significant differences were observed between 
these groups for global health status/QoL score at first questionnaire completion ( X =74 versus 
X =71, p=0.37) or for sex, age, stage, treatment, comorbidities, and educational level (data not 
shown).
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Comparison HRQoL of FL patients with the normative population
FL patients with a watchful waiting approach reported significantly and clinically relevant higher 
fatigue mean scores compared to the age- and sex-matched normative population (p=0.02, 
Figure 2). They also had lower mean scores on other HRQoL scales, although not statistically 
significant. No statistically significant differences were observed between FL patients who 
underwent radiotherapy and the normative population. FL patients treated with (R-)CVP/(R-)
chlorambucil reported significantly and clinically relevant deteriorated mean scores on all HRQoL 
scales except for pain and constipation; patients treated with (R-)CHOP reported significantly and 
clinically relevant deteriorated mean scores on all HRQoL scales except for global health status, 
pain, appetite loss and diarrhea (Figure 2). Cognitive and social functioning, fatigue, dyspnea 
and sleeping problems were the most affected HRQoL domains in patients treated with (R-)
CVP/(R-)chlorambucil or (R-)CHOP. 
HRQoL and symptoms/worries in relation to treatment
Patients treated with (R-)CHOP or (R-)CVP/(R-)chlorambucil reported statistically significant and 
clinically relevant higher mean fatigue scores compared to patients who underwent radiotherapy 
(p=0.02; Figure 2). No statistically significant differences were observed on the other HRQoL 
scales or on the symptoms/worries between the treatment groups (Figure 2 and Table 2). A 
sub analysis between patients who were under wait and see (n=19), who underwent one active 
treatment line (n=94)) and patients who underwent 2 or more active treatment lines (n=33) 
showed no differences on HRQoL (data not shown).
The most frequently reported symptoms/worries (by at least one-third of all patients) on T1 were 
worry about future health (65%), feeling slowed down (48%), skin problems (46%), night sweats 
(43%), abdominal discomfort (38%), being limited in social activities (35%), feeling lethargic (35%) 
and having a dry mouth (33%; Table 3). Although not significantly different, the prevalence of 
symptoms/worries seemed highest among patients up to one year after treatment (data not 
shown). 
Persistent symptoms/worries and the relation with HRQoL
The most frequently reported persistent symptoms (i.e. symptoms present at T1 and T2) by 
patients who completed the questionnaire again one year later, were worry about future health 
(51%), night sweats (35%), feeling slowed down (34%), skin problems (30%), feeling lethargic 
(25%), abdominal discomfort (24%), being limited in social activities (23%), and having a dry 
mouth (23%, Table 3). Furthermore, it was observed that that 2-20% of patients reported an 
improvement of symptoms from T1 to T2 and 8-17% of patients reported a deterioration of 
symptoms (Table 3). 
Patients who reported to be persistently slowed down, lethargic, being limited in social activities 
or worrying about future health had statistically significantly and clinically relevant lower EORTC 
global health status/HRQoL compared to patients without these persistent symptoms/worries 
(Figure 3; all p<0.01). These four symptoms were furthermore more often reported by patients 
with comorbid conditions. Persistent worry about future health was also reported more often 
by younger patients. Sex and time since diagnosis were not associated with the presence of 
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* * * 
* 
Note. *p<0.05 for: FL patients treated with (R-)CHOP compared to the normative population for physical, role, 
emotional, cognitive and social functioning. FL patients treated with (R-)CVP/(R-)Chlorambucil compared to the 
normative po ulation for physical, role, emotional, cognitive and social functioning and global quality of life.
Note. *p<0.05 for: FL patients under active surveillance compared to the normative population for fatigue. FL patients 
treated with (R-)CHOP compared to the normative population for fatigue, dyspnea, insomnia, constipation and 
financial problems. FL patients treated with (R-)CVP/(R-)Chlorambucil compared to the normative population for 
fatigue, dyspnea, insomnia, appetite loss, constipation, diarrhoea and financial problems. FL patients treated with 
(R-)CVP/(R-)Chlorambucil or (R-)CHOP compared to FL patients treated with radiotherapy. 
Figure 2. Differences on EORTC QLQ-C30 mean functioning, global quality of life and symptom 
scores between FL patients according to treatment schedule and an age- and sex-matched 
normative population (N=580).
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Table 2. Differences between FL patients under active surveillance, treated with radiotherapy,  (R-)




















EORTC CLL-16 N (%) N (%) N (%) N (%) p-value*
Weight loss 3 (16) 4 (18) 14 (23) 6 (16) 0.54
Dry mouth 6 (32) 6 (27) 22 (37) 13 (35) 0.79
Bruises 3 (17)     2 (9) 5 (8) 1 (3) 0.33
Abdominal discomfort 5 (26) 6 (27) 23 (38) 21 (57) 0.05
Temperature up/down 11 (58)     2 (9) 7 (12) 7 (19) 0.27
Night sweats 7 (37) 6 (27) 27 (45) 17 (46) 0.82
Skin problems 8 (42) 8 (38) 31 (52) 18 (49) 0.74
Feeling ill or unwell 6 (32) 4 (19) 17 (28) 4 (11) 0.08
Feeling lethargic 8 (42) 5 (24) 28 (47) 11 (30) 0.18
Feeling slowed down 6 (32) 6 (29) 36 (60) 18 (49) 0.22
Limited in activities 6 (32) 5 (23) 23 (39) 16 (43) 0.52
Worried future health 14 (74) 11 (50) 40 (66) 27 (73) 0.48
Chest infections 4 (22) 3 (14) 14 (24) 7 (19) 0.86
Other infections 3 (17)     2 (9) 10 (17) 4 (11) 0.53
Repeated antibiotics 2 (11) 3 (14) 10 (17) 5 (14) 0.98
Worried about infections 5 (28) 3 (14) 13 (22) 13 (35) 0.08
Tingling hands/feet 4 (21) 4 (18) 18 (30) 8 (22) 0.72
Note. FL=Follicular Lymphoma; (R-)CVP=rituximab, cyclophosphamide, vincristine, prednisone; (R-)CHOP=rituximab, 
cyclophosphamide, doxorubicin, vincristine, prednisone; (R-)Chlorambucil=rituximab, chlorambucil; EORTC CLL-
16=European Organisation for Research and Treatment of Cancer Chronic Lymphocytic Leukemia-16 questionnaire.
*p-value adjusted for age and time since diagnosis.
discussion
HRQoL was lower among FL patients treated with (R-)CHOP or (R-)CVP/(R-)chlorambucil 
compared to a normative population, which confirms what we expected. Patients under active 
surveillance or those who underwent radiotherapy reported similar HRQoL compared to 
the normative population, except for fatigue. Patients treated with (R-)CHOP or (R-)CVP/(R-)
chlorambucil reported fatigue more often compared to patients treated with radiotherapy. A 
quarter to 50% of patients reported persistent symptoms/worries which also affected their 
EORTC global health status/HRQoL negatively. About one third of patients reported fluctuating 
symptoms, of which 2-20% reported an improvement and 8-17% deterioration.  
Among 124 German patients a lower HRQoL was also observed between FL patients and a 
normative healthy population15. Studies comparing HRQoL between lymphoma patients in 





















































































































































































































































































































































































































































































































































































































































































































































































































 mean score 
Worry and symptoms 
Patients with symptom/worry Patients without symptom/worry
* * * * 
Note. EORTC QLQ-C30= European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-
Core 30. Symptoms/worries were dichotomized as present (answer categories ‘a bit’, ‘quite a bit’ or ‘very much’) or 
not present (answer category ‘not at all’). Persistent symptoms were defined as symptoms present at both T1 and T2.
*P-value <0.01; adjusted for sex, age, number of comorbidities and time since diagnosis
Figure 3. EORTC QLQ-C30 global health status/HRQoL scores of patients with persistent symptoms/
worries and patients without persistent symptoms/worries. 
Two studies also compared HRQoL between treatment regimes, although the majority of the 
included patients received several treatment lines compared to 77% with one treatment line in 
our study. FL patients who received high-dose chemotherapy and autologous stem cell transplant 
reported better HRQoL on two domains, i.e. social functioning and pain compared with patients 
after R-CHOP15. An American study among 137 FL patients observed that after frontline therapy 
no difference in HRQoL was observed between patients treated with rituximab maintenance 
therapy versus patients under active surveillance26. Our observation that FL patients who 
underwent immunochemotherapy reported fatigue more often compared to patients after 
radiotherapy can also result from the extensiveness of the disease, although there was no/little 
difference in HRQoL between patients who underwent one or more treatment line. 
We observed no significant differences in the prevalence of symptoms/worries with respect to 
time since treatment. This is in line with a study among 761 NHL survivors focusing on HRQoL13. 
A study among 459 Hodgkin lymphoma patients even observed that patients 7-10 years after 
diagnosis reported higher anxiety and depression scores compared to patients 3-6 years after 
diagnosis27. So, while lymphoma survivors may be expected to return to normal life soon after 
treatment ends, there is growing evidence that they continue to be burdened by the physical 
and psychosocial effects of the cancer and related treatment. 
FL patients who persistently reported to be slowed down or even lethargic scored on average 20 
points lower on global health status/HRQoL than patients without these complaints. Fatigue is 
a common problem among a variety of cancer patients28-30 as also among lymphoma patients31 
and it is associated with decreased HRQoL32, high levels of psychological distress33, 34 and has an 
effect on patient’s daily life. Healthcare providers should be encouraged to inquire about the 
presence of this symptom as fatigued patients may benefit from pharmacologic and/or non-
pharmacologic treatments, such as cognitive-behavioral interventions and exercise35.
The current study has some limitations: although the response rate at T1 was high (82%), 
the response on T2 was much lower. Patients who completed two questionnaires were more 
often diagnosed longer ago. This could imply survivorship bias, i.e. only patients who survived 
could participate a year later. Furthermore, the sample size of some treatment categories was 
small, which made it more difficult to draw conclusions on HRQoL with respect to variation 
in treatment. For example, FL patients under active surveillance did not report statistically 
significant different mean scores compared to the normative population. Although, the mean 
scores were substantially lower for physical, role, cognitive and social functioning and higher for 
insomnia and p-values were between 0.06 and 0.09. This might be a result of the small sample 
size, therefore, research with larger samples is recommended to study if FL patients under active 
surveillance in fact report a deteriorated HRQoL.
The strengths of our study are that we assessed HRQoL in a population-based setting that 
includes patients with comorbidities and elderly patients, resulting in a very representative 
group of FL patients treated in daily practice. In addition, comparison with an age- and sex-
matched normative population provides important information about the impact of cancer 
beyond the natural aging process and the impact of comorbidities. Furthermore, we assessed 
patients at two time points, which provides important information about the persistence of 
symptoms over time.
In conclusion, up to five years after diagnosis FL patients treated with (R-)CHOP or (R-)CVP/(R-)
chlorambucil still report a substantially lower HRQoL compared to an age- and sex-matched 
normative population. Furthermore, a quarter to 50% of patients persistently reported to be 
slowed down, lethargic, or persistently worried about future health or was limited in social 
activities. Subsequently, patients reporting these symptoms/worries had a lower global health 
status/HRQoL. Alertness for persistent symptoms that occur during and after treatment of FL 
patients is needed and may help to avoid lasting negative influence on their HRQoL.
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As survival of patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/
SLL) increases and the number of patients who live long rises, health-related quality of life 
(HRQoL) becomes a relevant endpoint. Few studies investigated this, mainly as a secondary 
endpoint in randomized clinical trials where patients with early stage CLL/SLL, and elderly/frail 
patients were underrepresented. The aim of our study was to assess HRQoL in a population-
based setting, including these previously underrepresented patients.
Out of 175 patients diagnosed with CLL/SLL between 2004 and 2011, 136 (78%) returned 
the HRQoL-questionnaire. The outcomes were compared to an age- and sex-matched norm 
population. Detailed data on stage and treatment were extracted from a population-based 
hematological registry (PHAROS). 
Patients ever treated for CLL/SLL reported significantly poorer HRQoL than the norm population 
(p<0.01) with large clinically important differences. Interestingly, no differences were observed 
between the norm population and patients under active surveillance. In contrast to our 
hypothesis, patients treated with chlorambucil reported the lowest HRQoL scores. 
Drastic, long-lasting negative effects of starting treatment on HRQoL can not be excluded, 
whereas active surveillance does not seem to provoke worrying, anxiety, or depressive 
symptoms. Therefore, it seems wise to conduct elaborate research into the impact of starting 
therapy on HRQoL, especially in patients that are underrepresented in most clinical trials, and 
thoroughly consider its results during revision of treatment guidelines. 
introduction
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in adults in western 
countries, both in terms of incidence and prevalence, with more than 700 diagnoses per year in 
the Netherlands. The incidence in Europe is 4.9 per 100,000 person years1. Small Lymphocytic 
Lymphoma (SLL) is an indolent form of non-Hodgkin Lymphoma with morphological and 
immunophenotypic features similar to CLL. Hence, the most recent World Health Organization 
(WHO) classification scheme for hematopoietic malignancies considers CLL and SLL to be different 
manifestations of the same disease and combines these entities into one disease category; 
CLL/SLL2. Median survival time is 10 years, ranging from months when the disease behaves 
aggressively, to decades for patients with an indolent course of the disease3. Approximately 
70% of the patients is older than 65 years at the time of diagnosis4.
Active surveillance remains standard practice for patients with asymptomatic, early stage CLL/
SLL, as randomized clinical trials (RCTs) failed to show a statistically significant difference in 
survival between early versus deferred therapy5. For young and more or less fit patients with 
advanced disease, fludarabine, cyclophosphamide, and rituximab (FCR) became standard first 
line treatment, after a phase III study showed improvement of survival after addition of a 
monoclonal antibody in 20106. During the study period, chlorambucil was the first choice for 
elderly and/or frail patients, as up until  recently, no RCTs with this group of patients showed 
improved therapeutic results over chlorambucil7, 8. In 2014, the results of the CLL11-trial were 
published, which showed that combining an anti-CD20 antibody with chemotherapy improves 
outcomes in patients with CLL and coexisting conditions9. 
Since the number of CLL/SLL patients who live long after their diagnosis is rising (due to 
improvement of response to treatment and survival rates), health-related quality of life (HRQoL) 
is a relevant endpoint.  Up to now, few studies have investigated HRQoL in CLL/SLL patients10-12, 
most as part of  randomized clinical trials13, underrepresenting patients with early stage CLL/
SLL, elderly patients and patients with comorbidities. 
The aim of the present study was therefore to assess HRQoL in a population-based setting that 
includes these previously underrepresented patients. We evaluated HRQoL among patients on 
and off treatment with different treatment modalities and subsequently compared this with 
an age-and sex-matched norm population to assess the effect of CLL. We hypothesize that 
patients who received chlorambucil report better HRQoL than patients receiving other chemo-/
immunotherapy, as chlorambucil is associated with less toxicity then most other regimens14. 
We expect patients in the active surveillance group to report better HRQoL than patients that 
were treated, as patients who are under active surveillance may suffer from symptoms from the 
disease but not from symptoms or side effects of active treatment. Furthermore, we expect that 
patients who were undergoing treatment during survey completion to report a worse HRQoL 
than patients who were off treatment, as they experience more effect of the disease on their 
daily life during treatment. Finally, we expected that active surveillance without treatment 
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provokes feelings of uncertainty; leading to worrying, anxiety and depressive symptoms as this 
was observed in men with prostate cancer under active surveillance15.
patients and methods
Setting and population
This study took place within the scope of the Population-based HAematological Registry for 
Observational Studies (PHAROS; www.pharosregistry.nl). PHAROS is a supplement to the 
Netherlands Cancer Registry (NCR), which is maintained and hosted by Comprehensive Cancer 
Centre South (CCCS) and Comprehensive Cancer Centre the Netherlands (CCCNL). The NCR 
was used to select all patients in an area covering approximately 40% of the Dutch population, 
who were diagnosed with CLL or SLL as defined by the International Classification of Diseases 
for Oncology-3 codes (ICD-O-3)16 between January 1st, 2004 and January 1st, 2011. The NCR-data 
of these patients were replenished with details on stage, (response to) treatment and adverse 
events. 
Additionally, a dynamic longitudinal population-based survey was set up among CLL/SLL patients 
registered with the Eindhoven Cancer Registry (ECR) of the CCCS, which is a component of NCR. 
Patients diagnosed between January 1st, 2004 and January 1st, 2011 were linked with the database 
of the Central Bureau for Genealogy, which collects data on all deceased Dutch citizens through 
the civil municipal registries, to exclude patients who had deceased. In this survey, patient 
reported outcomes were collected within PROFILES (Patient Reported Outcomes Following 
Initial treatment and Long term Evaluation of Survivorship). PROFILES is a registry for the study 
of the physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short and long-term cancer survivors. PROFILES contains a 
large web-based component and is linked directly to clinical data from ECR. Details of the data 
collection method are previously described17. Data from the PROFILES registry are available 
for non-commercial scientific research, subject to study question, privacy and confidentiality 
restrictions, and registration (www.profilesregistry.nl).
Ethical approval for the study was obtained from a certified Medical Ethics Committee (of the 
Maxima Medical Centre in Veldhoven, The Netherlands; number 0734).
Study measures
General information was available from the NCR that routinely collects data on tumor 
characteristics, including date of diagnosis and morphology, and patient’s background 
characteristics, including gender and date of birth. Detailed clinical information was available 
from the PHAROS-registry that collects additional data including stage and treatment.
We divided patients in treatment categories with hypothesized impact on HRQoL, from most to 
least: 1) ‘R-CHOP’, ‘FC(R)’, ‘(R-)CVP / Rituximab (+/- chlorambucil) / fludarabine monotherapy’, 
(indicated as ‘other chemo- and/or immunotherapy’) 2) ‘chlorambucil’, 3) ‘Radiotherapy’, 4) 
‘Active surveillance’, and 5) ‘No treatment’ (e.g. patients who fulfill treatment criteria but refuse 
therapy).  Patients were considered off treatment if the most recent therapy was administered 
more than three months prior to the date of filling in the questionnaire. Otherwise, patients 
were considered on treatment.  
The Dutch validated version of the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) was used to assess HRQoL18. Answer 
categories range from one (not at all) to four (very much). After linear transformation, all scales 
and single item measures range in score from 0 to 100. A higher score on function scales and 
global health and quality of life scale implies a better HRQoL, whereas for symptoms a higher 
score refers to more symptoms18.
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS). 
In this questionnaire, anxiety and depressive symptoms are measured in two separate subscales 
of seven items each. Answers range from 0 to 3, and a score ≥8 on either subscale indicates a 
substantial level of anxiety or depressive symptoms19, 20.
Worry was assessed with the items ‘Worry about future’, ‘Worry about health’, ‘Worry about 
cancer coming back’ and ‘Worry when new symptoms occur’ of the Impact of Cancer Scale (IOC). 
This measure presents statements to which respondents indicate their level of agreement from 
1 (strongly disagree) to 5 (strongly agree)21, 22. 
Co-morbidity at the time of survey was categorized according to the Self-Administered 
Comorbidity Questionnaire (SCQ). Survivors’ marital status and educational level were also 
assessed in the questionnaire. 
Data collection
Patients were included on three time points: May 2009 (patients diagnosed between January 
1999 and May 2008); November 2009 (patients diagnosed between May 2008 and May 2009) 
and May 2011 (patients diagnosed between May 2009 and December 2010).
In order to compare outcomes with those from a normative population we also collected the 
EORTC QLQ-C30, SCQ23, marital status and educational level data among 1352 persons without 
cancer24. From this normative population an age- and sex-matched selection was made of 209 
persons to compare HRQoL with the CLL patients. For matching, ten strata were formed using sex 
and age (5 categories). Within each stratum, a maximum number of persons from the reference 
cohort were randomly matched according to the strata frequency distribution of the patients. 
This resulted in 209 matched cancer-free individuals for 136 patients.
Statistical analyses
All statistical analyses were performed using SAS (version 9.3 for Windows; SAS Institute Inc., 
Cary, NC). P values of <0.05 were considered statistically significant. Clinically relevant differences 
were determined using the evidence-based guidelines for interpretation of the EORTC QLQ-C30 
between groups25. 
Patients were determined to be fatigued with an EORTC QLQ-C30 fatigue score >21.9 (mean 
normative population + small clinically important difference, i.e. 5 points) and low physical 
functioning was defined as an EORTC QLQ-C30 score <83.2 (mean normative population - small 
clinically important difference, i.e. 5 points). Patients were considered having anxious symptoms 
with a HADS anxiety score >8 and having depressive symptoms with a HADS depression score 
>820. Worry about health and worry about future were considered positive if patients (strongly) 
agreed with this item.
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Differences in demographic and clinical characteristics between respondents, non-respondents, 
and patients with unverifiable addresses and between treatment groups were compared with 
chi-square analyses and Fisher exact with Montecarlo estimate tests. 
Differences in mean EORTC QLQ-C30 scores between CLL/SLL survivors under active surveillance 
and CLL/SLL survivors treated with chemo- and/or immunotherapy versus an age- and sex-
matched Dutch normative population were compared with analysis of variance (ANOVA).
Analysis of covariance (ANCOVA) was carried out to investigate the differences in mean EORTC 
QLQ-C30, HADS and IOC Worry scores between treatment groups and between on and off 
treatment after adjustment for sex, age and comorbidity.  
Logistic regression models using the dichotomized EORTC QLQ-C30 physical functioning and 
fatigue scores, HADS anxiety and depression scores and IOC Worry items as outcomes, were 
conducted to identify variables associated with these outcomes. These were the outcomes 
that were mentioned to be affected most often in both focus groups and previous studies26, 27. 
Variables were a priori determined, including gender, age, number of comorbidities, time since 
diagnosis and treatment.   
results
Patients’ characteristics
We analyzed data of 200 CLL/SLL patients of whom 175 received a questionnaire that was 
returned by 136 (78% response rate). Despite the population-based nature of the study, not 
all eligible patients received a questionnaire. One hundred eight patients did not receive a 
questionnaire as they were treated in hospitals that did not participate in the survey. We did not 
expect this to affect the representativeness. Another 37 patients did not receive a questionnaire 
because their specialist indicated they had other severe medical problems. This could have 
resulted in a slightly better HRQoL-outcomes (Figure 1). 
Non-respondents were significantly older than respondents and patients with unverifiable 
addresses (mean age at diagnosis 67.7 years versus 63.1 and 61.5 years, respectively). Non- 
respondents were more often under active surveillance and diagnosed with an early stage, 
however those differences were not statistically significant. Almost half of the respondents 
(47%) were diagnosed less than two years prior to survey completion, and active surveillance 
was the most frequent treatment strategy (49%). Thirty-nine percent of the responding patients 
were diagnosed with Rai-stage 0. Slightly more than half of the respondents (53%) were younger 
than 65 years. Seventy-one percent of the patients reported one or more comorbid conditions, 
the most common were high blood pressure (27%), anemia (22%) and back pain (22%; Table 1).
As expected, patients under active surveillance had more often been diagnosed at an early stage 
than patients who had received chemo- and/or immunotherapy. Although the patients in the 
chlorambucil were older than the patients in the other groups (55% being older than 65 years 
versus 46% in the active surveillance group and 44% in the other chemo-group), and patients 
under active surveillance were more often males (70% versus 63% and 57% in the chlorambucil-
group and other chemo-group respectively), none of the differences other than stage were 
statistically significant (Table 2).  
Comparison CLL/SLL patients with age- and sex-matched normative population
CLL/SLL patients treated with chemo- and/or immunotherapy had statistically significantly worse 
scores on all HRQoL scales (all p <0.001) except for pain, constipation and diarrhea, compared to 
an age- and sex-matched normative population. A medium clinically important difference was 
observed for social functioning, fatigue, dyspnea, sleeping problems and financial problems. 
Other scores represented small clinically important differences. Differences between CLL/
SLL survivors under active surveillance and the normative population were not statistically or 
clinically significant (Figure 2). 
Comparison between treatment groups
Compared to patients under active surveillance, patients having received any type of chemo- 
and/or immunotherapy reported worse scores on physical and role functioning and had more 
financial problems. Patients treated with chlorambucil also reported worse scores on social 
functioning and dyspnea compared to patients under active surveillance. The prevalence of 
fatigue among the chlorambucil group (81%) was almost twice as high compared to the active 



































852 patients diagnosed and registered with CLL/SLL 
between 1/1/2004 and 1/1/2011 and living in the 
region of CCCS. 
 
345 eligible patients i.e. older than 18 years at 
diagnosis and still alive at time of questionnaire 
mailing. 
 
Specialists’ from 18 hospital locations received an 
invitation letter to participate in the study. 
 
Addresses for the remaining 200 patients were 
checked for accuracy. 
 
175 patients received a questionnaire. 
 
136 patients returned a completed questionnaire 
(78%). 
Refusal of 2 general hospitals and 2 
locations serving 108 patients. 
 
25 unverifiable addresses. 
 
39 patients (22%) did not complete the 
questionnaire. 
 
Exclusion of 37 patients (because of other 
medical problems) on advice of the 
specialists. 
Note. CLL/SLL= Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, CCCS= Comprehensive Cancer Center 
South.
Figure 1. Flow chart of the data collection process.
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Table 1. Socio-demographic and clinical characteristics of questionnaire respondents, non-









N (%) N (%) N (%) p-value
Gender 0.60
Male 90 (67) 26 (67) 14 (56)
Female 46 (33) 13 (33) 11 (44)
Age: mean (SD) 63.1 (10.5) 67.7 (11.0) 61.5 (14.1) <0.05
<55 years 31 (23) 6 (15) 7 (28)
55-64 year 41 (30) 4 (10) 7 (28)
65-74 year 46 (34) 17 (44) 7 (28)
75+ years 18 (13) 12 (31) 4 (16)
Treatment 0.19
R-CHOP 4 (3) 0 (0) 1 (4)
FC(R) / Fludarabine 10 (7) 2 (5) 1 (4)
(R-)CVP/ Rituximab 16 (12) 4 (10) 2 (8)
Chlorambucil 27 (20) 1 (3) 7 (28)
Radiotherapy 3 (2) 2 (5) 1 (4)
Active surveillance 68 (51) 26 (67) 12 (48)
None 8 (6) 4 (10) 1 (4)
Years since diagnosis: mean (SD) 2.7 (1.3) 2.6 (1.4) 2.9 (1.4) 0.36
<2 year 65 (48) 16 (41) 9 (36)
2-3 years 28 (21) 9 (23) 3 (12)
>3 years 43 (32) 14 (36) 13 (52)
Stage at diagnosis 0.87
Rai 0   53 (39) 21 (54) 11 (44)
Rai 1 25 (18) 6 (15) 6 (24)
Rai 2 16 (12) 4 (10) 3 (12)
Rai 3 4 (3) 0 (0) 0 (0)
Rai 4 7 (5) 0 (0) 0 (0)
Not Applicable (SLL) 31 (23) 8 (21) 5 (20)














Note: SLL= Small Lymphocytic Lymphoma; $Education levels included low= no/primary school; medium= lower general 
secondary education/vocational training; or high= pre-university education/ high vocational training/university.














N (%) N (%) N (%) p-value
Gender 0.4
Male 48 (70) 17 (63) 17 (57)
Female 20 (30) 10 (37) 13 (43)
Age: mean (SD) 64.9 (10.8) 68.8 (9.8) 64.2 (2.5) 0.6
<55 years 14 (21) 4 (15) 9 (30)
55-65 year 23 (34) 8 (30) 8 (27)
65-75 year 23 (34) 9 (33) 11 (37)
75+ years 8 (12) 6 (22) 2 (7)
Time since diagnosis: mean (SD) 2.3 (1.3) 2.9 (1.4) 2.5 (0.9) 0.1
<2 year 40 (59) 8 (30) 15 (50)
2-3 years 12 (18) 7 (26) 8 (27)
>3 years 16 (24) 12 (44) 7 (23)
Treatment phase 0.6
On treatment NA 8 (30) 7 (23)
Off treatment NA 19 (70) 22 (73)
Stage at diagnosis <0.0001
Rai 0 38 (56) 5 (19) 6 (20)
Rai 1 17 (25) 5 (19) 3 (10)
Rai 2 5 (7) 7 (26) 4 (13)
Rai 3 0 (0) 3 (11) 1 (3)
Rai 4 0 (0) 3 (11) 3 (10)
Not Applicable (SLL) 8 (12) 4 (15) 13 (43)
Self reported comorbidities 0.9
No comorbidities 15 (25) 4 (16) 8 (28)
1 comorbidity 18 (30) 9 (36) 9 (31)
2 or more comorbidities 28 (46) 12 (48) 13 (41)
Marital Status 0.1
Partner 55 (82) 17 (65) 23 (77)
Divorced 5 (7) 4 (15) 2 (7)
Widowed 6 (9) 5 (19) 2 (7)
Alone 1 (1) 0 (0) 3 (10)
Education level$ 0.7
High 14 (21) 6 (23) 4 (13)
Medium 34 (52) 13 (50) 20 (67)
Low 18 (27) 7 (27) 6 (20)
Note: NA= Not Applicable; SLL= Small Lymphocytic Lymphoma; $Education levels included low= no/primary school; 
medium= lower general secondary education/vocational training; or high= pre-university education/ high vocational 
training/university.
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Figure 2A and 2B. Differences on EORTC QLQ-C30 mean functioning and global quality of life scores 
(A) and symptom scores (B) of CLL/SLL patients treated with chemo and/or immunotherapy (N=57) 
and CLL/SLL patients under active surveillance (N=68) compared to an age- and sex-matched 
normative population (N=290).
Note: A higher score on functioning scores implies a better health-related quality of life, whereas a higher score on 
symptom scores refers to more symptoms. EORTC QLQ-C30=European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire Core 30; CLL= Chronic Lymphocytic Leukemia; SLL= Small Lymphocytic 
Lymphoma. 
*p<0.01 and clinically important difference between CLL/SLL patients treated with chemo and/or immunotherapy 
compared to the normative population; Differences between CLL/SLL patients under active surveillance and the 
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immunotherapy (63%), although not statistically significant. Similarly, patients treated with 
chlorambucil were also more worried about the future, their health, the cancer coming back 
and the occurrence of new symptoms than patients in the active surveillance group or patients 
treated with other chemo-/immunotherapy; although the latter did not reach statistical 
significance. No difference was observed for anxiety and depressive symptoms between any of 
the treatment groups (Table 3).
Comparison patients on and off treatment
Compared to an age- and sex-matched normative population, CLL/SLL patients receiving 
treatment at survey completion scored worse on physical and social functioning, global quality 
of life, fatigue and sleeping problems with large clinically important differences. Medium 
clinically important differences were reported for role functioning and pain. For emotional and 
cognitive functioning the differences between CLL/SLL patients on treatment and the normative 
population were considered small clinically important.   
CLL/SLL patients who no longer received treatment at survey completion scored worse on 
dyspnea, sleeping problems and financial problems (medium clinically important differences). 
For physical-, role-, emotional-, and social functioning, fatigue and appetite loss the differences 
between CLL/SLL patients off treatment and the normative population were considered of 
small clinically importance. A significantly and large clinically important difference on cognitive 
functioning was observed between patients still on treatment and patients off treatment 
(p<0.01, Figure 3).
Socio-demographic, disease and treatment variables associated with HRQoL and worry
Multivariate logistic regression analysis showed that low EORTC physical functioning score was 
positively associated with co-morbidity and treatment. High fatigue scores and health worries 
were both positively associated with having two or more comorbidities and treatment with 
chlorambucil. Worrying about the future was negatively associated with age and positively 
associated with treatment with chlorambucil. No statistically significant associations were 
observed between HADS anxiety and depressive symptoms and socio-demographic, disease 
and treatment characteristics (Table 4).
discussion
In contrast to our hypothesis, patients treated with chlorambucil reported poorest HRQoL. Being 
treated for CLL/SLL was associated with deteriorated HRQoL longer after treatment than we 
anticipated, as both patients on and off treatment scored worse on fatigue, sleeping problems 
and all functional scales (except cognitive functioning) compared to the norm population. We 
expected patients in the active surveillance group to worry most, but patients treated with 
chlorambucil worried significantly more. No significant differences in reported anxiety or 
depressive symptoms between the treatment groups were found.
Although the combination of the observed significantly worse HRQoL for CLL/SLL patients treated 
with chemo- and/or immunotherapy compared to the active surveillance group, and the lack of 
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Table 3. Differences between CLL/SLL patients under active surveillance, CLL/SLL patients treated 
with chlorambucil and CLL/SLL patients treated with other chemo and/or immunotherapy on 









EORTC QLQ-C30 Mean (SD) Mean (SD) Mean (SD) p-value* Clinical 
importance






(20) <0.01a,b a:medium, 
b:small
Role Functioning 86.5 (23) 72.8 (30) 69.4 (29) <0.01a,b a, b: small
Emotional Functioning 85.2 (19) 71.2 (31) 84.6 (20) <0.05a a: small
Cognitive Functioning 86.5 (20) 80.8 (32) 81.7 (21) ns
Social Functioning 92.2 (18) 79.5 (24) 82.8 (25) <0.01a a: medium
Global health status/QoL 76.6 (20) 71.9 (17) 70.6 (19) ns
Fatigue 22.4 (27) 35.5 (24) 31.5 (29) ns
Nausea / Vomiting 7.0 (18) 4.5 (9) 4.4 (11) ns
Pain 16.4 (26) 24.4 (28) 17.8 (25) ns
Dyspnea 10.8 (20) 23.1 (31) 21.1 (24) <0.05a a: medium
Insomnia 20.8 (30) 30.8 (35) 25.6 (30) ns
Appetite loss 10.8 (26) 8.6 (18) 12.2 (22) ns
Constipation 7.3 (16) 6.4 (16) 6.7 (16) ns
Diarrhea 8.9 (20) 9.0 (15) 5.6 (20) ns
Financial Problems 2.1 (8) 12.8 (27) 15.6 (27) <0.01a,b a, b: medium
% Fatigue cases 43 % 81 % 63 % <0.01a
HADS
Anxiety 4.5 (3.7) 6.0 (4.2) 3.5 (3.7) ns
Depression 3.6 (3.5) 4.9 (4.1) 4.1 (4.1) ns
% Anxiety cases 18 % 33 % 20 % ns
% Depression cases 13 % 30 % 20 % ns
IOC+
Worry about future 16 % 42 % 24 % 0.02a
Worry about health 27 % 67 % 31 % <0.01a
Worry about cancer 
coming back
28 % 67 % 48 % <0.01a
Worry when new 
symptoms occur
21 % 46 % 43 % 0.03a
Note: CLL= Chronic Lymphocytic Leukemia; SLL= Small Lymphocytic Lymphoma; EORTC QLQ-C30=European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; HADS=Hospital Anxiety 
and Depression Scale; IOC=Impact of Cancer Scale; ns=non-significant.
*p-value is adjusted for age, sex, and number of comorbidities;aDifference significant between the active surveillance 
group and the chlorambucil group; bDifference significant between the active surveillance group and the other 
chemo/immunogroup. +Percentage of patients who answered these IOC items with “agree” or “strongly agree”.
Patients were defined as a fatigue case if they had an EORTC QLQ-C30 fatigue score >21.9 (mean norm population 
+ small clinical important difference).Patients were defined as an anxiety case if they had a HADS anxiety score >8. 
Patients were defined as a depression case if they had a HADS depression score >8.
Note: A higher score on functioning scores implies a better health-related quality of life, whereas a higher score on 
symptom scores refers to more symptoms. EORTC QLQ-C30=European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire Core 30; CLL= Chronic Lymphocytic Leukemia; SLL= Small Lymphocytic 
Lymphoma. 
*=p<0.05 and clinically important difference between CLL/SLL patients on treatment and the normative population.
+=p<0.05 and clinically important difference between CLL/SLL patients off treatment and the normative population.
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Figure 3A and 3B. Differences on EORTC QLQ-C30 mean functioning and global quality of life scores 
(A) and symptoms scores (B) of  CLL/SLL patients on treatment (N=15) and CLL/SLL patients off 
treatment (N=42) compared to an age- and sex-matched normative population (N=209).































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































differences between CLL/SLL survivors under active surveillance and the normative population, 
suggests that treatment is responsible for the poorer HRQoL and not so much the disease itself, 
it is also possible that disease severity (stage) could explain the observed association between 
treatment and HRQoL, as treatment is generally not initiated until the patient experiences 
symptoms28. This explanation is strengthened by the outcomes of an RCT with relatively young 
patients treated with fludarabine (+/- cyclophosphamide)10. In concordance with our results, 
it showed that CLL patients receiving treatment had a significantly impaired HRQoL on all 
functioning scales as well as on fatigue, nausea, and all single-items scales with the exception 
of pain, compared to a norm population. However, the baselines scores of these patients were 
similar or even worse than the scores twelve months after starting treatment, suggesting that 
the symptoms of disease affects HRQoL rather than therapy. On the other hand, our results also 
showed that patients receiving treatment scored lower than the norm population even after 
treatment had ended and symptoms are likely to be reduced. Therefore, we assume the poorer 
HRQoL among treated patients is caused by a combination of treatment effects and symptoms 
of active CLL. This hypothesis is confirmed by the results of a survey performed in 2006, where 
physical en functional well being and fatigue were related to both stage and treatment. HRQoL 
scores were lower among individuals with advanced stage disease29. 
Remarkably, patients treated with chlorambucil reported lower scores on physical and social 
functioning, dyspnea and fatigue than patients receiving other chemo-/immunotherapy. In 
contrast to our findings, are the results of a previous RCT that showed that during treatment 
patients receiving fludarabine, particularly FC, reported more HRQoL impairment compared 
with patients receiving chlorambucil, on role/social functioning and fatigue.11 These differences 
resolved after completing therapy. There are several explanations for the discrepancies. First of 
all, we assessed HRQoL in a population-based setting that includes elderly and/or frail patients 
and patients with significant comorbidities, resulting in a representative subset of CLL/SLL 
patients receiving standard care, whereas patients with significant comorbidities or a short life 
expectancy were excluded from the trial30. Second, due to the observational nature of our study, 
the results might be biased by confounding by indication, i.e. elderly and/or frail patients with a 
poorer HRQoL being more likely to be treated with chlorambucil. However, we adjusted for age 
and comorbidity in the analyses and no statistical differences were observed in age, number 
of comorbidities, socio-demographic or clinical characteristics between patients treated with 
chlorambucil and from the other chemo group. Third, the information provided to patients 
in a RCT is probably more elaborate and uniform than in a population-based setting. In the 
latter situation patients who receive a ‘simple’ oral treatment (chlorambucil) might receive less 
information than patients who are frequently hospitalized to receive ‘complex’  intravenous 
chemo-/ immunotherapy. Receipt of less information has been associated with lower HRQoL31. 
In conclusion, despite the cross-sectional design of our study, this large population-based study 
with high  patient response rates and detailed information about treatment, gives a quite 
representative overview of the symptoms and HRQoL that patients with CLL/SLL experience 
in all phases of disease. The recent success in prolonging survival might lead to adjustment 
of the current guidelines regarding starting treatment in asymptomatic patients. However, 
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drastic and long-lasting effects of starting treatment in CLL/SLL patients on HRQoL can not be 
excluded, whereas active surveillance does not seem to provoke worrying, anxiety, or depressive 
symptoms. Drastic, long-lasting negative effects of starting treatment on HRQoL can not be 
excluded, whereas active surveillance does not seem to provoke worrying, anxiety, or depressive 
symptoms. Further elaborate research into the impact of starting therapy on HRQoL is needed, 
especially in patients that are underrepresented in most clinical trials. Specifically, a larger cohort, 
which allows the comparison of more treatment groups  and a design with questionnaires on 
specific moments (e.g. at diagnosis, 6 and 12 months after diagnosis, at start therapy, etc.) are 
preferable. Its results should be thoroughly considered during revision of treatment guidelines, 
as the gain in survival time by starting (a certain type of) treatment should outweigh the possible 
negative impact of it on patients HRQoL. 
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chapter 6
The course of anxiety and depression for patients with Hodgkin’s 
lymphoma or diffuse large B-cell lymphoma: a longitudinal study of the 
PROFILES registry
S. Oerlemans, F. Mols, M.R. Nijziel, W.P. Zijlstra, J.W.W. Coebergh, L.V. van de Poll-Franse
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Prospectively assess anxiety and depression among patients with Hodgkin Lymphoma (HL) 
and Diffuse Large B-Cell lymphoma (DLBCL). Also, to compare its prevalence with a normative 
population, identify subgroups with more anxiety and depression, and assess its impact on 
health-related quality of life (HRQoL).
Methods 
The population-based Eindhoven Cancer Registry was used to select patients diagnosed with 
HL or DLBCL from 1999-2010, 489 responded (T1). The HADS was completed four times (T1-T4), 
with a one-year interval. Linear mixed-models were used to assess the course of anxiety and 
depression and identify high-risk subgroups.
Results 
Both anxiety and depression were reported more often by patients compared to the normative 
population (p<0.05). Over the four time points, approximately 10% of patients reported to be 
always and 15% reported to be sometimes anxious or depressed. Anxiety and depression did 
not improve in time. Patients with comorbidity and patients who were lower educated reported 
higher anxiety and depression scores (p<0.05). Younger DLBCL patients reported higher anxiety 
scores, whereas older DLBCL patients reported higher depression scores over time (p<0.05). 
Global health status/HRQoL was clinically relevant lower in patients with anxiety and depression 
and this appeared to be constant over time. 
Conclusion 
More HL and DLBCL patients experience anxiety and depression compared to their counterparts 
in the general population and it did not improve in time. 
Implication for Cancer Survivors 
Clinicians should be aware that former lymphoma patients with anxiety and depression have a 
deteriorated global health status/HRQoL and refer patients to suitable aftercare when necessary.
introduction
Survival for patients with Hodgkin Lymphoma (HL) and Diffuse Large B-Cell Lymphoma (DLBCL) 
has improved dramatically over the past decades. Currently, the overall 5-year relative survival 
rate (2002-2008) is 81-90% for HL and 71-82% for DLBCL1, 2. As lymphoma patients survive 
longer, they often face long-term effects caused by their treatment, such as treatment-induced 
secondary tumors and cardiovascular disease3-10. Apart from these adverse physical effects, many 
lymphoma patients also report long-term psychosomatic and psychosocial problems, such as 
depression and anxiety11-19.  
Studies focusing on depression and anxiety in lymphoma patients observed prevalence rates of 
depression between 2-35%14, 20-22 and rates of anxiety between 12-42%14, 20-23, with also differences 
in assessment methods, as well as in patients and tumor characteristics. Furthermore, 
comparisons with normative populations are scarce. Little is known about the longitudinal 
course of anxiety and depression in these patients during their post-treatment follow-up and 
their return to normal life and the impact of it on health-related quality of life (HRQoL).
The aims of the present study were to (1) compare the prevalence of anxiety and depression of HL 
and DLBCL patients with an age- and sex-matched normative population, (2) prospectively assess 
the course of anxiety and depression following primary treatment and identify subgroups of 
patients who report higher or lower scores and (3) assess the relation of anxiety and depression 
with global health/HRQoL. We hypothesised that prevalence rates of anxiety and depression 
would be higher in HL and DLBCL patients compared to the normative population. Furthermore, 
anxiety and depression would decrease during follow-up with longer survival.
design and methods
Lymphoma patients
This study is part of a longitudinal population-based survey among HL and DLBCL patients 
registered by the Eindhoven Cancer Registry (ECR). The ECR records data on all patients who 
are newly diagnosed with cancer in the southern part of the Netherlands, an area with 2.3 
million inhabitants, 18 hospital locations and 2 large radiotherapy institutes. The ECR was used 
to select patients who were diagnosed with HL or DLBCL between January 1st, 1999 and July 1st, 
2010 as defined by the International Classification of Diseases for Oncology-3 codes (ICD-O-3)24 
and were 18 years or older at time of diagnosis. Patients who had deceased were excluded 
through linkage with the database of the Central Bureau for Genealogy. Ethical approval for the 
study was obtained from a certified Medical Ethics Committee (of the Maxima Medical Centre 
in Veldhoven, The Netherlands; number 0734).
Study measures
The Hospital Anxiety and Depression Scale (HADS)25-27, measures symptoms in separate subscales 
of 7 items each. Answers range from 0 to 3 and scores for each subscale are calculated by 
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addition of the items, with a higher score meaning more anxiety or depression. A score  on 
either subscale of ≥8 indicates a substantial level of anxiety or depression25-27. This questionnaire 
measures the extent to which patients experience anxiety or depressive symptoms and can not 
diagnose a clinical anxiety or depressive disorder. The term depression in this manuscript does 
not imply a diagnosis of a clinical depression. Estimated reliability was assessed at T1 for both 
patients’ samples by Cronbach’s alpha. For the HL sample, Cronbach’s alpha was 0.87 for the 
anxiety and 0.85 for the depression scale and for the DLBCL sample, Cronbach’s alpha was 0.82 
for the anxiety and 0.84 for the depression scale.  
The ‘global health status and Quality of Life scale’ of the Dutch validated version of the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC 
QLQ-C30) was used to assess global health status/HRQoL. It consists of two questions, i.e. “How 
would you rate your overall health during the past week?” and “How would you rate your overall 
quality of life during the past week?” with a 7-point likert scale as answer categories. After linear 
transformation, the scale ranges in score from 0 to 100, whereby a higher score implies a better 
global health status/HRQoL28.
Comorbidity at time of survey was categorized according to the adapted Self-administered 
Comorbidity Questionnaire (SCQ)29. Patients’ marital status and educational level were also 
assessed in the questionnaire. Clinical information was available from the ECR that routinely 
collects data on tumor characteristics, including date of diagnosis, tumor grade, histology, Ann 
Arbor stage30, primary treatment, and patients background characteristics, including gender 
and date of birth. 
Data collection
Data collection was done within PROFILES (Patient Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship). PROFILES is a registry for the study of 
the physical and psychosocial impact of cancer and its treatment from a dynamic, growing 
population-based cohort of both short and long-term cancer survivors. PROFILES contains 
a large web-based component and is linked directly to clinical data from ECR. Details of the 
data collection method have been previously described31. Data from the PROFILES registry 
are available for non-commercial scientific research, subject to study question, privacy and 
confidentiality restrictions, and registration (www.profilesregistry.nl).
In May 2009, patients diagnosed between January 2004 and January 2009 were included in 
the study and received the first questionnaire. In November 2009 and in May 2011 (last cohort 
included) patients newly diagnosed up to July 1st 2010 were subsequently invited to participate. 
Thus three cohorts in which all patients received the subsequent questionnaires with a one year 
interval starting from time of enrollment. The first cohort is assessed 4 times, the second cohort 
is measured 3 times, and the third cohort is measured 2 times (see Figure 1).
Normative population
The normative population was selected from a reference cohort of 2040 individuals from the 
general Dutch population (CentER panel). This cohort is representative for the Dutch-speaking 
population in the Netherlands32. The set of questionnaires completed by this normative 
population in November 2011 included the HADS, SCQ, and data on socio-demographics. From       
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
+ 
   
   
   
   
   
   
   
   
   
   
   
   
   
+ 
   
   
   
   
   
   
   
   
   
   
   
   
   
 
         
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  +
   
   
   
   
   
   
   
   
   
   
   
   
   
 +
   
   
   
   
   
   
   
   
   
   
   
   
   
  
       
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  +
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
       
   
   
   
   
   
   
   
   
   
   
   
   

























   












   

























   












   






































   












   

























   












   







































   












   



























   












   


























































































   





































   



































   


























   




































   





































   


























   




































   


























   












































































































chapter 6 anxiety and depression among hodgkin and non-hodgkin lymphoma patients
9594
6
this normative population, two age- and sex-matched selections were made to compare anxiety 
and depression with the two patient groups, one for HL (N=360) and one for DLBCL (N=425). 
For matching, ten strata were formed using sex and age (5 categories). Within each stratum a 
maximum number of persons from the reference cohort were randomly matched according 
to the strata frequency distribution of the patients. This resulted in 360 matched cancer-free 
individuals for the 180 HL patients and 425 matched cancer-free individuals for the 309 DLBCL 
patients.
Statistical analyses
Differences in baseline socio-demographic and clinical characteristics between respondents and 
non-respondents (never completed a questionnaire) or patients with unverifiable addresses 
were compared with a chi-square or t-test, where appropriate. Differences in baseline socio-
demographic and clinical characteristics between patients who completed one questionnaire or 
patients who completed more questionnaires were also compared with a chi-square or t-test, 
where appropriate.
Prevalence rates of anxiety and depression from the HL and DLBCL patients were compared with 
an age- and sex-matched Dutch normative population using chi-square tests. We categorized 
patients as ‘always anxious/depressed’ with a HADS anxiety or depression score ≥8 on every 
measurement (T1-T4) and ‘never anxious/depressed’ if patients never reported a score ≥8 at 
every measurement. Patients who scored ≥8 at some of the four measurements were categorized 
as ‘sometimes anxious/depressed’. 
The course of anxiety and depression was analyzed separately using linear mixed-effects models 
(i.e., covariance pattern model with an unstructured error covariance matrix and maximum 
likelihood estimation)33. Time was analyzed as a regular categorical predictor with four levels 
(i.e. four time points). Socio-demographic (age, sex, marital status, education level) and clinical 
variables (comorbidity, treatment type, stage of disease, time since diagnosis) were determined 
a priori and analyzed as time-invariant predictors (i.e. baseline characteristics were used). The 
interaction of sex and age was tested separately and interactions were only maintained in 
the final model if they were significantly associated with anxiety and/or depression. In order 
to correctly interpret all model parameters, all continuous variables have been grand-mean 
centered33, 34.
The course of global health status/HRQoL was also analyzed using linear mixed-effects models 
(i.e., covariance pattern model with unstructured error covariance matrix and maximum 
likelihood estimation)33. Anxiety and depression scores were analyzed as continuous time-
varying predictors33 (separate models) and sex, age and number of comorbidities were entered 
as covariates into both models. 
Analyses were performed in IBM SPSS 19.0 and SAS (version 9.3 for Windows; SAS Institute Inc., 
Cary, NC) using significance level of α=.05. Clinically relevant differences were determined using 
the evidence-based guidelines for interpretation of the EORTC QLQ-C30 between groups35, a 
difference ≥4 indicates at least a small clinical relevant difference on the global health status/
HRQoL scale. Norman’s ‘rule of thumb’ was used for the HADS whereby a ± 0.5 SD difference 
(i.e. 1.7 points) indicates a threshold of discriminating change in scores36, 37.
results
Patients and normative population
Figure 1 shows the number of patients throughout the measurements. One hundred eighty HL 
and 309 DLBCL patients completed the first questionnaire (T1, 85%). Subsequently, among HL 
patients, 109 (61%) completed the second measurement, 64 (39%) the third and 48 (32%) also 
the fourth measurement. Among DLBCL patients, 175 (57%) completed the second measurement, 
95 (36%) the third and 67 (32%) also the fourth measurement. Mean age at T1 was 46.1 years for 
HL and 63.6 years for DLBCL patients with a mean time since diagnosis of 4.7 years and 3.5 years 
respectively (Table 1). Combination of radiotherapy and chemotherapy was most frequently 
received in HL patients (55%) and chemotherapy alone in DLBCL patients (67%). Half of HL 
patients and two-third of DLBCL patients reported one or more comorbid conditions, the most 
common were arthritis and back pain. 
Despite matching on age and sex, patients with DLBCL more often reported to have one comorbid 
condition and less often reported to have two comorbid conditions compared to the normative 
population. The average number of comorbidities however did not differ between these groups 
(Table 1). DLBCL patients were furthermore lower educated and more often married than the 
normative population. No differences on socio-demographic characteristics were observed 
between HL patients and the normative population. 
Quality of data
Non-response analysis
At T1, HL patients who responded were more often female than HL patients who did not 
respond or had unverifiable addresses (45% versus 34% and 27% was female; p=0.049). DLBCL 
patients who responded were more often male than DLBCL patients who did not respond or had 
unverifiable addresses (65% versus 44% and 44%; p<0.01). They had also more often received 
chemotherapy alone compared to DLBCL non-respondents and patients with unverifiable 
addresses (67% versus 51% and 50%; p<0.01). No statistically significant differences between 
respondents, non respondents and patients with unverifiable addresses were observed for age, 
time since diagnosis, and stage (data not shown).
Analysis between patients who completed one or more questionnaires
HL patients who completed more questionnaires had a significantly longer mean time since 
diagnosis at time of first enrollment than HL patients who completed only one questionnaire 
(5.2 vs. 3.9 years, p<0.01). No statistically significant differences were observed between these 
groups on anxiety ( X =5.0 versus X =4.4, p=0.35) or depression scores ( X =3.7 versus X =3.6, 
p=0.87) or for sex, age, stage, primary treatment, comorbidities, marital status, and educational 
level. Also for DLBCL patients no statistically significant differences were observed between 
patients who completed one or more questionnaires for anxiety ( X =4.0 versus X =4.3, 
p=0.38) or depression scores ( X =4.2 versus X =4.3, p=0.77) or for the other above mentioned 
characteristics. 
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Table 1. Socio-demographic and clinical characteristics of HL (N=180) and DLBCL (N=308) survivors, 


















N (%) N (%) p-value N (%) N (%) p-value
Sex 0.90 0.95
Male 99 (55) 200 (56) 201 (65) 282 (66)
Female 81 (45) 160 (44) 108 (35) 143 (34)
Age at time of survey: mean (SD) 46.1 (16) 48.3 (16) 0.12 63.6 (13) 63.7 (13) 0.79
<35 years 52 (29) 74 (21) 11 (4) 14 (3)
35-44 years 40 (22) 81 (23) 16 (5) 24 (6)
45-54 years 34 (19) 69 (19) 45 (15) 59 (14)
55-64 years 28 (16) 70 (19) 68 (22) 88 (21)
65-74 years   15 (8) 46 (13) 103 (33) 152 (36)
75+ years 11 (6)    20 (6) 66 (21) 88 (21)
Stage at diagnosis
I 32 (18) 106 (35)
II 94 (53) 74 (24)
III 35 (20) 61 (20)
IV 18 (10) 63 (21)
Primary treatment
Radiotherapy alone 5 (3) 5 (2)
Chemotherapy alone 74 (41) 208 (67)
Radio and chemotherapy  99 (55) 85 (28)
Years since diagnosis: mean (SD) 4.7 (2.9) 3.5 (2.4)
0-1 years 9 (5) 30 (10)
1-3 years 55 (31) 122 (39)
3-5 years 36 (20) 84 (27)
5-7 years 33 (18) 39 (13)
7-10 years 47 (26) 34 (11)
Self-reported comorbidity: mean (SD) 1.0 (1.3) 1.0 (1.4) 0.52 1.3 (1.2) 1.4 (1.4) 0.15
No comorbid condition 84 (49) 167 (46) 0.95 89 (31) 144 (34) 0.14
1 comorbid condition 49 (29) 99 (28) 0.95 101 (35) 104 (24) 0.01
2 or more comorbid conditions 38 (22) 94 (26) 0.20 98 (34) 177 (42) <0.01
Frequent reported  comorbid conditions
Arthritis 23 (15) 44 (12) 0.37 62 (27) 101 (24) 0.41
Back pain 29 (20) 89 (25) 0.21 66 (29) 122 (29) 0.96
Partner 0.38 0.04
Yes 136 (76) 284 (79) 245 (80) 313 (74)
No  44 (24)  76 (21)  60 (20) 112 (26)
Education level$ 0.14 <0.01
Low 14 (8) 15 (4) 51 (17) 22 (5)
Medium 109 (61) 212 (59) 176 (59) 240 (57)
High   56 (31) 131 (37) 73 (24) 162 (38)
HADS anxiety (mean (SD) 4.8 (4) 3.8 (3) <0.01 4.1 (4) 3.4 (3) <0.01
HADS depression (mean (SD) 3.7 (4) 3.4 (3) 0.41 4.3 (4) 3.9 (3) 0.08
EORTC HRQoL (mean (SD) 76.9 (18) 74.7 (20)
Note. HL=Hodgkin lymphoma, DL=Diffuse Large B-Cell lymphoma; $Education levels included low= no/primary 
school; medium= lower general secondary education/vocational training; or high= pre-university education/ high 
vocational training/university.
Prevalence of anxiety and depression
The prevalence of anxiety in HL patients on T1 was 24% compared to 13% in the normative 
population (p<0.01) and the prevalence of depression was 18% compared to 12% in the norm 
(p=0.045; Figure 2). Among DLBCL patients, the prevalence of anxiety on T1 was 17% compared 
to 11% in the normative population (p<0.01) and the prevalence of depression was 19% compared 
to 14% in the norm (p=0.044; Figure 2).
On average over the four time points, 13% of HL and 8% of DLBCL patients were always anxious, 
and 18% and 17%, respectively was sometimes anxious. Furthermore, 11% of HL and 9% of DLBCL 
patients were always depressed, whereas 14% and 18% respectively was sometimes depressed. 
Factors longitudinally associated with anxiety and depression
Hodgkin lymphoma
No change was observed in HL patients’ anxiety or depression mean scores during the four 
assessments (p=0.38 and p=0.56, respectively; Table 2). HL patients with comorbid diseases 
reported higher anxiety and depression scores over time (both p<0.01). Furthermore, higher 
depression scores over time were reported by HL patients with a low education level (p<0.01) 
and by younger women and older men (interaction effect sex*age p<0.01). No association 
was observed between time since diagnosis, sex, treatment or disease stage and anxiety or 
depression scores.  
Diffuse Large B-Cell Lymphoma
For DLBCL patients no time effect was observed for anxiety (p=0.48) but a significant effect of 
time was found for depression (p<0.01; Table 2). The largest change for depression was observed 
between the first (T1) and last assessment (T4), although this mean change of 1.1 point was 
not clinically relevant (i.e. not higher than the 0.5 SD of 1.7). Younger DLBCL patients reported 
more anxiety (p=0.03), whereas depression scores became higher in older DLBCL patients 
(p=0.02). In addition, DLBCL patients with a low or medium education level and patients with 
comorbid diseases reported more anxiety and depression over time (all p<0.05). No longitudinal 
association was observed between time since diagnosis, sex, marital status, treatment or disease 
stage and anxiety or depression scores.  
Anxiety and depression in relation with HRQoL
Of HL and DLBCL patients who always reported high anxiety scores (score ≥8 on all measurements), 
global health status/HRQoL mean scores were on average 18 to 29 points lower among patients 
who never reported anxiety (Figure 3). Patients who always reported high depression scores 
(score ≥8 on all measurements) reported global health status/HRQoL mean scores that were 
on average 28 to 34 points lower than patients who never reported depression scores. These 
differences in global health status/HRQoL between patients always and never reporting anxiety/
depression scores were clinically very relevant, i.e. >15 points difference35). Linear mixed-effect 
models supported this observation of the raw data and showed that higher levels of anxiety and 
depression were statistically significant associated over time with lower global health status/
HRQoL (between-subject effects βs between -1.9 and -3.4; p<0.01, not tabulated).
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Note. HL= Hodgkin Lymphoma, DLBCL= Diffuse Large B-Cell Lymphoma; HADS=Hospital Anxiety and Depression 
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Figure 2. Prevalence of HADS anxiety and depression among HL (A) and DLBCL (B) patients on T1 
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Anxiety and depression were reported more often by HL and DLBCL patients compared to the 
age- and sex-matched normative populations, i.e. patients reported rates between 17-24% and 
the normative populations between 11-14%, which confirms our hypothesis. Over the four time 
points, approximately 10% of HL and DLBCL patients reported to be always anxious or depressed 
and an additional 15% sometimes. Importantly, global health status/HRQoL was relevantly, up to 
34 points, lower in patients with anxiety or depression and appeared to be constant over time.
Up to now only four studies, three cross-sectional and one longitudinal, focused on anxiety and 
depression among lymphoma patients of which two were conducted more than 15 years ago. 
Three of these studies also observed higher anxiety or depression scores among lymphoma 
patients compared to a normative population14, 21, 23. The observed prevalence of anxiety between 
Table 2. Final model of a priori determined time, socio-demographic and clinical factors associated 
with HADS anxiety and depression for HL and DLBCL patients.
HL DLBCL
Anxiety Depression Anxiety Depression
Beta p-value Beta p-value Beta p-value Beta p-value
Time variables
Time 0.38 0.56 0.48 <0.01
T4 versus T1 0.5 -0.06 -0.5 -1.1 <0.01
T4 versus T2 0.4 0.2 -0.4 -0.8 0.04
T4 versus T3 0.6 -0.02 -0.3 -0.9 0.02
Time since diagnosis# -0.02 0.84 0.04 0.58 -0.01 0.93 0.02 0.85
Sociodemographic variables
Age# -0.03 0.17 -0.05^ 0.04^ -0.04 0.03 0.04 0.02
Sex (men) 0.02 0.97 0.7^ 0.14^ -0.3 0.51 0.7 0.10
Married (yes) -1.0 0.07 -0.8 0.08 0.01 0.98 0.5 0.35
Education 0.09 <0.01 <0.01 <0.01
High-low 2.4 4.5 <0.01 2.9 <0.01 2.1 <0.01
High-mid 0.8 0.9 0.06 1.1 0.02 1.4 <0.01
Sex*age# - 0.09 <0.01 - -
Clinical variables
Comorbidities# 0.6 <0.01 0.4 <0.01 0.6 <0.01 0.4 <0.01
Radiotherapy (yes) -0.8 0.16 -0.8 0.10 0.04 0.94 0.5 0.37
Chemotherapy (yes) 0.8 0.60 2.1 0.13 0.01 0.99 0.97 0.32
Stage 0.65 0.89 0.64 0.22
Stage I versus II -1.1 -0.3 0.5 1.1
Stage I versus III -1.1 0.4 -0.3 0.2
Stage I versus IV -0.6 0.06 0.1 -0.07
Note. #Continuous variables are grand-mean centered; ^ANOVA tests of main effects are not to be interpreted 
because of interaction effect. The interaction of sex and age was tested separately and interactions were only 
maintained in the final model if they were significantly associated with anxiety and/or depression. This was only 
the case for HL depression. All other presented models are without the interaction factor. HL= Hodgkin Lymphoma, 
DLBCL= Diffuse Large B-Cell Lymphoma; HADS=Hospital Anxiety and Depression Scale.





N=30 N=30 N=18 N=14
DLBCL patients: always 
depressed
N=21 N=20 N=6 N=2
T1 T2 T3 T4
DLBCL patients: never 
depressed
N=131 N=125 N=71 N=51
DLBCL patients: 
sometimes anxious
N=27 N=26 N=18 N=15
DLBCL patients: always 
anxious
N=17 N=17 N=4 N=2
T1 T2 T3 T4
DLBCL patients: never 
anxious
N=138 N=132 N=73 N=50
N=12 N=12 N=8 N=5
HL patients: sometimes 
depressed
N=16 N=16 N=8 N=5
N=85 N=81 N=48 N=38
T1 T2 T3 T4
HL patients: never 
anxious
HL patients: sometimes 
anxious
HL patients: always 
anxious
HL patients: never 
depressed





































HL patients: never anxious
HL patients: sometimes anxious





















HL patients: never depressed
HL patients: sometimes depressed






















DLBCL patients: never anxious
DLBCL patients: sometimes anxious






















DLBCL patients: never depressed
DLBCL patients: sometimes depressed
DLBCL patients: always depressed
D 
Note. Only scores of HL/DLBCL patients who completed at least two measurements are included in these figures. 
The higher the EORTC global health status/HRQoL mean score, the better the health-related quality of life. Patients 
were categorized as ‘always anxious/depressed’ as they reported a HADS anxiety or depression score ≥8 on every 
measurement (T1-T4) and ‘never anxious/depressed’ as they never reported a score ≥8 on every measurement. 
Patients that scored ≥8 on some of the measurements were categorized as ‘sometimes anxious/depressed’.
Figure 3. EORTC global health status/HRQoL observed mean scores over time for HL (A) and DLBCL 
(C) patients who were never, sometimes, or always anxious and for HL (B) and DLBCL (D) patients 
who were never, sometimes, or always depressed.
17-24% and depression between 18-19% was also in line with a longitudinal study using the HADS 
scale that studied lymphoma patients until one year after diagnosis21. Other cross-sectional 
studies reported prevalence rates of 15-42% for HADS anxiety and 4-35% for HADS 
depression14, 22.
In the present study, patients showed no improvement in time in anxiety or depression. One 
cross-sectional study among 459 Norwegian HL patients observed that patients 7-10 years 
after diagnosis reported higher anxiety and depression compared to patients 3-6 years after 
diagnosis14, contrasting our hypothesis. So, it seems that anxiety and depression are not limited 
to the first few years after diagnosis.
DLBCL patients who were lower educated, reported anxiety more often and depression was 
reported more often by both lower educated HL and DLBCL patients. This is in line with a cross-
sectional study among 459 HL patients in Norway14. We furthermore observed more depression 
among older DLBCL patients which was in line with a longitudinal study among lymphoma 
patients21. We observed no association between primary treatment and stage of disease and 
anxiety/depression, which was in line with a Norwegian study among HL patients14. 
The difference in prevalence of anxiety and depression was larger between the age and sex-
matched normative population and HL patients than the difference between the norm and 
the DLBCL patients. This might suggest that since the HL patients group was on average 18 
years younger, being diagnosed with lymphoma on an earlier age has a greater impact. Larger 
differences between younger lymphoma patients compared to a normative population were 
also observed with respect to HRQoL38. An explanation might be that older patients may have 
better coping strategies through more life experience and they are likely to be faced with lower 
work-related and social demands. It is also possible that, as more health events occur with aging, 
cancer may not have such a specific impact on patients mental health relative to comparably 
aged adults without cancer who experience other health issues impacting mental health. 
The strong relation observed between anxiety and depression and global health status/HRQoL 
appeared consistent over time, resulting in clinically relevant lower global health status/HRQoL 
in patients with anxiety or depression. This stipulates the importance for recognition and referral 
for treatment of anxiety and depression in order to maintain HRQoL. Furthermore, a systematic 
review showed that adequate information provision was associated with lower levels of anxiety 
and depression in cancer patients39. Since up to one-third of lymphoma patients was not satisfied 
with the amount of received information and at least a quarter wanted more information, there 
might be room for improvement40. Moreover, patients with depressive symptoms seem to have 
a twofold risk for all-cause mortality, even after adjustment for major clinical predictors41.
The current study has some limitations. We do not know if patients did not participate because 
of poor health or rather absence of symptoms. Moreover, detailed information on additional 
treatments after primary treatment or on receiving treatments at the time of completion of the 
questionnaire is not available. The longitudinal design provided important information about 
the course of anxiety and depression. In addition, data of an age- and sex-matched normative 
chapter 6 anxiety and depression among hodgkin and non-hodgkin lymphoma patients
103102
6
population makes is possible to determine what the ‘normal’ levels of anxiety and depression 
are for people without cancer. Furthermore, the population-based sampling frame and the ten-
year range in elapsed time since diagnosis facilitates to extrapolate the results to a broad range 
of lymphoma patients in the population. 
In conclusion, up to approximately a quarter of both HL and DLBCL patients can experience 
persistent anxiety and depression long after diagnosis and treatment. Clinicians might be more 
aware that former lymphoma patients with anxiety and depression have a lower global health 
status/HRQoL and refer patients to suitable aftercare when necessary. Special attention should 
go to patients with comorbidities and patients who are lower educated as they were more likely 
to report anxiety and depression over time. 
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The course of fatigue and quality of life in survivors of non-Hodgkin’s lymphoma is unknown. 
The aims of this study were, therefore, to assess fatigue and quality of life in patients with non-
Hodgkin’s lymphoma following primary treatment, compare fatigue and quality of life in these 
patients with those of an age- and sex matched normative population to assess the severity 
of concerns and identify associations with fatigue of survivors who remained fatigued. The 
population-based Eindhoven Cancer Registry was used to select all patients diagnosed with non-
Hodgkin’s lymphoma from 1999-2009. The European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire and the Fatigue Assessment Scale were completed once 
by 824 survivors of non-Hodgkin’s lymphoma (80% response rate); 434 survivors completed 
these questionnaires again 1 year later. Survivors of non-Hodgkin’s lymphoma reported more 
clinically relevant fatigue up till 10 years post-diagnosis compared to a normative population 
(P<0.001). Mean fatigue scores remained fairly stable over time (T1: x=28, SD=26; T2: x=30, 
SD=27, P=0.14): 22-28% of survivors reported deterioration, 19-23% reported improvement 
and 44-54% reported constant fatigue. Survivors who reported constant fatigue were more 
often diagnosed with stage IV disease and had more comorbid diseases. They were additionally 
more often female and divorced. Having comorbidities and being without a partner were also 
associated with constant fatigue in the normative population. In conclusion, six out of every ten 
responding non-Hodgkin’s lymphoma survivors reported a high level of fatigue up till 10 years 
after diagnosis. Mean fatigue scores remained stable over time and survivors reporting constant 
fatigue more often had stage IV disease at diagnosis and comorbidities.
introduction
As a result of new therapies, the survival of patients with non-Hodgkin’s lymphoma (NHL) has 
improved considerably. Although the statistics vary, depending on the type of NHL, stage of 
disease at diagnosis, treatment, and age of the patient, the overall 5-year relative survival rate 
for all types of NHL (2001–2007) is 50–62%1. A person diagnosed with cancer is defined as a 
survivor from the moment of diagnosis through the rest of his or her life2. The number of NHL 
survivors in the USA increased from approximately 347,000 in 2001 to approximately 454,000 in 
20081. In the Netherlands there were approximately 19,600 NHL survivors at the end of 20083, 4.
As many cancer survivors live longer, they are at risk of adverse physical and psychosocial 
long-term effects, secondary tumors, and recurrence as a result of their cancer and/or of their 
medical treatments5-7. These long-term effects, such as fatigue, depression, marital disruption, 
and problems with infertility, can have a negative influence on survivors’ health-related quality 
of life (HRQoL)8-12.
In the last decades, more attention is being paid to HRQoL after cancer diagnosis. Some studies 
have investigated HRQoL and fatigue in NHL survivors13-21, but almost all used a cross-sectional 
approach (only one measurement at a defined time)13, 17-21. However, the longitudinal course of 
fatigue and HRQoL in patients with NHL and their return to normal life remains largely unknown. 
The aims of the present study were, therefore, to: (i) assess fatigue and HRQoL twice following 
primary treatment, (ii) compare fatigue and HRQoL with an age- and sex matched normative 
population to assess the severity of the concerns, and (iii) identify associations with fatigue in 
survivors who remained fatigued.
design and methods
Setting and population
This study is part of a dynamic, longitudinal, population-based survey among NHL survivors 
registered with the Eindhoven Cancer Registry (ECR) of the Comprehensive Cancer Centre 
South (CCCS). The ECR records data on all patients who are newly diagnosed with cancer in the 
southern part of the Netherlands, an area with 2.3 million inhabitants, 18 hospital locations 
and two large radiotherapy institutes. The ECR was used to select all patients who were 
diagnosed with NHL between January 1st, 1999 and July 1st, 2009. We included all patients with 
indolent (including chronic lymphocytic leukemia) and aggressive B-cell NHL as defined by the 
International Classification of Diseases for Oncology-3 (ICD-O–3) codes22.
Participants aged ≥85 years at time of the first measurement were excluded, because they would 
likely have had difficulty in completing self-administered questionnaires without assistance. 
To exclude patients who had died, our database was linked on every measurement with the 
database of the Central Bureau for Genealogy, which collects data on all deaths of Dutch citizens 
through the civil municipal registries. Ethical approval for the study was obtained from a local, 
certified Medical Ethics Committee.




We used the Dutch validated version of the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) to assess HRQoL and fatigue. 
Answer categories range from one (not at all) to four (very much). After linear transformation, 
all scales and single item measures range in score from 0 to 100. A higher score on function 
scales and global health and quality of life scales implies a better HRQoL, whereas for symptoms 
a higher score refers to more symptoms23.
Fatigue was also assessed with the Fatigue Assessment Scale (FAS), a questionnaire consisting of 
ten items: five questions exploring physical fatigue and five questions exploring mental fatigue. 
The response scale is a 5-point scale (1 never to 5 always) and scores can range from 10 to 50. A 
score >21 indicates substantial fatigue. The psychometric properties are good24, 25.
Comorbidity at the time of the survey was categorized according to the adapted Self-administered 
Comorbidity Questionnaire (SCQ)26. Survivors’ marital status and educational level were also 
assessed in the questionnaire. Clinical information was available from the ECR which routinely 
collects data on tumor characteristics, including date of diagnosis, tumor grade, histology, Ann 
Arbor stage27, primary treatment, and patients background characteristics, including gender 
and date of birth. 
Data collection
Data were collected within PROFILES (Patient Reported Outcomes Following Initial treatment 
and Long term Evaluation of Survivorship). PROFILES is a registry for the study of the physical 
and psychosocial impact of cancer and its treatment from a dynamic, growing population-based 
cohort of both short and long-term cancer survivors. PROFILES contains a large web-based 
component and is linked directly to clinical data from the ECR. Details of the data collection 
method have been described previously28.
From May until November 2009, patients diagnosed between 6 months and 10 years previously 
received the baseline questionnaire (T1). A year later, patients who were willing to participate 
again received a 1-year follow-up questionnaire (T2). 
EORTC QLQ-C30, SCQ, marital status and educational level data were also collected from an 
age-and sex-matched normative population29 for comparison with the NHL survivors. 
Statistical analyses
All statistical analyses were performed using SAS (version 9.1 for Windows; SAS Institute Inc., 
Cary, NC, USA). P values <0.05 were considered statistically significant. Clinically relevant 
differences were determined using evidence-based guidelines for the interpretation of EORTC 
QLQ-C30 scores between groups30 and changes in scores31 and Norman’s ‘rule of thumb’ was 
used for the FAS whereby a ± 0.5 SD difference indicates a threshold of discriminating change 
in HRQoL scores32.
Differences in socio-demographic and clinical characteristics between respondents and non-
respondents or patients with unverifiable addresses and patients who completed one or two 
questionnaires were compared with a chi-square or t-tests, where appropriate. The mean EORTC 
QLQ-C30 scores among the NHL survivors were compared with those from an age- and sex-
matched Dutch normative population using independent sample t-tests. Paired sample t-tests 
were performed to compare the mean EORTC QLQ-C30 (both NHL survivors and the normative 
population) and FAS (only NHL survivors) Fatigue scale scores on T1 and T2.
Multivariate logistic regression analyses were carried out to investigate the independent 
association between the socio-demographic and clinical variables and constant fatigue (versus 
not constant fatigue). The “constant fatigue group” was defined by survivors/respondents of the 
normative population who had a Fatigue score >22 on both T1 and T2 for the EORTC QLQ-C30 
(i.e. at least a small, clinically relevant higher score than that of the normative population30) 
versus the group who did not have a fatigue score >22 on both T1 and T2. With respect to the 
FAS, the ‘constant fatigue group’ was defined by survivors who had a Fatigue score >21 on both 
T1 and T2 (i.e. indication of substantial fatigue25) versus the group who did not have a fatigue 
score >21 on both T1 and T2.
results
Characteristics of the patients and normative population
Eight hundred and twenty-four NHL survivors completed the first questionnaire (80% response 
rate). Subsequently, 434 (53%) survivors completed this questionnaire again 1 year later, which 
represents 36% of the total group of NHL survivors. Of the 1731 respondents of the normative 
population who completed the EORTC QLQ-C30, 602 could be age- and sex-matched with the 
NHL survivors. Of those 602, 515 (86%) respondents completed the questionnaire again 1 year 
later. Survivors with unverifiable addresses were more often female and younger compared 
to respondents, and non-respondents were more often diagnosed with indolent NHL and less 
often diagnosed with stage I disease (Table 1). 
The mean age at completion of the baseline survey was 63.5 years with a mean time since 
diagnosis of 4.2 years. Chemotherapy was the most frequent primary treatment (42%; Table 
1). Two-thirds of survivors reported one or more comorbid conditions, the most common 
being arthritis, back pain and hypertension (Table 2). In the age-and sex-matched normative 
population, the mean age at completion of the baseline survey was 63.5 years. Almost two thirds 
(65%) of respondents reported one or more comorbid conditions, the most common again being 
hypertension, back pain and arthritis (Table 2).
A comparison between survivors who completed one or both questionnaires indicated that 
those who completed both questionnaires had a significantly longer mean time since diagnosis 
at time of first enrollment (4.2 versus 5.1 years, p<0.001) and more often had a high educational 
level (19% versus 25%, p=0.013). No differences were observed between these groups for EORTC 
QLQ-C30 – Fatigue ( X =28.6 versus X =28.3, p=0.88) or FAS Fatigue ( X =21.9 versus X =21.4, 
p=0.33) scores.
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Table 1. Socio-demographic and clinical characteristics of questionnaire respondents, non-










N(%) N(%) N(%) p-value
Sex 0.021
Male 509 (62) 128 (61)   94 (51)
Female 315 (38)  84 (39)   90 (49)
Age at time of survey: mean (SD) 63.5 (12.4) 62.4 (14.0) 60.3 (14.8) 0.021
<55 years 189 (23)  58 (27)   62 (34)
55-69 years 336 (41)  75 (35)   59 (32)
70+ years 299 (36)  79 (37)   63 (34)
Years since diagnosis: mean (SD) 4.2 (2.7) 4.3 (2.9) 5.1 (2.9) 0.12
0-1 years 168 (20) 64 (30) 32 (17)
2-4 years 316 (38) 70 (33) 65 (35)
5-7 years 210 (25) 44 (21) 50 (27)
8-10 years 130 (16) 34 (16) 37 (20)
Stage at diagnosis 0.012
I 202 (25)   41 (19)   48 (26)
II 127 (15)   33 (16)   20 (11)
III 116 (14)   23 (11)   19 (10)
IV 202 (25)   44 (21)   51 (28)
Unknown# 177 (21)   71 (33)   46 (25)
Grade 0.042
Indolent 443 (54) 134 (63) 106 (56)
Aggressive 381 (46)   78 (37)   78 (44)
Primary treatment 0.05
Radiotherapy 75 (9)   21 (10)   21 (11)
Chemotherapy 345 (42)   65 (31)   63 (34)
RT+CH*  99 (12)   29 (14)   21 (11)
Active surveillance+ 224 (27)   76 (36)   63 (34)
CH+/-RT+Transplant* 11 (1)   6 (3)   0 (0)
S+/-RT+/-CH* 70 (9) 14 (7) 16 (9)
Note. 1p-value reflects differences between respondents and patients with unverifiable addresses. 2p-value reflects 
differences between respondents and non-respondents. #Tumor stage could not be determined in some subtypes 
of indolent non-Hodgkin Lymphoma. *RT= radiotherapy, CH= chemotherapy, Transplant= autologous stem cell or 
bone marrow transplantation, S= surgery, +/- = with or without. + Patients are under active surveillance and receive 
no therapy.
Table 2. Socio-demographic characteristics of NHL survivors (N=824), and respondents of an age- 





N (%) N (%)
Sex
Male 509 (62) 400 (66)
Female 315 (38) 202 (34)
Age at time of survey: mean (SD) 63.5 (12.4) 63.5 (13.2)
<55 years 189 (23) 144 (24)
55-69 years 336 (41) 242 (40)
70+ years 299 (36) 216 (36)
Self-reported comorbidity 
No comorbid condition 215 (26) 214 (36)
1 comorbid condition 245 (30) 166 (28)
2 comorbid conditions 155 (19) 112 (19)
>2 comorbid conditions 148 (18) 108 (18)
Most frequent comorbid conditions
Arthritis 183 (22) 125 (21)
Back pain 177 (21) 178 (30)
Hypertension 164 (20) 173 (29)
Marital status
Partner 646 (78) 460 (76)
Alone 41 (5) 142 (24)
Divorced 41 (5) Unknown
Widowed 80 (10) Unknown
Education level$
Low 139 (17) 36 (6)
Medium 485 (59) 338 (56)
High 179 (22) 224 (37)
Note. NHL=Non-Hodgkin Lymphoma; $Education levels included low= no/primary school; medium= lower general 
secondary education/vocational training; or high= pre-university education/ high vocational training/university
Health-related quality of life and fatigue among survivors of non-Hodgkin’s lymphoma and 
the normative population
Compared to an age- and sex-matched normative population, responding NHL survivors had, on 
average, worse scores for the EORTC QLQ-C30 Physical, Role, Cognitive and Social Functioning 
domains. NHL survivors also reported more Fatigue, Dyspnea, Sleeping Problems, Appetite Loss, 
Diarrhea and Financial Problems (all p≤0.001 and clinically relevant; Figure 1A and 1B). Scores 
between survivors of indolent and aggressive NHL were not significantly different. No clinically 
significant differences were found in EORTC QLQ-C30 mean fatigue scores depending on years 
since diagnosis (Figure 2).
Thirty-nine percent (n=321) of the NHL survivors did not have clinically relevant worse scores, 
i.e. they had a ≤5 point difference, for the EORTC QLQ-C30 Fatigue scale than the normative 
population. The other 61% did have clinically relevant worse scores for Fatigue, with the 
difference being small (>5 to 13 point difference) in 17% (n=140) of survivors; medium (>13 to 19 
point difference) in 15% (n=124) and large (>13 point difference) in 29% (n=239).



















Aggressive NHL (N=445) Indolent NHL (N=379) Norm population (N=602)
* ** * ** ** ** 


















** * ** ** 
Note. *p<0.001; **p<0.001 and small clinically important differences30; ***p<0.001 and medium clinically important 
differences30. A higher score refers to more symptoms.
Figure 1a. Differences on EORTC QLQ-C30 mean functioning and global quality of life scores 
between aggressive NHL survivors (N=445), indolent NHL survivors (N=379) and an age- and sex-
matched normative population (N=602).
Figure 1b. Differences on EORTC QLQ-C30 mean symptom scores between aggressive NHL survivors 
















NHL survivors Norm population
years since diagnosis 
Note. All p<0.001 and small or medium clinically important differences30. A higher score refers to more fatigue.
Figure 2. Differences between EORTC QLQ-C30 fatigue scores of all NHL survivors (N=824) according 
to survival years since diagnosis and an age- and sex-matched normative population (N=602).
Fatigue over time
The 1-year follow-up questionnaire was completed by 434 NHL survivors and 514 respondents 
of the normative population. With respect to FAS Fatigue (NHL survivors only), mean scores 
remained significantly stable over time – (T1: X =21; T2: X =22, Table 3). However, 22% reported 
deteriorated fatigue scores with a mean difference of 6.4 and 19% reported improved scores 
with a mean difference of 5.9. With respect to the EORTC QLQ-C30 Fatigue, mean scores 
also remained significantly stable over time – (T1: X =28; T2: X =29, Table 3), 32% reported 
deteriorated scores with a mean difference of 21 points, and 31% showed improved scores 
with a mean difference of 19 points. Similar mean scores and percentages of deterioration 
and improvement were observed when focusing on diffuse large B-cell lymphoma or follicular 
lymphoma only (Table 3). Mean scores of the normative population – changed slightly over 
time (T1: X =17; T2: X =18, p<0.04; Table 2) with 31% reporting deteriorated and 24% reporting 
improved EORTC QLQ-C30 Fatigue scores.
Of NHL survivors, 54% reported constant EORTC QLQ-C30 Fatigue, i.e. had a Fatigue score above 
22 for both T1 and T2. Of respondents of the normative population, 30% reported constant 
EORTC QLQ-C30 Fatigue. With respect to FAS Fatigue, 40% of NHL survivors reported constant 
fatigue i.e. had a Fatigue score above 21 on both T1 and T2.








































































































































































































































































































































































































































































































































































































































































Multivariate logistic regression analyses showed that NHL survivors who reported constant 
fatigue (on both EORTC QLQ-C30 and FAS) were more often diagnosed with stage IV disease and 
more often reported comorbid diseases. They were additionally more often female and divorced 
(Table 4). Survivors who remained fatigued (however only on FAS fatigue) were also more often 
diagnosed longer ago, were under active surveillance and had a lower educational level.
With respect to survivors of diffuse large B-cell and follicular lymphoma, survivors who reported 
constant fatigue (on both the EORTC QLQ-C30 and FAS) reported comorbid diseases more often. 
Survivors of follicular lymphoma who reported constant fatigue were also more often females; 
however, this was only found on the FAS (Table 4).
Respondents of the normative population who reported constant fatigue also reported comorbid 
diseases more often and more often had no partner (Table 4).
discussion
The majority of NHL survivors showed a constant, high level of fatigue in this population-based 
study up to 10 years after diagnosis. Six out of 10 survivors reported clinically relevant worse 
fatigue scores compared to the normative population. HRQoL was also worse to a clinically 
relevant degree among survivors. Mean fatigue scores remained significantly stable over time; 
22–28% reported clinically relevant deterioration, whereas 19–23% reported clinically relevant 
improvement; 44–54% reported constant fatigue. No clinically significant differences in EORTC 
QLQ-C30 mean fatigue scores were observed in relation to years since diagnosis.
Changes over time in NHL survivors have so far been investigated in three small studies, only 
including short-term survivors for a maximum of 18 months after primary treatment. One 
prospective study found no clinically significant change in mean EORTC QLQ-C30 Fatigue scores16. 
One Dutch study and another Norwegian study showed mean deteriorations in EORTC QLQ-C30 
Fatigue scores of 14 and 10 points when comparing start of treatment scores with those at 18 
months and 1 year of follow up, respectively14,15. A limitation of these studies is that they all 
focused on mean differences. Mean scores do not reflect individual changes. Given the large 
standard deviations, there must be high degrees of variations within these groups. A better 
way is, therefore, to make a distinction between patients who improved and patients who 
deteriorated.
The present study showed that survivors with stage IV disease and comorbid conditions more 
often reported constant fatigue. Females and divorced survivors were also more likely to remain 
fatigued. In the normative population, we also observed a relation between comorbidity and 
having a partner and fatigue. This relation is not, therefore, specific to NHL survivors but is 
probably applicable to people in general. Type of NHL (aggressive or indolent), treatment, 
and survival time since diagnosis were not associated, or only associated with one measure 
of fatigue in NHL survivors. The ECR collects data on primary treatment only. More detailed 
treatment information, longitudinally assessed, will enable us to study the relation between 
initial treatment and HRQoL and fatigue in more detail. Furthermore, detailed information about 













































































































































































































































































































































































































































































































































































































































































































































































































































































disease progression could also contribute to unraveling the course of HRQoL and fatigue and will 
help health care providers to give their patients better information about their expected HRQoL. 
As our HRQoL study is embedded in PHAROS (Population based HAematological Registry for 
Observational Studies) in which more detailed disease and treatment information is collected, as 
well as long-term side effects, we will be able to determine this relation better in the near future.
NHL survivors reported worse HRQoL compared to that of an age- and sex-matched normative 
population. Clinically relevant worse scores for survivors were observed for fatigue, appetite 
loss, diarrhea, dyspnea and all function scales including financial problems. One prospective 
and three cross-sectional studies also observed clinically worse scores for HRQoL domains for 
NHL survivors compared with those of a normative population13, 15, 17, 20.
Numerous patients in our study showed large improvements (19–23%) or deteriorations (22–
28%) within 1 year, which both indicate a clinically relevant change31. However, it is too soon to 
determine whether this can be defined as an actual change, due to regression to the mean. A 
longer follow-up time is needed to identify whether these differences can be considered as real 
changes or fluctuations over time.
Significant differences were not observed between patients with indolent or aggressive NHL, 
recapitulating findings in an American cross-sectional study33 nor between short- or long-term 
survivors, confirming results of a cross-sectional study among 761 NHL survivors20. This suggests 
that there is no improvement in time, which is also shown by our 1-year follow-up results.
Prevalence rates for cancer-related fatigue vary widely. Percentages between 32% and 60% 
have been reported34-36 and in a recently published study an overall prevalence of 48% was 
found37. The observed percentage of 61% in this study is somewhat higher. In our study, 29% of 
survivors reported large, clinically important fatigue, whereas 15% reported medium clinically 
important fatigue, making a total of 44%. Adding the survivors with small, clinically important 
fatigue produced the observed total of 61% of patients with cancer-related fatigue. Besides 
differences between types of cancer, the use of different cut-off scores and fatigue assessment 
instruments contribute to the differences in reported prevalence38-40.
The underlying mechanisms that cause constant cancer-related fatigue are not yet clear41. Many 
factors are associated with the development of fatigue, such as type of treatment, the disease 
itself, medication-related adverse events, biological modifiers (such as interferon), depression, 
physical inactivity, anxiety, pain and sleep disturbances42-46. Although the cause of fatigue is 
not completely clear, results of a recently published review47 show that patients with fatigue 
may benefit from pharmacological and/or non-pharmacological treatments, such as cognitive-
behavioral interventions and exercise48. Further research is necessary to determine whether 
an early intervention for fatigue can reduce this long-term complication and whether patients 
can benefit from late intervention.
The present study had the following limitations: although information was available concerning 
socio-demographic and clinical characteristics of the non-respondents and patients with 
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unverifiable addresses, it remains unknown whether non-respondents declined to participate 
in the study because of poor health or the absence of symptoms. Comparing patients who 
completed one questionnaire with patients who completed two questionnaires only indicated 
differences in mean time since diagnosis and educational level. This perhaps resulted in a small 
selection bias. In addition, there is always an uncertainty with the reproducibility of self-reported 
questionnaires. Some of the changes might be ascribed to that arbitrariness. The strengths of 
our study are the population-based sampling frame instead of a hospital-based sampling frame. 
Furthermore, the large range in elapsed time since diagnosis facilitates extrapolation of the 
results to a broad range of NHL survivors in the population. In addition, the longitudinal design 
provides important information about development over time.
In conclusion, six out of every ten NHL survivors reported a high level of fatigue up until 10 
years after diagnosis. HRQoL and fatigue scores of survivors were clinically relevant and worse 
than those of an age- and sex-matched normative population. Fatigue mean scores remained 
significantly stable over time and 44–54% of survivors reported constant fatigue. Survivors with 
stage IV disease, comorbid conditions as well as females and divorced survivors were more likely 
to remain fatigued. Having comorbidities and being without a partner were also associated with 
continuous fatigue in the normative population. As research on the underlying determinants 
of fatigue proceeds, health care providers should continue to screen patients on their level of 
fatigue and inform them about possible rehabilitation programs.
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To improve post treatment care for (long-term) lymphoma survivors in the Netherlands, 
survivorship clinics are being developed. As information provision is an important aspect 
of survivorship care, our aim was to evaluate the current perceived level of and satisfaction 
with information received by non-Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma (HL) and 
multiple myeloma (MM) survivors, and to identify associations with socio-demographic and 
clinical characteristics. The population-based Eindhoven Cancer Registry was used to select all 
patients diagnosed with NHL, HL and MM from 1999 to 2009. In total, 1,448 survivors received 
a questionnaire and 1,135 of them responded (78.4%). The EORTC QLQ-INFO25 was used to 
evaluate the perceived level of and satisfaction with information. Two thirds of survivors were 
satisfied with the amount of received information, with HL survivors being most satisfied (74%). 
At least 25% of survivors wanted more information. Young age, having had chemotherapy, having 
been diagnosed more recently, using internet for information, and having no comorbidities were 
the most important factors associated with higher perceived levels of information provision. 
Although information provision and satisfaction with information seems relatively good in 
lymphoma and MM survivors, one-third expressed unmet needs. Furthermore, variations 
between subgroups were observed. Good information provision is known to be associated 
with better quality of life. Survivorship care plans could be a way to achieve this. 
introduction 
On January 1, 2009 there were approximately 21,000 non-Hodgkin lymphoma (NHL), 5,300 
Hodgkin lymphoma (HL), and 3,300 multiple myeloma (MM) survivors in the Netherlands1. 
These numbers are expected to increase to approximately 32,000 NHL, 6,300 HL and 4,300 
MM survivors by 20201. This substantial raise will result in an increasing health care burden 
in haematology, especially indolent lymphomas and MM, which both are characterised by a 
prolonged clinical course with repeated relapses and slow but on-going progression2. 
To improve care for this growing group of cancer survivors, a nationwide initiative of 
haematologists, radiation oncologists, epidemiologists and internists has founded a Working 
Group named ‘BETTER’ (‘BETER’ in Dutch), which is currently developing protocols for 
standardized long-term care for HL and NHL survivors and establishing survivorship clinics. The 
goals of these clinics are to minimize the occurrence and influence of late effects and to improve 
survivors’ quality of life (QoL) by: informing survivors about long-term risks, advice preventive 
measures, suggest screening and improve aftercare by providing rehabilitation programs3.
Patient information is an essential component of cancer care and rehabilitation4. Patients, who 
are well-informed about their cancer, treatment, and aftercare, are more likely to complete their 
therapy and are less anxious thereafter5, 6. Providing adequate information to cancer patients 
can reduce the psychological burden and improve patients QoL and their satisfaction with 
care7, 8. This is important since lymphoma and MM survivors report lower QoL compared to 
normative populations even years after diagnosis9, 10.
Up to now, no studies have investigated the perceived level of and satisfaction with information 
provision in NHL, HL and MM survivors. If factors associated with information satisfaction are 
known, health care providers can better give adequate information to those who need it, 
which can contribute to an improved quality of care and QoL. The aim of the present study 
was therefore to measure the perceived level of, and satisfaction with information received 
by survivors of indolent NHL (I-NHL), aggressive NHL (A-NHL), HL and MM, and to identify 
associations with socio-demographic and clinical characteristics for each tumour type. 
methods
Setting and population
This study is part of a dynamic longitudinal population-based survey among lymphoma and MM 
survivors registered within the Eindhoven Cancer Registry (ECR) of the Comprehensive Cancer 
Centre South (CCCS) and is embedded in PHAROS (Population based HAematological Registry 
for Observational Studies). The ECR records data on all patients who are newly diagnosed with 
cancer in the southern part of the Netherlands, an area with 2.3 million inhabitants, 18 hospital 
locations and 2 large radiotherapy institutes. The ECR was used to select all patients who were 
diagnosed with NHL, HL and MM between January 1st 1999 and January 1st 2009. We included 
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all subtypes of indolent (including Chronic Lymphocytic Leukaemia-like) and aggressive B-cell 
NHL, HL, and MM as defined by the International Classification of Diseases for Oncology-3 codes 
(ICD-O-3)11.
Deceased patients were excluded by linking the ECR database with the Central Bureau for 
Genealogy. Ethical approval for the study was obtained from a regional, certified Medical Ethics 
Committee.
Data collection
Data collection took place in 2009 and was done within PROFILES (Patient Reported Outcomes 
Following Initial treatment and Long term Evaluation of Survivorship). PROFILES is a registry for 
the study of the physical and psychosocial impact of cancer and its treatment from a dynamic, 
growing population-based cohort of both short and long-term cancer survivors. PROFILES 
contains a large web-based component and is linked directly to clinical data from ECR. Details 
of the data collection method have been previously described12. Data from the PROFILES registry 
will become available for non-commercial scientific research, subject to study question, privacy 
and confidentiality restrictions, and registration (www.profilesregistry.nl).
In May 2009, patients between 1 and 10 years after diagnosis where included in the study and 
received the first questionnaire. In November 2009, patients diagnosed between May and 
November 2009 were invited to participate.
Study measures
The Dutch version of the European Organisation for Research and Treatment of Cancer (EORTC) 
QLQ-INFO25 questionnaire was used to evaluate the perceived level of and satisfaction with 
information among NHL, HL and MM patients13. This 25-item questionnaire incorporates four 
information provision subscales: perceived receipt of information about the disease; medical 
tests; treatment and other care services. Additionally, it contains several single items on receiving 
written information or information on CD or tape/video and items on the satisfaction with 
and helpfulness of the received information. Answer categories range from one (not at all) to 
four (very much), except for four items which have a two point scale. Furthermore, an open 
question is asked on what topics survivors would like to receive more information on. After linear 
transformation, all scales and items range in scores from 0 to 100, with higher scores indicating 
better perceived information provision. The questionnaire has been internationally validated; 
and internal consistency for all scales is good (ɑ>0.70), as is test-retest reliability (interclass 
correlations >0.70)14.  Our data revealed Cronbach’s alphas of 0.75 (disease), 0.88 (medical test), 
0.88 (treatment) and 0.82 (other services) for the four subscales respectively. In addition to 
the EORTC QLQ-INFO25, we asked patients two single questions about the use of internet for 
seeking additional information, which could be answered with either yes or no.
Comorbidity at time of survey was categorized according to the adapted Self-administered 
Comorbidity Questionnaire (SCQ)15. Questions on survivors’ marital status and educational level 
were also added to the questionnaire. Clinical information was available from the ECR that 
routinely collects data on tumour characteristics, including date of diagnosis, histology, Ann 
Arbor stage (where appropriate)16, primary treatment, and patients’ background characteristics, 
including gender and date of birth. 
Statistical analysis
All statistical analyses were performed using SPSS version 17.0 (Statistical Package for Social 
Sciences, Chicago, IL, USA) and P values of <0.05 were considered statistically significant. For 
the EORTC QLQ-INFO25 we used a score of ≥ 10 points difference on subscales to define a clinical 
important difference17. 
Differences in socio-demographic and clinical characteristics between respondents, non-
respondents, and patients with unverifiable addresses and between tumour types were 
compared with a chi-square, t-test, or its non-parametric equivalent where appropriate. 
Multi-item scales of the EORTC QLQ-INFO25 were included in the analyses if at least half of the 
items from the scale were answered, according to the EORTC QoL guidelines13, 14, 18. ANOVA and 
chi-square were performed to investigate mean differences between tumour type (independent 
variables) and the EORTC QLQ-INFO25 scales (dependent variables).
Multivariate regression analyses were performed to investigate the independent association 
of socio-demographic and clinical characteristics with the subscales of the EORTC QLQ-INFO25. 
All socio-demographic and clinical variables were included, this was determined a priori. Stage 
was only included in the analyses for A-NHL and HL, since it was not available for I-NHL and 
MM (Table 1). 
Logistic regression analyses were performed with received information satisfaction as outcome 
measure; one for the total group and four for the tumour types. Therefore, patients were 
categorized into two groups: (a) patients who were unsatisfied or only a little satisfied, classified 
as unsatisfied and (b) patients who were quite satisfied or very satisfied, classified as satisfied. 
Again, all socio-demographic and clinical variables were included. Stage was only included in 
the analyses for A-NHL and HL, since stage was not available in I-NHL and MM.
results
Patient and tumour characteristics
Of the 1,448 lymphoma and MM survivors who were sent a questionnaire, 1,135 (78%) completed 
it. Non-respondents were more recently diagnosed and less often diagnosed with stage I disease. 
Furthermore, they were less often treated with chemotherapy compared to respondents. 
Patients with unverifiable addresses were younger, diagnosed longer ago, less often treated 
with chemotherapy and more often had active surveillance as primary treatment compared 
to respondents. There were no differences in response according to tumour type or gender 
(Table 1). 
Participating HL survivors were significantly younger, more often had a job and reported fewer 
comorbid conditions than I-NHL, A-NHL and MM survivors. MM survivors were most recently 
diagnosed compared to the other three tumour groups (Table 2). 
Satisfaction with and amount of information
Satisfied cancer survivors (n=724; 67%) perceived to have received more information (disease, 
medical tests, treatment and other services) and found the information more useful than 
dissatisfied patients (n=411; 33%), with mean differences ranging between 46 to 74 points (all 
p<0.01).
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Table 1. Socio-demographic and clinical characteristics of questionnaire respondents, non-










N (%) N (%) N (%) p-value
Tumour type 0.06
I-NHL 443 (39) 140 (45) 110 (41)
A-NHL 375 (33)   80 (26)   82 (30)
HL 164 (14)   37 (12)   44 (16)
MM 153 (14)   56 (23)   35 (13)
Age (at time of survey) (mean ± SD) 61.6 (14) 60.5 (16) 57.2 (16) <0.01
<55 312 (28) 104 (33) 113 (42)
55-69 452 (40)   99 (32)   79 (29)
≥70 369 (33) 110 (35)   79 (29)
Years since diagnosis (mean ± SD) 3.7 (2.7) 3.2 (3.0) 3.9 (2.9) <0.01
0-1 313 (28) 130 (42)   71 (26)
2-4 422 (37)   92 (29) 102 (38)
5-7 264 (23)   46 (15)   56 (21)
8-10 136 (12)   45 (14)   42 (16)
Gender 0.38
Male 677 (60) 184 (59) 147 (55)
Female 457 (40) 127 (41) 120 (45)
Stage at diagnosis <0.01
I 248 (22)   52 (17)   65 (24)
II 220 (19)   57 (18)   39 (14)
III 183 (16)   40 (13)   42 (16)
IV 218 (19)   50 (16)   58 (21)
Unknown 266 (23) 114 (36)   67 (25)
Primary treatment
Radiotherapy    88 (7.8)    17 (5.4)      20 (7.4) 0.09
Chemotherapy 515 (45) 118 (38) 106 (39) 0.02
Chemotherapy + radiotherapy 239 (21)   56 (18)    52 (19) 0.11
Active surveillance+ 233 (21)   89 (23)    71 (26) <0.01
Stem cell transplantation    58 (5.1)    16 (5.1)       8 (3.0) 0.07
Note. I-NHL= indolent non-Hodgkin lymphoma, A-NHL= aggressive non-Hodgkin Lymphoma, HL= Hodgkin lymphoma, 
MM= multiple myeloma. + Patients are under active surveillance and receive no therapy.
In total, 29% of survivors would have liked to receive more information (29% I-NHL, 25% A-NHL, 
30% HL, 29% MM). Most frequently mentioned topics to receive more information about were 
cause and course of disease (45% I-NHL, 59% A-NHL, 24% HL, 54% MM), late effects of treatment 
(46% I-NHL, 37% A-NHL, 50% HL, 30% MM) and psychosocial aftercare (10% I-NHL, 23% A-NHL, 
26% HL, 30% MM).










N (%) N (%) N (%) N (%) p-value
Age (at time of survey) (mean ± SD) 64.1 (11) 63.3 (14) 46.6 (15) 66.1 (10) <0.01
<55 90 (20) 90 (24) 112 (69) 20 (13)
55-69 199 (45) 136 (36) 38 (23) 79 (52)
≥70 154 (35) 148 (40) 13 (8.0) 54 (35)
Years since diagnosis (mean ± SD) 4.0 (2.7) 3.5 (2.6) 4.4 (2.9) 2.4 (2.3) <0.01
0-1 100 (23) 108 (29) 36 (22) 69 (45)
2-4 169 (38) 144 (38) 50 (31) 59 (39)
5-7 113 (26) 85 (23) 49 (30) 17 (11)
8-10 61 (14) 38 (10) 29 (18) 8 (5.2)
Gender 0.10
Male 266 (60) 239 (64) 89 (54) 83 (55)
Female 177 (40) 136 (36) 75 (46) 69 (45)
Stage at diagnosis <0.01
I NA 118 (32) 30 (18) NA
II NA 90 (24) 83 (51) NA
III NA 68 (18) 33 (20) NA
IV NA 93 (25) 17 (10) NA
Unknown NA 6 (1.6) 1 (0.6) NA
Primary treatment
Radiotherapy (only) 64 (14) 12 (3.2) 4 (2.4) 8 (5.2) <0.01
Chemotherapy (only) 157 (35) 235 (63) 65 (40) 58 (38) <0.01
Chemotherapy+ radiotherapy 14 (3.2) 98 (26) 94 (57) 33 (22) <0.01
Active surveillance+ 187 (42) 25 (6.7) 1 (0.6) 20 (13) <0.01
Stem cell transplantation 8 (1.8) 22 (5.9) 0 (0) 28 (18) <0.01
Comorbidity <0.01
None 108 (26) 103 (30) 75 (48) 26 (19)
1 122 (30) 118 (34) 46 (30) 43 (31)
2 90 (22) 65 (19) 14 (9.0) 35 (26)
3 or more 90 (22) 60 (17) 20 (13) 33 (24)
Marital status 0.41
Partner 353 (81) 287 (79) 122 (75) 116 (77)
No partner 84 (19) 77 (21) 41 (25) 35 (23)
Education level$ 0.11
Low 69 (16) 62 (17) 16 (9.8) 30 (20)
Medium 264 (61) 219 (61) 99 (61) 95 (63)
High 101 (23) 80 (22) 48 (29) 27 (18)
Current occupation <0.01
Employed 166 (46) 128 (45) 112 (84) 39 (34)
Not working/retired 198 (54) 155 (55) 21 (16) 76 (66)
Follow-up care <0.01
No   42 (10) 32 (10) 12 (8) 30 (24)
2-4 times a year 324 (80) 245 (74) 81 (52) 95 (75)
Once a year 35 (9) 52 (16) 62 (40) 1 (1)
Once every two years 3 (1) 2 (1) 1 (1) 0 (0)
Note: I-NHL= indolent non-Hodgkin lymphoma, A-NHL= aggressive non-Hodgkin Lymphoma, HL= Hodgkin lymphoma, 
MM= multiple myeloma. +Patients are under active surveillance and receive no therapy. $Education levels included 
low = no/primary school; medium = lower general secondary education/vocational training; or high = pre-university 
education/ high vocational training/university. NA=Not Available.
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EORTC QLQ-INFO25 Mean (SD) Mean (SD) Mean (SD) Mean (SD) p-value
Information about disease 50 (22) 53 (20) 56 (16) 51 (22) <0.05a
Information about medical tests 63 (22) 64 (23) 68 (21) 65 (23) 0.15
Information about treatment 41 (24) 50 (21) 57 (19) 47 (24) <0.01b
Information about other services 16 (21) 25 (24) 27 (22) 22 (21) <0.01c
Satisfaction with information 60 (28) 61 (26) 66 (25) 61 (28) 0.15
Usefulness of information 62 (25) 66 (24) 73 (21) 62 (25) <0.01d
% Yes % Yes % Yes % Yes
Want more information 29% 25% 30% 29% 0.48
Want less information    3%   3%   2%   1% 0.74
Note. EORTC-QLQ INFO25 scales 0-100: a higher scores reflect better perceived information received. I-NHL= indolent 
non-Hodgkin lymphoma, A-NHL= aggressive non-Hodgkin Lymphoma, HL= Hodgkin lymphoma, MM= multiple 
myeloma. a= between I-NHL and HL; b= between I-NHL and A-NHL, HL, MM; between HL and A-NHL, MM; c= between 
I-NHL and A-NHL, HL, MM; d= between HL and I-NHL, A-NHL, MM.
Associations with perceived level of and satisfaction with information 
Mean scores on perceived level of and satisfaction with information on all scales were the highest 
for HL survivors and the lowest for I-NHL survivors (Table 3). Furthermore, HL survivors found 
the information more useful compared to all other tumor groups.  
Multivariate linear regression analyses including all patients in one model showed that receiving 
more disease-related information was associated with, having no comorbid conditions, using 
internet for information and hospital (β=0.11; p<0.01; Table 4). More information on medical tests 
was associated with less comorbidity, high education and use of internet. Furthermore, receiving 
more information about treatment and other services was associated with younger age, having 
had chemotherapy, less comorbidity, and hospital (β between 0.08 and 0.10; p<0.05). Being 
diagnosed with I-NHL and being under active surveillance was associated with a lower perceived 
level of receiving information about treatment. Satisfaction with information was independently 
associated with having had chemotherapy and negatively associated with comorbidity. 
Additional multivariate analyses within the different tumour types showed similar findings 
(data not shown in table). Younger age (β between -0.13 and -0.46; p<0.05) and a more recent 
diagnosis (β between -0.10 and -0.20; p<0.05) were frequently positively associated with 
perceived information provision, whereas comorbidity (β between -0.13 and -0.23; p<0.05) 
was frequently negatively associated with perceived information provision. 
I-NHL survivors with a low or medium educational level reported lower levels of treatment 
information (β=-0.15; p<0.05) compared to those who were highly educated. A-NHL survivors 
with stage II or III disease (β=0.22; p<0.01) or those who received chemotherapy (β=0.17; p<0.01) 
reported higher perceived levels of information compared to those who did not. HL survivors 
with a low educational level (β=0.23; p<0.05) and those using internet (β=-0.18; p<0.05) reported 
higher levels of perceived information. Lastly, MM survivors under active surveillance reported 
lower perceived levels of information about treatment (β=-0.45; p<0.05) compared to patients 
who were actively treated. 
Table 4. Standardized betas of multivariate linear regression analyses evaluating the association 
of independent variables with the information provision subscales.
Disease Medical 
tests
Treatment Other Satisfaction with 
received information
Beta Beta Beta Beta Odds ± 95%CI
Tumour type
I-NHL -0.07 -0.07  -0.12** -0.09 0.89 (0.52-1.52)
A-NHL -0.05 -0.07  -0.04  0.03 0.78 (0.48-1.28)
HL Ref Ref     Ref    Ref Ref
MM -0.05 0.02  -0.03 0.00 0.81 (0.43-1.56)
Age -0.05  0.01 -0.12** -0.11** 1.00 (0.99-1.01)
Years since diagnosis -0.01  0.01   0.02 -0.05 0.97 (0.92-1.03)
Gender
Male Ref Ref Ref Ref Ref
Female 0.01 0.02 -0.01 -0.01 0.77 (0.58-1.03)
Chemotherapy
No Ref Ref Ref Ref Ref
Yes 0.03 -0.01   0.14*  0.14** 1.81 (1.04-3.13)*
Radiotherapy
No Ref Ref Ref Ref Ref
Yes -0.08 -0.06 -0.06 -0.07 1.00 (0.68-1.45)
Active surveillance
No Ref Ref Ref Ref Ref
Yes -0.09 -0.08 -0.16** -0.06 1.39 (0.76-2.55)
Stem cell transplantation
No Ref Ref Ref Ref Ref
Yes 0.07 0.06 0.05 0.06 1.51 (0.73-3.13)
Comorbidity
None Ref Ref Ref Ref Ref
1 -0.07 -0.04 -0.07 -0.02 0.74 (0.51-1.52)
2 -0.07 -0.05    -0.14** -0.03    0.55 (0.36-0.85)**
3 or more  -0.90*  -0.90*   -0.07* -0.01    0.55 (0.36-0.84)**
Marital status
Partner Ref Ref Ref Ref Ref
No partner 0.01 0.02 -0.02 0.00 1.21 (0.84-1.73)
Educational level$
Low  0.02 -0.04 -0.02 -0.03 0.85 (0.52-1.38)
Medium -0.03  -0.08* -0.06 -0.05 0.81 (0.57-1.16)
High Ref Ref Ref Ref Ref
Use of internet
Yes Ref Ref Ref Ref Ref
No -0.08* -0.07* -0.04 -0.03 0.97 (0.71-1.32)
Note. *p<0.05; **p<0.01. I-NHL= indolent non-Hodgkin lymphoma, A-NHL= aggressive non-Hodgkin Lymphoma, 
HL= Hodgkin lymphoma, MM= multiple myeloma. $Education levels included low= no/primary school; medium= 
lower general secondary education/vocational training; or high= pre-university education/ high vocational training/
university.




In the present study among 1,135 NHL, HL and MM survivors, two-thirds of survivors were satisfied 
with the amount of received information about their haematological malignancy, respectively 
65% of I-NHL, 67% of A-NHL, 74% of HL and 68% of MM survivors. However, variations were 
observed and at least a quarter of survivors wanted more information, with large differences 
between hospitals (range 24-40%).
Younger age, having had chemotherapy, using internet for information and having no comorbid 
conditions appeared to be the most important factors associated with higher perceived levels 
of information provision. Analyses per tumour type showed similar findings. Worth mentioning 
is that in the analyses per tumour, I-NHL, A-NHL and MM survivors who had been diagnosed 
more recently had higher perceived levels of information provision, which possibly indicates 
that information provision has improved with time. However, it is also possible that recall bias 
influenced these findings, for those diagnosed more recently the information received is still 
fresh in their memory and by the more frequent contacts with their physician in the phase more 
closely to diagnosis.
Our findings that the perceived level of information provision is associated with age, education, 
time since diagnosis, and disease stage are in line with other studies19-24. Studies have shown 
that older and lower educated patients tend to ask fewer questions during their visit with their 
physician, and might therefore receive less information25, 26. Furthermore, older patients have 
been found to take a more passive role in interaction with their physician and have a greater 
reliance that their physician will provide all information24. In addition, higher educated patients 
are more likely to seek information from other sources such as the internet and consequently 
obtain more information24.
The results of our study, with 67% of survivors being satisfied with the amount of information 
received, were different compared to a study among mostly early stage melanoma survivors in 
which only 39% of survivors indicated to be satisfied22. These differences might be explained by 
the more chronic level and intense treatment of lymphoma and MM compared to early stage 
melanoma. In addition, lymphoma and MM survivors will have more visits with the physician 
and therefore a possible improved information provision. Patients’ satisfaction is also influenced 
by patients’ expectations of the course of their disease27. Patients expectations can vary widely, 
depending of the type of tumour27. HL survivors may be more satisfied with and score better on 
perceived information since they have a better prognosis compared to NHL and MM survivors. 
Survivors who were satisfied with the received information scored significantly and clinically 
relevant higher on all information provision subscales and on the usefulness of information 
scale compared to the unsatisfied survivors. To improve information provision in the group of 
unsatisfied survivors, physicians could screen their patients by asking if they are satisfied with 
the amount of information received, and when unsatisfied, physicians can ask what the patients’ 
information needs are. 
To provide the needed (written) information to patients, physicians should think of the 
educational level of the information provision. Patients with a lower educational level and 
patients with a low level of literacy will need extra help to understand the information. In the 
US, more attention is being paid to health literacy20, 21, 28, i.e. ‘the degree to which individuals have 
the capacity to obtain, process and understand basic health information and services needed 
to make appropriate health decisions’29, than in the Netherlands. Since our and other studies 
have observed that lower educated survivors report worse scores, more attention should be 
paid to providing information on a basic comprehensive level19, 22, 23. 
One-third of survivors would have liked to receive more information. The topic that was 
mentioned most often was information on late effects (37-50%) followed by information on the 
cause and course of the disease (24-59%) and psychosocial aftercare (10-26%). Inviting survivors 
for the ‘BETTER’ initiative could be an efficient solution to address these lasting information 
needs and leads to improved health care perception.
The present study has a few limitations. Although information was present concerning 
demographic and clinical characteristics of the non-respondents and patients with unverifiable 
addresses, it remains unknown why non-respondents declined to participate in the study. In 
addition, the cross-sectional design of our study limits the determination of causal associations 
between the study variables. Furthermore, the mean time since diagnosis was 3.7 years, which 
could influence the recall effect of information received. However, in the case of indolent 
lymphoma and MM patients who visit their physicians more often, this may not have been a 
major problem as the majority of those patients (95%) was still under active follow-up. 
The strengths of our study are the population-based sampling frame instead of a hospital based 
sampling frame, the high response rate, and the large range in elapsed time since diagnosis. This 
facilitates to extrapolate the results to a broad range of lymphoma and MM survivors.  
In conclusion, although information provision and satisfaction with information is relatively 
good in lymphoma and MM survivors, one third of the survivors were not satisfied with the 
perceived information provision and variations between subgroups of patients were observed. 
The differences found between the participating hospitals with an assumed similar patient 
population suggests that their remains room for improvement. As survival of NHL, HL and MM 
has improved over the past decades and the numbers of long-term survivors’ increases, late 
effects of therapy become more important. Optimal, tailor-made and repeated information 
provision will lead to improved patient satisfaction and QoL. Implementation of survivorship 
care plans could contribute to the improvement of information provision30. 
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chapter 9
Assessing the impact of cancer among Dutch non-Hodgkin lymphoma 
survivors compared with their American counterparts: A 
cross-national study
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To understand cultural differences in the impact of cancer (IOC), by (1) performing an independent 
psychometric evaluation of the Dutch version of the Impact of Cancer Scale version 2 (IOCv2) 
in a non-Hodgkin lymphoma (NHL) sample and (2) examining differences between Dutch and 
American NHL survivors in perceived IOC and identifying associations with socio-demographic 
and clinical characteristics.
Methods
Data collected from 491 Dutch and 738 American NHL survivors were used in this study. IOCv2 
responses were obtained from all survivors; the Dutch survivors also completed the European 
Organisation for Research and Treatment of Cancer Quality of Life Core questionnaire, which 
measures quality of life. 
Results
Exploratory factor analysis of the Dutch version yielded a factor solution similar to the American 
structure but with some subscales merging into single factors. Internal consistency was good; 
Cronbach’s alpha was 0.88 for the Positive and 0.94 for the Negative summary scales. Large 
differences were observed between survivors, whereby Dutch survivors reported fewer Positive 
(Δ-0.4, p<0.001, effect size: 0.27) and more Negative (Δ0.2, p≤0.001, effect size: 0.13) impacts 
of cancer independent of socio-demographic and clinical characteristics. 
Conclusion
Similar impact domains of the IOCv2 were observed in the Dutch sample, providing evidence that 
IOCv2 scales measure common and important survivor concerns across two different Western 
nations. Higher positive impacts for US survivors might be explained by more personal control 
and availability of supportive services. Future research should focus on determinants of the 
impact of cancer in both Dutch and American survivors to gain better understanding of the 
factors that might improve it and suggest how health care may be modified toward that end. 
introduction
Advances in cancer treatment have led to an expansion in  the number of cancer survivors in 
developed countries. Non-Hodgkin’s lymphoma (NHL) is one of the diseases that has benefited 
from such advances. For both the Netherlands and the United States (US), the annual age-
adjusted incidence of NHL is 1 in 5,000 persons, with approximately 3,000 new cases in 
the Netherlands1, 2 and 65,000 new cases in the US3 annually. The number of NHL survivors 
has increased rapidly from 13,400 in 2001 to 19,600 in 2008 in the Netherlands1, 2 and from 
approximately 347,000 in 2001 to 454,000 in 2008 in the US3. An individual has a 1 in 50 chance 
of being diagnosed with NHL during his or her lifetime.
As cancer survivors live longer, they develop risks such as late effects of therapy and adverse 
physical and psychosocial long-term effects4. These long-term effects include persistent fatigue, 
depression, anxiety and marital disruption that can have a negative influence on survivors’ 
health-related quality of life (HRQoL)5-10. While cancer survivors may be expected to return to 
normal life soon after treatment ends, they may continue to be burdened by the physical and 
psychosocial effects of the cancer and related treatments. 
In a recent systematic review, we found that, on average, lymphoma cancer survivors have 
decreased HRQoL compared to the general population even several years post-diagnosis (i.e., 
no resolution at more than five years post-diagnosis)11. However, most survivorship studies lack 
the use of an instrument that addresses the unique concerns related to the cancer experience 
such as those measured by the impact of cancer (IOC) scale12-14. This self-reported questionnaire 
was developed in the US to measure positive and negative impacts of cancer that long-term 
survivors attribute to their cancer experience. A translation of the IOC into Dutch has been 
undertaken, but its psychometric properties have not been described. 
Cultural differences may affect the perception of the impact of cancer on HRQoL15, 16. Moreover, 
attitudes towards health practice and illness may also be defined by culture17. Therefore, we 
undertook an examination of two samples of NHL patients in the Netherlands and the US, and 
compared their responses to the IOC. To better understand the commonality of psychosocial 
problems between cultures, it is important to examine cross-national differences18. This 
undertaking will provide more knowledge of culture-specific determinants of psychosocial well-
being. Therefore, the aims of the present study were to (1) perform an independent psychometric 
evaluation of the Dutch version of the IOCv2 in a NHL sample and (2) explore differences between 
Dutch and American NHL survivors regarding the impact of cancer and identify associations with 
socio-demographic and clinical characteristics associated with the IOC score.






NHL survivors aged ≥18 were identified using the Eindhoven Cancer Registry (ECR) to select all 
patients who were diagnosed with NHL between January 1st, 1999 and July 1st, 2009. We included 
all patients with indolent (including Chronic Lymphocytic Leukemia) and aggressive B-cell NHL 
as defined by the International Classification of Diseases for Oncology-3 codes (ICD-O-3)19. To 
identify and exclude patients who were deceased, the database was linked with the database 
of the Central Bureau for Genealogy, which collects data on all deceased Dutch citizens through 
the civil municipal registries. 
Data collection took place in summer 2009 and was done within PROFILES (Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship). PROFILES is a 
registry for the study of the physical and psychosocial impact of cancer and its treatment from 
a dynamic, growing population-based cohort of both short and long-term cancer survivors. 
PROFILES contains a large web-based component and is linked directly to clinical data from ECR. 
Details of the data collection method have been previously described20.
Of the 1,026 eligible survivors who were assumed to have received an invitation, 824 (80%) 
returned survey materials. Non-respondents were more often diagnosed with indolent NHL 
(63% versus 54%, p<0.05) and less often diagnosed with stage I disease (19% versus 25%, p<.05). 
There were no differences between respondents and non-respondents in gender or age.
American sample 
NHL survivors were identified through Duke University Medical Center and University of North 
Carolina at Chapel (UNC) Hill Lineberger tumor registries in November 2004 as previously 
described21. Patients were eligible if ≥18 years old at diagnosis, and ≥2 years post-diagnosis. 
Prospective participants were mailed a self-administered survey. Of the 1,195 eligible survivors 
who were assumed to have received an invitation, 886 (74%) returned survey materials. 
Participants, compared with non-participants, were less frequently African American (10% versus 
20%, p<0.001) and older at study enrolment (mean age 62.9 versus 58.8 years p<0.001).
Total sample
To create more comparable samples, we selected those survivors with overlapping ICD-O-3 
codes, i.e. excluding survivors diagnosed with Chronic Lymphocytic Leukemia in the Dutch 
sample and survivors with T-cell and NK-cell NHL in the American sample. We also excluded 
survivors diagnosed ≤2 years post-diagnosis in the Dutch sample since the IOC was developed 
for longer term survivors and the US sample included only this population13, 14. The total sample 
consisted of 1229 survivors, 491 Dutch and 738 American survivors (Figure 1). Institutional Review 
Board approval was obtained in both countries at all institutions participating in the study and 
written informed consent was obtained from each participant.






















































































































































































































































































































































































































The IOC presents statements regarding specific impacts of cancer to which respondents indicate 
their level of agreement from 1 (strongly disagree) to 5 (strongly agree).  Initial psychometric 
scaling of a 81-item IOC questionnaire yielded the 41-item IOC version 1 (IOCv1) 13, 14.  A more 
recent and comprehensive scaling of the IOC questionnaire yielded the 37-item IOC version 2 
(IOCv2)12. The Dutch survivors completed the IOCv1, which is missing 7 items that are in IOCv2. 
A newly developed algorithm was used to impute the 7 missing IOCv2 item scores for the Dutch 
survivors based on their IOCv1 responses22. The American survivors completed the 81-item IOC 
questionnaire and had their responses scored as IOCv2 scales.  Other reports from the American 
sample have used both the IOCv1 and IOCv2 scoring formats9, 10.
The Dutch survivors also completed the Dutch validated version of the European Organisation for 
Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-C30) which assesses 
HRQoL in cancer patients23. Response categories range from 1 to 4. After linear transformation, all 
scales and single item measures range in score from 0 to 100. A higher score on function scales 
and the global health and quality of life scale implies a better HRQoL, whereas for symptoms 
(scales and items) a higher score refers to more symptoms23.
For both samples, comorbidity was assessed with the Self-administered Comorbidity 
Questionnaire (SCQ)24. Marital status and educational level were also assessed in both samples. 
For the Dutch sample, clinical information was available from the ECR that routinely collects data 
on tumor characteristics, including date of diagnosis, tumor grade, histology, Ann Arbor stage25, 
primary treatment, and demographic characteristics, including gender and date of birth. Clinical 
data pertaining to the American sample were obtained from Duke University Medical Center 
and University of North Carolina at Chapel Hill Lineberger Tumor Registries and complemented 
with self-reported data.
Statistical analysis
All statistical analyses were performed using SAS (version 9.1 for Windows; SAS Institute Inc., 
Cary, NC). P values of <0.05 were considered statistically significant. Differences in socio-
demographic and clinical characteristics between Dutch and American NHL respondents were 
assessed using chi-square and t-tests.
Psychometric evaluation 
An exploratory factor analysis was conducted on the 37 items of the IOCv2 of the Dutch sample. 
Factors were extracted using principal components; the number of factors was selected using 
eigenvalue >1 and scree plots and promax rotation were performed. We repeated the factor 
analysis three times, with six, seven and eight factors, as the scree plot showed a stabilization 
point after six and eight factors. Internal consistency of the IOCv2 of the Dutch sample was 
measured using Cronbach’s alpha. The Cronbach’s alpha coefficient should reach 0.7 or above 
to be judged as good internal consistency and reliability26. Concurrent validity was evaluated 
by calculating Spearman correlation coefficients between IOCv2 scales and EORTC QLQ-C30 
subscales. We hypothesized that the IOCv2 positive scales would be uncorrelated with the 
EORTC QLQ-C30, because they measure distinct constructs. We hypothesized that the IOCv2 
negative scales would be substantially correlated with the EORTC QLQ-C30, because limitations 
in functioning and having cancer-related symptoms could have negative impacts on one’s QOL.
Comparison of Dutch and American survivors
The mean IOCv2 scores of the Dutch NHL survivors were compared with the scores of the 
American NHL survivors using independent sample t-tests. Multivariate linear regression analysis 
was performed to investigate the independent association between socio-demographic and 
clinical variables and IOCv2 scales for the samples (Dutch and American) separately and for 
the total NHL sample. Since there were no large differences between countries in associations 




Comparisons between Dutch and American NHL survivors showed significant differences on 
most socio-demographic and clinical characteristics (all p<0.001) except for age, marital/partner 
status and NHL histology (Table 1). Dutch respondents were more often male, had on average 
a lower educational level and were less likely to be employed during study enrollment. Mean 
interval since diagnosis was shorter among Dutch survivors, who also had a smaller range of 
interval (i.e., standard deviation). Dutch survivors also reported fewer comorbid conditions. 
Despite statistically significant differences in disease stage and treatment, both survivor groups 
were most often diagnosed with stage I disease followed by stage IV disease, and chemotherapy 
and radiotherapy were the most common treatments received. The mean age at the time of 
survey for both groups was 63 years and about 80% of survivors were married or in a committed 
relationship.
Psychometric evaluation
Exploratory factor analysis 
The six factor structure yielded the most interpretable solution. ‘Health Awareness and Worry’ 
emerged as a single factor as did ‘Body Change Concerns and Life Interferences’. The additional 
factors represented the four other domains of the IOCv2, i.e. Meaning of Cancer, Positive Self-
Evaluation, Altruism/Empathy, and Appearance Concerns (Appendix 1). Item IOC29 loaded higher 
on Meaning of Cancer than on Health Awareness (0.57 vs. 0.35). The emerging of Body Change 
Concerns and Life Interferences as a single domain was also observed in the factor analysis of 
the American NHL sample27. Cronbach’s alpha was 0.88 for the Positive and 0.94 for the Negative 
Impact scales, respectively, and ranged from 0.75 to 0.93 for the subscales.
Concurrent validity
The correlations between IOCv2 Positive scales and the EORTC QLQ-C30 were all below 0.30, 
supporting the distinctive content of the IOCv2 Positive scales from this HRQOL measure 
(Appendix 2). With respect to IOCv2 Negative scales we observed an overall pattern of moderate 
(r≥0.30) to substantial correlation (r≥0.45) with the EORTC QLQ-C30. The strongest correlation 
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N (%) N (%) p-value
Gender <0.001
Male 290 (59) 363 (49)
Female 201 (41) 375 (51)
Age at time of survey: mean (SD) 63.0 (12.5) 63.0 (13.3) 0.98
<50 years   71 (15) 111 (15)
50-64 years 174 (35) 273 (38)
65+ years 246 (50) 339 (47)
Education$ <0.001
Low 111 (23) 81 (11)
Medium 291 (61) 353 (49)
High   74 (16) 284 (40)
Marital/partner status 0.16
Married/committed 390 (81) 567 (78)
Not married/committed   92 (19) 164 (22)
Employment status <0.001
Currently employed 116 (25) 287 (42)
Not employed or retired 339 (75) 400 (58)
Years since diagnosis: mean (SD) 5.3 (2.2) 10.2 (7.3) <0.001
2-4 years 263 (54) 180 (24)
5-7 years 153 (31) 223 (26)
8-10 years   75 (15) 151 (17)
>10 years 0 293 (32)
NHL histology 0.89
Indolent 226 (46) 314 (43)
Aggressive 265 (54) 374 (54)
Unknown 0 50 (6)
NHL stage at diagnosis 0.001
I 153 (31) 183 (28)
II   93 (19) 149 (18)
III   75 (15) 133 (17)
IV 146 (30) 205 (24)
Unknown#  24 (5) 68 (13)
Primary treatment/ treatment <0.001
Radiotherapy 148 (30) 363 (49)
Chemotherapy 343 (70) 618 (84)
Biologic 0 224 (30)
Active surveillance+ 78 (16) 0
Transplant* 28 (6) 126 (17)
Surgery 33 (7) 237 (33)
Self-reported comorbidity <0.001
No comorbid condition 136 (30)   75 (10)
1 comorbid condition 138 (31) 135 (19)
2 comorbid conditions   93 (21) 141 (19)
>2 comorbid conditions   86 (19) 374 (52)
Note. $Education levels included low= no/primary school; medium= lower general secondary education/vocational 
training; or high= pre-university education/ high vocational training/university; #Tumor stage could not be determined 
in some subtypes of indolent non-Hodgkin Lymphoma. +Patients are under active surveillance and receive no therapy; 
*Transplant= autologous stem cell or bone marrow transplantation.
was observed between IOCv2 Body Change Concerns and Fatigue of the EORTC QLQ-C30 
(r=0.61). 
Comparison of Dutch and American survivors
Significant differences were observed between Dutch and American NHL survivors on all IOCv2 
scales (all p<0.01) except for Meaning of Cancer and Life Interferences (Table 2). Dutch survivors 
scored lower on the Positive Impact subscales (i.e., Altruism/Empathy, Health Awareness and 
Positive Self-Evaluation) and higher on the Negative Impact subscales (i.e., Appearance Concerns, 
Body Change Concerns and Worry). The difference on the Positive Impact Summary scale was 
larger compared to the Negative Impact Summary scale (0.4 vs. 0.2 points, both p<0.01).
Multivariate linear regression analysis also showed lower Positive IOCv2 scores and higher 
Negative IOCv2 scores (p<0.001) for Dutch survivors (Table 3). Based on the total sample of 
Dutch and American NHL survivors, females scored significantly higher on several Positive Impact 
subscales and on Appearance Concerns. Older survivors scored significantly lower on both 
Positive and Negative Impact Summary  scales. In addition, higher educated survivors showed 
less Altruism/Empathy, survivors without a partner reported more Worry, and survivors who 
were not employed or were retired showed less Life Interferences.
With respect to the clinical characteristics, survivors with a longer survival time post-diagnosis 
showed higher Positive Self-Evaluation scores, and less Negative Impacts on Body Change 
Concerns, and Worry. Survivors with an aggressive NHL histology reported less Worry. 
Furthermore, survivors with more advanced disease stage, especially stage IV disease, showed 
higher scores on Health Awareness and on all Negative Impact scales. Survivors treated with 
chemotherapy reported a higher Positive Self-Evaluation and Positive Impact Summary scale as 
well as higher scores on Body Change Concerns. Lastly, survivors with three or more comorbidities 
had higher Negative Impact subscale scores.










SD Range Mean SD Range Δ p-value Effect 
size r
Altruism/Empathy 3.3 0.8 1-5 3.9 0.9 1-5 - 0.6 <0.001 0.33
Health Awareness 3.2 0.9 1-5 3.7 0.9 1-5 - 0.5 <0.001 0.27
Meaning of Cancer 2.7 0.9 1-5 2.7 1.1 1-5 0 0.12 0.00
Positive Self-Evaluation 3.4 0.8 1-5 3.9 1.0 1-5 - 0.5 <0.001 0.27
Appearance Concerns 1.8 0.9 1-5 1.7 0.9 1-5 0.1 0.004 0.06
Body Change Concerns 2.6 1.0 1-5 2.4 1.2 1-5 0.2 0.002 0.09
Life interferences 2.0 0.7 1-5 2.0 0.7 1-4.8 0 0.62 0.00
Worry 2.8 1.0 1-5 2.6 1.0 1-5 0.2 <0.001 0.10
Positive Impact Scale 3.1 0.6 1-4.9 3.5 0.8 1-5 - 0.4 <0.001 0.27
Negative Impact Scale 2.4 0.8 1-4.9 2.2 0.7 1-4.8 0.2 0.001 0.13
Note. IOCv2= Impact of Cancer Scale version 2.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The findings of this study show that similar impact domains were observed for Dutch and 
American NHL survivors, providing evidence that the IOCv2 measures common and important 
survivor concerns across two different Western nations. The internal reliability and consistency 
of the Dutch scales were good and construct validity was observed between the IOCv2 negative 
scales and the EORTC QLQ-C30. Unfortunately, we could not evaluate the construct validity of 
the IOCv2 Positive Impact subscales, since the Dutch study did not have a relevant questionnaire 
that measured positive growth. 
We also observed significant differences between Dutch and American NHL survivors, whereby 
Dutch survivors reported less positive impacts and more negative impacts of cancer. These 
differences, combined with construct validity, suggest that the IOCv2 scales are able to distinguish 
between cultures of the impacts of cancer, and this questionnaire is thus culturally sensitive. 
One explanation for these differences might be that living in different cultures cultivates other 
psychological resources which influence health. The structure of a society, such as the social 
safety net and health care systems, contributes to shaping population health and attitudes 
towards health care28. Individuals in the US are socialized to rely more on individual resources 
compared with collective resources in Western Europe16, 29. In the US, health care programs fall 
under the responsibility of the individual30, 31, whereas in the Netherlands they are administered 
by the government32, 33. To be more responsible for one’s own health care creates a situation 
wherein control must be exercised. This sense of control is reflected in the emergence of a 
patient autonomy movement that began in America during the 1970s. Since then, a shift was 
made from a more paternalistic relationship between physicians and patients to a more equal 
relationship34, 35, whereby information provision is one of the key elements of patient autonomy36. 
Studies have shown that personal control is associated with better self-reported health37, 38 since 
individuals who believe that they have some degree of control over their lives may be more 
likely to take action in difficult situations39. Furthermore, the sense of personal control is more 
prevalent in North America than in Europe15, which might result in the ability to alter perceptions 
of the cancer experience in a more positive way among American survivors. Additionally, the 
hospitals where the American NHL survivors were treated have well-developed programs in 
cancer survivorship care. For example, support groups are readily available and Duke University 
Medical Center provides free psychosocial counseling and UNC social workers were available 
to assist patients free of charge. A recent study reported that social support is associated with 
more positive and less negative Impacts of cancer (Smith et al., under review). Therefore, the 
higher positive and lower negative impact scores of the American survivors might be ascribed 
partly to having received more social support. Other evaluation of the sample demonstrated 
that females scored significantly higher on the positive impacts of cancer (Smith et al., under 
review). However, in the Dutch sample no differences in impact between men and women were 
observed, which may reflect other differences between the genders across the two samples.
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Our results related to the impact of cancer are largely consistent with another Dutch study of 
562 melanoma survivors40. In both studies, it appeared that time since diagnosis, tumor stage, 
and comorbidity were found to be associated with negative impacts of cancer.
The present study had some limitations. Although the response rate was high for both samples 
and information was available on socio-demographic and clinical characteristics of the non-
respondents in both samples, it remains unknown whether non-respondents declined to 
participate in the study because of poor health. In addition, the seven missing items for the 
IOCv2 were calculated with a newly developed algorithm which has not been tested in other 
samples yet. Furthermore, the US data were collected from two institutions only, which limits 
the heterogeneity of the American sample.
In spite of these limitations, this study provides important information about the valid use of 
the IOCv2 in the Netherlands and with a preliminary look at the cross-national difference of the 
IOCv2 between Dutch and American NHL survivors. Results suggest that Dutch NHL survivors 
have lower positive and higher negative impacts of cancer compared with their American 
counterparts. Higher positive impacts for US survivors might be explained by more personal 
control and availability of supportive services. Future research should focus on determinants 
of the impact of cancer in both Dutch and American survivors to gain better understanding of 
the factors that might improve it. 
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Appendix 1. Exploratory factor analyses and reliability analyses of IOCv2 items for the Dutch non-
Hodgkin lymphoma survivor sample (N=491).
Dutch NHL survivors
Factor loadings Cronbach’s α
Altruism/Empathy .82
IOC64 Having had cancer has made me more willing to help others 0.84
IOC63 Because I had cancer I am more understanding of what other people 
feel
0.66
    
IOC62 I feel a special bond with people with cancer 0.60 
IOC65 I feel I should give something back to others 0.81 
Health Awareness* .75
IOC16 Having had cancer has made me more concerned about my health 0.81 
IOC15 I do not take my body for granted since I had cancer 0.73 
IOC17 I am more aware of physical problems or changes 0.65 
IOC29 Having had cancer made me take better care of myself 0.23***
Meaning of Cancer .88
IOC55 Because of cancer I have more confidence in myself 0.85 
IOC56 Having had cancer has given me direction in life 0.80 
IOC54 Because of cancer I have become better about expressing what I want 0.81 
IOC58 Because of having had cancer I feel that I have more control of my life 0.90 
IOC53 Having had cancer turned into a reason to make changes in my life 0.63 
Positive Self-Evaluation .78
IOC32 I consider myself to be a cancer survivor 0.90 
IOC33 I feel a sense of pride or accomplishment from surviving cancer 0.85 
IOC37 I feel that I am a role model 0.53 
IOC34 I learned something about myself because of having had cancer 0.55 
Appearance Concerns .80
IOC26 I worry about how my body looks 0.68 
IOC27 I feel disfigured 0.80 
IOC28 I sometimes wear clothing to cover parts of my body 0.81 
Body Change Concerns** .79
IOC25 I am bothered that my cannot do what it could before 0.63 
IOC24 I am concerned that my energy has not returned 0.60 
IOC39 Having had cancer has me feel old 0.54 
Life Interferences** .90
IOC67 Having had cancer has made me feel alone 0.79 
IOC57 I feel like cancer runs my life 0.78 




IOC40 I feel guilty today for not having been available to my family 0.46 
IOC73 Ongoing symptoms interfere with my life 0.76 
IOC70 Uncertainty about my future affects my decisions to make plans 0.86 
IOC72 Having had cancer keeps me from doing activities I enjoy 0.86 
Worry* .93
IOC23 Having had cancer make me feel uncertain about my health 0.89 
IOC9 I worry about the future 0.75 
IOC8 Having had cancer makes me feel unsure about the future 0.78 
IOC21 I worry about cancer coming back or getting another cancer 0.79 
IOC22 New symptoms make me worry about cancer coming back 0.74 
IOC19 I worry about my health 0.76 
IOC12 I feel like time in my life is running out 0.47 
Positive impact scale .88
Negative impact scale .94
Note. IOCv2=Impact of Cancer Scale version 2, NHL= non-Hodgkin lymphoma *Body change concerns and life 
interferences emerged as a single domain. **Health awareness and worry emerged as a single domain. *** Item 































































































































































































































































































































































































































































































































































































































































































































































































































Summary and general discussion




This thesis started with a systematic literature review focusing on health-related quality of life 
(HRQoL) of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)  (Chapter 
2). The aims were to identify the HRQoL domains that were most affected, study the impact 
of clinical (including treatment) and socio-demographic factors on HRQoL, and investigate the 
methodological strengths and limitations of the literature. Twenty-four articles were identified, 
14 focusing on HL and 10 on NHL. The shortcomings of these studies were mainly the lack of a 
prospective design and the lack of information on non-respondents. The reviewed literature 
reflects that several domains of HRQoL, also in long-term lymphoma survivors, are affected. 
Compared to a normative population, HL survivors experience the most problems in (role) 
physical, social and cognitive functioning, general health, fatigue and financial problems, 
whereas NHL survivors experience the most problems in physical functioning, appetite loss, 
vitality and financial problems. In addition, HL survivors with older age and females reported 
worse outcomes. The results are less clear for NHL as only a few studies were performed. 
Furthermore, these studies were mainly focusing on all NHL subtypes combined instead of 
major subtypes of NHL. 
As an answer to the limited attention for subtypes of NHL, we performed three studies on the 
impact of treatment on the HRQoL of patients with diffuse large B-cell lymphoma, (DLBCL), 
follicular lymphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/
SLL). The population-based Eindhoven Cancer Registry was used to select all patients diagnosed 
with DLBCL, FL and CLL/SLL from 2004-2010 and respectively 256 (84%), 148 (82%) and 136 
(78%) patients responded.  
Patients with DLBCL who were treated with rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone every two weeks (R-)CHOP14 more often reported tingling in hands 
and feet, were more often fatigued and had more often a slowed down feeling compared to 
patients treated with (R-)CHOP every three weeks ((R-)CHOP21). Furthermore, older patients 
more often had persistent tingling in hands and feet and persistent worry about future health 
while a persistent slowed down feeling was reported more often by patients with comorbidities. 
Based on these observational findings with respect to HRQoL and symptoms, it seems that 
R-CHOP21 impacts less on HRQoL and symptoms of patients with DLBCL included in this study 
compared to R-CHOP14 (Chapter 3).
With respect to FL (N=148), HRQoL was worse among patients who underwent 
immunochemotherapy compared to an age- and sex-matched normative population. Patients 
under active surveillance or those who underwent radiotherapy reported similar HRQoL compared 
to the normative population, except for fatigue. Patients who received immunochemotherapy 
reported fatigue more often compared to patients who underwent radiotherapy. A quarter 
to 50% of patients reported persistent symptoms/worries over a one-year period such as 
worry about future health, feeling slowed down, lethargic, limited in social activities; they also 
exhibited significantly lower HRQoL than those without these symptoms/worries (Chapter 4).
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CLL/SLL patients (N=136) whose malignancy was ever treated reported a significantly worse 
HRQoL than the normative population, whereas no differences were observed between the 
normative population and patients under active surveillance. Furthermore, younger patients 
tended to worry more about their future and patients with comorbid diseases reported more 
fatigue, more worry about their health and scored lower on physical functioning. 
In contrast to our hypothesis, patients who received chlorambucil reported the worst HRQoL 
scores. We furthermore expected patients in the active surveillance group to worry most, since 
they were not actively treated for their cancer, but our data showed that patients who received 
chlorambucil worried significantly more. Long-lasting negative effects of starting treatment on 
HRQoL cannot be excluded, whereas active surveillance did not seem to provoke worrying, 
anxiety, or depressive symptoms in responders (Chapter 5).
As cancer patients with solid tumors often report anxiety, depressive symptoms and fatigue, we 
wanted to investigate the longitudinal prevalence of these symptoms among lymphoma patients. 
Anxiety and depressive symptoms were reported more often by responding patients with HL 
(N=180) and DLBCL (N=309) compared to the age- and sex-matched normative populations, 
i.e. patients reported rates between 17-24% and the normative populations between 11-14%. 
Over the four time points, approximately 10% of HL and DLBCL patients reported to be always 
anxious or depressed and an additional 15% sometimes. Importantly, global health status/HRQoL 
was lower in patients with anxiety or depressive symptoms and appeared to be constant over 
time (Chapter 6). 
The level of persistent fatigue among NHL survivors was assessed in Chapter 7. The population-
based Eindhoven Cancer Registry was used to select all patients diagnosed with NHL from 
1999-2009; 824 survivors (80%) completed the first questionnaire and subsequently 434 
survivors (53%) completed these questionnaires again one year later. The data showed that 
a majority of responders had a constant high level of fatigue up to 10 years after diagnosis. 
Six out of 10 survivors reported clinically relevant worse fatigue scores compared to the 
normative population. Also HRQoL was clinically relevant worse among survivors compared to 
the normative population. Fatigue mean scores remained significantly stable over a one-year 
period; 22-28% reported clinically relevant deterioration, whereas 19-23% reported clinically 
relevant improvement; 44-54% reported constant fatigue. Related to years since diagnosis, no 
clinically significant differences in mean fatigue scores were observed. 
In Chapter 8, the level of perceived information, provision and satisfaction with this information 
among patients with lymphoma and multiple myeloma (MM, a plasma cell tumor) were 
investigated. Among 1,135 NHL, HL and MM survivors, 65% of indolent NHL, 67% of aggressive 
NHL, 74% of HL and 68% of MM survivors were satisfied with the amount of received information 
about their hematological malignancy and treatment trajectory. However, about one third of 
responding survivors were not satisfied and at least a quarter wanted more information. The 
topic that was mentioned most often when in need of more information was related to: 
- late effects (37-50%), 
- information on the cause and course of the disease (24-59%) and 
- psychosocial aftercare (10-26%). 
Young age, treatment with chemo, a recent diagnosis, using internet for information, and being 
without comorbidities were the most important determinants of higher perceived levels of 
information provision. The large variation in perceived information provision that was reported 
by patients from different hospitals, with an assumed similar patient population, suggest that 
there is room for improvement at hospital level. 
To assess cultural differences between the HRQoL of American (from North Carolina; N=738) 
and Dutch (N=491) NHL survivors we performed a cross-national study comparing the positive 
and negative impact of cancer. We observed that compared to their American counterparts 
Dutch survivors scored:
- lower on the positive impact subscales (Altruism/Empathy, Health Awareness and Positive 
Self-Evaluation),
- higher on the negative impact subscales (Appearance Concerns, Body Change Concerns 
and Worry). 
These findings seemed independent of socio-demographic and clinical characteristics (Chapter 
9). Higher positive impacts for US survivors might be explained by more personal control and 
availability of supportive services in the investigated American hospitals.
general discussion
With the continuing improvements of new therapies among lymphoma patients, the rising 
incidence and the aging of the population, the number of lymphoma survivors will grow 
continuously. It is expected that in 2020 there will be 38,300 lymphoma survivors in the 
Netherlands1 and 831,000 in the US2, an increase of approximately 65% compared to 2010 in 
both countries. It is of utmost importance to evaluate the consequences of treatment on the 
health-related quality of life (HRQoL) of these patients, in order to optimize treatment and help 
clinicians to inform cancer patients about the potential (long-term) effects from the specific 
treatment they receive(d). The goal of new therapies should, besides improvement of survival, 
include achieving or maintaining optimal well-being. Not only after primary treatment but also 
long after treatment has ended, since many survivors are at risk for late effects of treatment3-8. 
The objective of this thesis was to gain knowledge and provide an overview of the associations 
between clinical factors such as treatment and lymphoma type and HRQoL. Besides, the relation 
between socio-demographic factors (such as age, educational level and nationality) and HRQoL 
and the relation between disease and/or treatment related symptoms and HRQoL was evaluated 
(Figure 1).
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lymphoma treatment impacts on the HRQoL of patients
DLBCL: RCHOP14 versus RCHOP21
In this thesis we observed that patients with diffuse large B-cell lymphoma (DLBCL) who received 
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone every two weeks ((R-)
CHOP14) reported more symptoms, among others neuropathy and a worse HRQoL compared to 
patients who received (R-)CHOP every three weeks ((R-)CHOP21). Short-term toxicity is known 
among these therapies9, 10 as is neuropathy by more or less comparable treatment regimens11, 12. 
No studies had focused yet on the longer-term toxicity and self-reported HRQoL of lymphoma 
patients who underwent (R-)CHOP14 or (R-) CHOP21. An explanation for more neuropathy 
among patients treated with (R-)CHOP14 might be that these patients receive vincristine (with 
neuropathy as a known side-effect) in a quicker succession compared to patients treated with 
(R-)CHOP21. With respect to overall survival, it was thought that CHOP every 14 days was superior 
to a 21-day schedule13, and therefore younger and fitter patients were more often treated with 
RCHOP14. However recently, two trials showed no differences in overall survival between 
RCHOP14 and RCHOP21 and advise RCHOP21 as the standard first line treatment for DLBCL9, 10. 
Based on these observational findings with respect to HRQoL and symptoms, it seems again that 
R-CHOP21 is the preferred treatment since it impacts less on HRQoL and symptoms of patients 
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Figure 1. Conceptual model: associations between patient, tumor, treatment and hospital factors 
with patient reported outcomes. 
FL: immunochemo- and radiotherapy
We observed that patients with follicular lymphoma (FL) who underwent immunochemotherapy 
reported fatigue more often compared to patients who underwent radiotherapy. No other 
differences on the HRQoL or symptom scales were observed between these treatment 
types. Two other studies were identified that compared HRQoL between treatment regimes, 
although they evaluated other regimens compared to our study14, 15. Our observation of higher 
fatigue levels among patients who underwent immunochemotherapy can also result from the 
extensiveness of the disease, although there was no difference in HRQoL between patients who 
underwent one or more treatment lines. The discussion on how much treatment is optimal for 
FL is ongoing16, 17. In early stage FL it seems that patients benefit from radiotherapy with respect 
to overall survival but still many asymptomatic patients are not treated and are under active 
surveillance instead18-21. The number of early stage FL patients in our sample was too small to 
study differences in HRQoL between patients who underwent radiotherapy and patients under 
active surveillance. Future research, whereby we expand our HRQoL research to other regions 
of the Netherlands could evaluate this.  
CLL: active surveillance versus chlorambucil versus intense immunochemotherapy
In contrast to our hypothesis, CLL/SLL patients who received chlorambucil and rituximab reported 
the worst HRQoL scores. Although their scores were not significantly different compared to CLL 
patients who underwent more intense immunochemotherapy, we expected a smaller impact 
of chlorambucil treatment, since chlorambucil is viewed as a ‘simple’ oral therapy. Our findings 
are not completely in line with a randomized clinical trial (RCT) that observed that HRQoL was 
better among patients treated with chlorambucil compared to patients receiving fludarabine. 
This difference was only observed during and not after treatment22 and might furthermore 
be explained by the different settings in which the studies were performed, i.e. population-
based study including elderly and frail patients versus an RCT with a strict selection of relatively 
healthy patients. We also expected patients in the active surveillance group to worry most, but 
patients who received chlorambucil worried significantly more. Due to the observational nature 
of our study we cannot exclude that patients with a lower HRQoL before treatment were more 
often treated with chlorambucil which may have influenced the results. Although, based on our 
observational findings it seems that starting treatment in CLL/SLL patients conveys a drastic, 
long-lasting negative effect on HRQoL, whereas active surveillance does not appear to provoke 
worrying, anxiety, or depressive symptoms. Our data therefore suggest that, with respect to 
HRQoL, it seems wise to stay conservative in starting treatment in asymptomatic patients.
Besides the impact of treatment, as discussed above, the disease itself could also affect the 
HRQoL of lymphoma patients. Therefore, it is important to notice that the deterioration in HRQoL 
can be a result of the disease itself, its treatment, or a combination of those.
The importance of including a normative population
To evaluate the specific impact of lymphoma and its treatment beyond the natural aging 
process and the impact of comorbidities, a comparison with an age- and sex-matched normative 
population was made. This comparison helps to define what ‘normal’ levels of functioning 
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are for people without cancer. In four articles of this thesis this comparison was made and 
worse scores for lymphoma survivors were observed. The HRQoL domains that were most 
affected were cognitive functioning (memory and concentration problems), social functioning 
(limitations in family life and social activities), fatigue, dyspnea and sleeping problems. Also 
financial problems were reported more often compared to the general population, which is 
a known problem among cancer patients23. Furthermore, higher rates for fatigue, anxiety and 
depressive symptoms compared with a normative population were observed in this thesis. 
These findings are consistent with the literature, that also shows worse HRQoL and higher 
prevalence of fatigue, anxiety and depressive symptoms among lymphoma patients compared 
to the general population14, 24-38.
patient and clinical characteristics associated with health-related 
quality of life: identification of patients at high-risk 
Besides treatment and lymphoma itself, socio-demographic and clinical factors may contribute 
to differences in HRQoL (Figure 1). This information was evaluated in order to identify patients 
at high risk for developing symptoms and deteriorated HRQoL.
Socio-demographic factors 
Age and sex differences
In this thesis it was observed that among HL patients, younger women and older men reported 
higher levels of depressive symptoms. Female NHL patients reported more persistent fatigue. 
However, no consistent relation between gender and HRQoL can be drawn from the results in 
this thesis, which is in line with other studies among NHL patients that report contradicting 
results33, 39, 40. With respect to HL, there is some evidence that older patients and women report 
clinically important worse outcomes with respect to HRQoL25, 30, 32, 41, although this was not 
observed in this thesis.
In this thesis it was observed that the difference in prevalence of anxiety and depressive 
symptoms was larger between HL patients and the normative population than the difference 
between DLBCL patients and the norm. This might suggest that since HL patients were on average 
18 years younger, being diagnosed with lymphoma at an earlier age has a greater impact. In our 
study among 363 DLBCL patients we also observed larger differences compared to the norm for 
patients aged 18-59 than for patients aged 76-85 years42. An explanation might be that older 
patients may have better coping strategies through more life experience and they are likely to 
be faced with lower work-related and social demands and therefore experience less impact. 
So, on the one hand it seems logical to be careful with giving older patients toxic treatments 
since this could have a large impact on their HRQoL. However, it is also important to be careful 
with younger patients and not assume that they are able to take very aggressive therapies since 
they are young and relatively healthy. On the other hand, several studies show that older age in 
itself is stated by doctors as a reason for suboptimal treatment, even in the absence of a poor 
performance status43-45. It is often assumed that a standard treatment will lead to deterioration 
in HRQoL. The results of our study suggest that that is not the case in DLBCL survivors. However, 
we cannot exclude that elderly patients perhaps received less aggressive treatment schedules. 
Either way, besides survival, treatment should also focus on achieving or maintaining optimal 
well-being to make sure that patients are able to live with the consequences. 
Education
It was observed in this thesis that both HL and DLBCL patients who were lower educated 
experienced more anxiety and depressive symptoms compared to higher educated patients, 
which is consistent with previous research31, 46. It has been suggested that the adaptive needs such 
as problem solving and long-term planning are affected by the educational level of patients47. 
Furthermore, higher educated patients or patients with a higher socioeconomic status may be 
better able to understand and remember the information they have received and therefore 
better manage their disease. The understanding of the patients is an aspect that should receive 
more attention48. Awareness of the background characteristics of patients could help health care 
professionals to provide more patient-centered information.
Cultural differences
Differences between Dutch and American (from North Carolina) NHL survivors were observed 
in this thesis for the impact of cancer, whereby Dutch survivors reported less positive and 
more negative impacts of cancer. Could living in different cultures cultivate other psychological 
resources, which influence health? In the US, health care programs fall more under the 
responsibility of the individual49, 50, whereas in the Netherlands they are the responsibility of 
the government51, 52. To be more responsible for one’s own health care creates a situation wherein 
control must be exercised. Studies have shown that personal control is associated with better 
self-reported health53, 54 since individuals who believe to have some degree of control over 
their lives may be more likely to take action in difficult situations55. Furthermore, the sense of 
personal control is more prevalent in North America than in Europe56, which might result in the 
ability to alter perceptions of the cancer experience in a more positive way among American 
survivors. Since most cancer survivorship research is done in the US and it seems that there are 
differences between US and Dutch lymphoma survivors it is important to gain more knowledge 
about the experienced quality of care and quality of life reported by patients in the Netherlands. 
Clinical factors
Comorbidity  
In this thesis it was observed that compared to lymphoma patients (HL and/or NHL) without 
comorbidities those with concomitant diseases reported worse HRQoL, more fatigue, anxiety 
and depressive symptoms, more negative impacts of cancer and worried more about their future 
health. Research shows that comorbidity explains more variance in physical and emotional 
function, pain, and fatigue in comparison with socio-demographic and cancer characteristics 
in cancer survivors57. These findings emphasize the importance of alertness on comorbidity by 
health care professionals. Recognition of comorbidity will help to better tailor (after) care for 
patients with lymphoma or other cancers. When interpreting HRQoL results between groups, 
taking the presence of comorbid conditions into account, as was done in this thesis, is relevant as 
this influences the results. Studying comorbidity among lymphoma patients is also important as 
chapter 10 summary and general discussion
161160
10
many patients live long after their cancer diagnosis and are at risk for late effects of treatment3-8. 
Comorbidity should therefore be registered carefully and at several times since cancer diagnosis 
to distinguish between already existing comorbidity at time of cancer diagnosis and late effects 
of treatment. However, after diagnosis it becomes difficult to distinguish between (late) effects 
of treatment and comorbidity.
Time since diagnosis
No significant differences in HRQoL, fatigue, anxiety and depressive symptoms with respect to 
time since diagnosis were observed in all studies in this thesis. This is in line with a study among 
761 NHL survivors36. A study among 459 HL patients even observed that patients 7-10 years after 
diagnosis reported higher anxiety and depression scores compared to patients 3-6 years after 
diagnosis31. So, while most lymphoma survivors may be expected to return to normal life soon 
after treatment ends, there is growing evidence that a large proportion continues to be burdened 
by the physical and psychosocial effects of the cancer and related treatment. 
Tumor type
In this thesis it was observed that HL survivors reported a higher perceived level of and 
satisfaction with information than NHL and MM survivors. Patients’ satisfaction is influenced 
by patients’ expectations of the course of their disease58 and these can vary widely, depending 
of the type of tumor. HL survivors may be more satisfied with and score better on perceived 
information since they have a better prognosis than NHL and MM survivors. Or maybe they 
actually receive more (and better) information since they are on average 20-30 years younger, 
and perhaps better educated, compared to the other patient groups.
continuation of problems and associations between symptoms and 
HRQoL
In this thesis it was observed that at least a quarter of lymphoma survivors reported persistent 
disease and/or treatment related symptoms, 17-24% reported anxiety or depressive symptoms 
and 44-54% reported constant fatigue. Other researchers are also focusing on the persistence 
of symptoms and HRQoL among lymphoma patients59. It consistently seems that about 30% of 
lymphoma survivors report persistent problems. As described in the above sections, clinical and 
socio-demographic factors are associated with outcomes; however until now no specific profile 
for patients experiencing problems can be made. In this thesis no biological, psychological and 
environmental factors were included which might help to determine a potential profile.  
This thesis furthermore shows negative associations, sometimes also longitudinal, between 
(persistent) disease and/or treatment related symptoms, anxiety and depressive symptoms 
and HRQoL. Alertness by patients and health care professionals for the presence of persistent 
symptoms that occur during and after treatment of lymphoma patients is needed and may help 
to avoid lasting negative influence on their HRQoL.
strengths, limitations and suggestions to improve population-based 
research
Study design
A major strength of our studies is that HRQoL was assessed in a population-based setting, 
facilitated by the Eindhoven Cancer Registry (ECR) that includes patients with comorbidities 
and elderly patients. Studies focusing on populations including these patients are of critical 
importance as comorbidity and age affect the HRQoL of patients and influences treatment 
decision making45, 60, 61.  Furthermore, the infrastructure of the PROFILES registry provides an 
excellent system for collecting HRQoL data of lymphoma patients and also for other tumors. The 
linkage between PROFILES and data from the ECR and PHAROS made it possible to evaluate the 
associations between clinical factors and patient-reported outcomes on a routine basis and to 
evaluate the impact of specific treatment regimens on the HRQoL of NHL patients.
Another strength is that, in the chapters 3, 4, 6 and 7 patients were examined at two or more 
time points. This longitudinal design provided insight into changes and the persistence of issues 
and is therefore important. However, the observational nature of our design limits in establishing 
causality and the results might be biased by confounding by indication, i.e. elderly and/or frail 
patients with a worse HRQoL are more likely to receive a less aggressive treatment compared to 
young and relative healthy patients. The inclusion of patients at different times since diagnosis 
(between 6 months and 10 years) moreover resulted in a heterogeneous group of patients with 
respect to survival time.
Comparative effectiveness research
To continue with the evaluation of the short- and long-term effects of the new and changing 
treatment regimens that are given to lymphoma patients, more comparative effectiveness 
research should be performed. Both RCTs and population-based observational studies have 
their advantages and disadvantages. In general, RCTs can be expensive and not always applicable 
to patients treated in daily practice while observational studies are somewhat limited in 
establishing internal validation since the absence of randomization. Recently, the suggestion 
of a randomized registry trial has been made, which might be a solution for the disadvantages 
of the study designs described above62. The idea of the randomized registry trial is to perform 
a trial based on a platform of an already-existing high-quality observational registry, in which 
detailed clinical data is embedded. Large patients groups can then be selected and randomized 
for a new trial. Although it sounds ideal, this design also has its limitations, it is for example 
not possible in every country and the question is if these data are complete enough and are of 
high enough quality. This should therefore be further explored. Until then it seems logical that 
the knowledge gained from clinical trials should be complemented by data from longitudinal 
population-based observational studies. Cancer registries are an excellent basis for this. The 
Netherlands Cancer Registry (NCR) collects data on primary treatment and in the Eindhoven 
Cancer Registry (ECR) also comorbidity at time of diagnosis is registered which is very valuable 
in the evaluation of quality of care. Although, in HRQoL assessment among (long-term) cancer 
survivors, the registration or collection of self-reported comorbidity data at time of questionnaire 
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completion is needed in order to evaluate the specific impact of patients current comorbid 
diseases on HRQoL.
Since patients are living longer and receive treatment when they have disease recurrence, follow-
up registry of a specific number of items is required. PHAROS (an extension of the NCR) is the first 
registry in the Netherlands that started collecting follow-up data on among others treatment, 
adverse events and treatment outcomes, such as survival for hematological malignancies. To 
avoid getting lost in details and time consuming registration only a limited number of items 
should be registered.
In this thesis, data from PHAROS were used for several analyses. However, sample sizes for the 
evaluation of HRQoL were somewhat small since PHAROS, although started in 2009 was still in 
startup, but the registry is getting more and more complete. The impact of treatment on HRQoL 
of patients was investigated apart from survival. Future studies should focus on the combination 
of HRQoL and survival, to gather a more comprehensive perspective. Furthermore, since patients 
were included after treatment and baseline differences between treatment groups cannot be 
excluded as part of the explanation of the differences in HRQoL, future longitudinal population-
based studies should also include HRQoL assessment before treatment. Moreover, to obtain 
a less heterogeneous patient group with respect to times since diagnosis, patients should be 
included at a fixed time since diagnosis and be followed from then on. 
Response rates and representativeness of data
The number of patients responding to our questionnaire was high for the first measurement 
(75-85%). After that response rates began to decline, i.e. varying between 50-67% of the original 
cohort for the second measurement, around 40% for the third measurement and around 30% 
for the subsequent measurements. A meta-analysis reported average response rates for mailed 
cross-sectional surveys between 40-70%63 so our response rate for the first measurement was 
much higher. The response rates for follow-up are similar to other longitudinal population-
based observational studies. Since such studies are dependent of continuous cooperation of 
patients and referring, it always remains a challenge to maintain participation. To investigate 
ways to increase the response rate for patients who were invited for the third time, our research 
group conducted an experiment to evaluate the effectiveness of a monetary incentive on the 
response rate. Sixty lymphoma patients received a gift card of 10 Euros and the other 65 did 
not. It appeared that the gift card not only improved the overall response (90% versus 66%), it 
also quickened the response time. Furthermore, the cost of the incentive could outweigh the 
cost of having to send reminders.
Maybe even more important than the response rate is the representativeness of the data. 
We therefore always compared socio-demographic and clinical factors available from the ECR 
between respondents and non-respondents in our studies. Also the scores between patients 
who completed one, two or more questionnaires on outcomes of interest, such as HRQoL, were 
compared to verify potential selection bias. To even better understand the non-responder group 
and the group that stops participating after a certain measurement, future research could focus 
on the differences in disease and survival outcomes between these groups. It might be that 
non-respondents and patients who stop with the questionnaires are suffering more from their 
lymphoma or even decease earlier. On the other hand it might be that they feel very well and do 
not feel the necessity to complete the questionnaires. Either way, for the representativeness of 
a study, future studies should collect as much data as possible on non-respondents, and explore 
why people stop participating, to identify possible bias.
Recruitment strategies
Hematologists and oncologists involved in the treatment and follow-up of lymphoma patients in 
the region of the ECR were asked to participate in our studies and almost all did (83%), indicating 
the interest and importance of the research. Since research assistants from PROFILES coordinated 
and facilitated the mailing of the questionnaires at each hospital, the effort requested of the 
specialists was little and this improved participation. This might not be possible in every country, 
but if so researchers should try to facilitate this as much as possible.
Determination of clinical relevance
When comparing scores of patients with those of normative populations or between treatment 
groups, it is important to use a certain criterion for clinical relevance of the results to identify 
the HRQoL domains and symptoms that are clinically relevant affected in patients. Although 
many studies base their conclusions on statistical significance, it is recommended to also use 
a criterion for the interpretation of clinical relevance to really attribute to the care of patients. 
For some questionnaires, such as the EORTC QLQ-C30, evidence-based guidelines have been 
developed for the determination of clinical important differences between groups and within 
patients over time64, 65. The differences can be divided into four size classes: 
- large (representing unequivocal clinical relevance), 
- medium (clinically relevant, but to a lesser extent), 
- small (subtle but, nevertheless, clinically relevant) 
- and trivial (circumstances unlikely to have any clinical relevance or being without a 
difference). 
If no specific guideline is available for a questionnaire, then for example Norman’s ‘rule of thumb’ 
can be used, whereby a ± 0.5 SD difference indicates a threshold of discriminating change in 
HRQoL scores66.
Development of lymphoma specific HRQoL questionnaires
To measure HRQoL the European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30 (EORTC QLQ-C30)67 was used. HRQoL is a multidimensional construct 
that covers patients’ perceptions of his or her physical, emotional, social and cognitive functions 
and disease and/or treatment related symptoms and represents patients’ subjective experience 
with cancer. The EORTC QLQ-C30 is a cancer specific HRQoL questionnaire, but consists of such 
questions that this questionnaire (on for example memory and concentration problems, hair 
loss, fatigue and pain) is also applicable to the general population, to enable comparisons68. 
In addition to a cancer specific questionnaire, HL, NHL and CLL/SLL specific questionnaires 
should be used to detect side-effects and symptoms particularly relevant to these patients 
and survivors. HL, NHL and CLL/SLL specific questionnaires will be able to do this with more 
sensitivity compared to cancer specific questionnaires. In the absence of a true HL or NHL 
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HRQoL questionnaire, the EORTC CLL-16 was used to assess disease and treatment-related 
specific symptoms and worries for all (HL, NHL and CLL) patient groups. As the name suggests, 
this questionnaire was originally developed for patients with CLL/SLL. However, after discussion 
with specialists treating both CLL, HL and other NHL patients it was decided to administer the 
questionnaire for all lymphoma patients included in our studies.
Since a specific HL and NHL questionnaire is absent and the existing CLL/SLL module required an 
update, the EORTC Quality of life Group (QLG), with Lonneke van de Poll-Franse, Fabio Efficace 
and Simone Oerlemans as principal investigators, started with the development of a set of 
questionnaires to assess symptoms and HRQoL of these patients. Participants come from the 
UK, Italy, France, Austria, Taiwan and the Netherlands. The development consists of four phases, 
according to the guidelines of the EORTC QLG69. At the moment, phase I and II are completed 
and data collection for phase III is on-going. Phase I was aimed at compiling an exhaustive list 
of relevant HRQoL issues for CLL/SLL, NHL and HL patients, wherefore I performed extensive 
literature searches and held focus groups. Phase II consisted of the operationalization of the 
final phase I list of HRQoL issues into questions compatible with the EORTC QLQ-C30 in terms of 
format (response categories: ‘not at all’, ‘a little’, ‘quite a bit’, and ‘very much’) and time frame 
(one week). In phase III, the principal investigators as well as the collaborators from the UK, 
Italy, France, Austria, Taiwan and the Netherlands are now administering the questionnaire to 
the different patient groups to identify and solve potential problems in its administration and 
to identify missing or redundant issues. The aim is to complete phase III in 2014 and start with 
international field testing (phase IV) of the modules in 2015, so this questionnaire can soon be 
used in future research to assess disease and treatment specific concerns among these patients.
Future directions: improving HRQoL and care by interventions
The substantial rise in patients who have or ever had lymphoma will result in an increasing 
health care burden in hematology. To improve care for this growing group of cancer survivors, 
several initiatives are being undertaken and these as well as directions for the future will be 
discussed in this section.  
Patient-centered information provision
An important aspect of patient care is the provision of information70. The goal of providing 
information is to prepare patients for their treatment, to increase treatment adherence and 
abilities to cope with cancer and to promote recovery71. Patients, who are well-informed about 
their cancer, treatment, and aftercare, are more likely to complete their therapy and are less 
anxious thereafter72, 73. Providing information is a difficult task since information is often complex, 
meant to make serious decisions, and potentially upsetting 74. Information needs furthermore 
vary by sex, age, cultural background, time since diagnosis, educational level, stage of the 
disease and adjustment style74, 75. It can in this way reduce the psychological burden and improve 
patients’ quality of life and their satisfaction with care76, 77. 
Personalized survivorship care plans could be a way to improve information provision and 
thereby care among lymphoma survivors. These personalized care plans consist of 
- detailed information provision about diagnosis and treatment of cancer, 
- possible long-term and late effects and management thereof, 
- lifestyle and cancer surveillance recommendations, and 
- available resources78. 
A recent trial among 43 oncology providers in the south of the Netherlands showed that 
oncology providers are generally positive about personalized care plans and are motivated to 
keep using it, they furthermore believe that patients are positively affected by it79. Another 
initiative with respect to improving information provision taken by the NFK (Dutch federation 
of cancer patient organizations), Dutch Cancer Society and Comprehensive Cancer Centre the 
Netherlands resulted in www.kanker.nl, developed in 2013. This website aims to provide patient-
centered information, knowledge from cancer survivors and e-health focused on optimal quality 
of life. Through the library of www.kanker.nl visitors receive patient-tailored information, based 
on their profile. Leaflets of www.kanker.nl are available in most Dutch hospitals and health care 
professionals are encouraged to inform patient about the website.
Self-management
In the past decades, health care has changed through a gain in knowledge and technologies, 
whereby more and more patients take an active role in treatment decision and take responsibility 
for receiving good (after) care, also called self-management. Self-management is defined as ‘the 
individual’s ability to manage symptoms, treatment, physical and psychosocial consequences and 
life style changes resulting from their chronic illness’80. Also in the Netherlands, self-management 
is getting a more important role in cancer survivorship care80. Studies have shown that personal 
control is associated with better self-reported health53, 54 since individuals who believe that 
they have some degree of control over their lives may be more likely to take action in difficult 
situations55. One of the key elements for personal control or self-management support is access 
to accurate and personalized information81. Self-management support is furthermore oriented at 
fostering intrinsic motivation and the acquisition of knowledge and skills. However, since patients 
vary in their existing knowledge and the amount and type of information they want or can 
understand as well as their expectations of the consultation, self-management support will not 
be profitable for everyone. It is therefore important that health care providers discuss patients’ 
needs and expectations during consultations to be able to provide patient-centered care.
Intervening on self-management
Providing feedback and information to patients on their self-reported HRQoL and symptoms 
compared to results of other cancer patients or compared to a normative population might 
help empower patients to initiate to discuss the relevant topics with their physicians. I therefore 
performed a pilot study to investigate if patients would like to receive this kind of feedback. 
Of 47 lymphoma patients (response rate 73%), two-third reported that they would like to 
receive feedback on their reported HRQoL and symptoms and especially see their scores in 
comparison with other lymphoma patients (80%). To gain more evidence on how to support 
self-management in lymphoma cancer care, future studies should focus on interventions for 
supporting self-management82. For example by the provision of feedback and information on 
patients self-reported HRQoL and symptoms and by providing interventions to target specific 
information needs of patients. 
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Establishment of cancer survivorship clinics
To further improve care for lymphoma patients and survivors, a nationwide initiative of 
hematologists, radiation oncologists, epidemiologists and general internists has founded a 
working group named ‘BETTER’ (‘BETER’ in Dutch)83. ‘BETTER’ is currently developing protocols 
for standardized long-term care for HL and NHL survivors and establishing survivorship clinics. 
The goals of these clinics are to minimize the occurrence of late effects and to improve survivors’ 
HRQoL by: 
- informing survivors about long-term risks, 
- advise preventive measures, 
- suggest screening 
- and improve aftercare by providing rehabilitation programs. 
Inviting survivors for the ‘BETTER’ initiative could certainly be an efficient solution to improve 
care and address their lasting physical and psychosocial needs. 
concluding remarks
Due to the ongoing improvements of new therapies, the rising incidence and the aging of the 
population, the number of lymphoma survivors will increase continuously. Both HL and NHL 
survivors experience physical and psychosocial problems as a result of cancer and its treatment, 
also long after completion of primary therapy. Furthermore, at least a quarter of lymphoma 
survivors reported persistent disease and/or treatment related symptoms, such as neuropathy 
and feeling lethargic, about half of patients worried about future health, 17-24% reported anxiety 
or depressive symptoms and 44-54% reported constant fatigue. Awareness and recognition of 
the specific health problems that lymphoma patients are facing is important to provide optimal 
supportive care. Strategies to improve this care, via the ‘BETTER’ initiative and the empowerment 
of patients, need to be examined. 
Note. The data used for this thesis (data of patients and data of normative populations) are or 
become available at www.profilesregistry.nl and are free of use for non-commercial researchers.
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Lymfeklierkanker is een vorm van kanker van het lymfestelsel en ontstaat doordat een afwijkende 
lymfekliercel abnormaal groeit. Lymfekliercellen, ook wel lymfocyten genoemd, zijn een soort 
witte bloedcellen. Er zijn twee grote groepen van lymfeklierkanker te onderscheiden, namelijk 
het Hodgkin lymfoom en het non-Hodgkin lymfoom. Het Hodgkin lymfoom is vernoemd 
naar Thomas Hodgkin, die in 1832 voor het eerst afwijkingen beschreef in het lymfestelsel. 
Het non-Hodgkin lymfoom is een verzamelnaam voor ongeveer vijftig verschillende soorten 
lymfeklierkankers die alle soorten omvat behalve het Hodgkin lymfoom. De meest voorkomende 
typen non-Hodgkin lymfoom zijn diffuus grootcellig B lymfoom, folliculair lymfoom en chronische 
lymfatische leukemie/klein lymfocytair lymfoom.
Behandeling van lymfeklierkanker 
Gezien de grote variëteit aan soorten lymfeklierkanker is er niet één type behandeling. De 
behandeling voor lymfeklierkanker kan bestaan uit chemotherapie, bestraling, doelgerichte 
therapie, immunotherapie of stamceltransplantatie. Vaak wordt er een combinatie van deze 
behandelingen gegeven. Bij sommige soorten lymfeklierkanker hoeft er niet (meteen) behandeld 
te worden, omdat de lymfomen langzaam groeien of omdat de ziekte na behandeling meteen 
weer terug komt, dit beleid heet ‘wait and see’.
Toenemend aantal patiënten 
Dankzij vroegere opsporing en verbeterde behandelingen leven patiënten met lymfeklierkanker 
steeds langer. Ook de vergrijzing van onze bevolking draagt bij aan de forse toename van het 
aantal (ex-)kankerpatiënten. In Nederland was de prevalentie (aantal mensen dat ooit de 
diagnose lymfeklierkanker kreeg en nu nog in leven is) in 1990 ongeveer 9.800 en verwacht 
wordt dat dit aantal zal stijgen naar ongeveer 38.300 in 2020.
Kwaliteit van leven
Doordat patiënten na de diagnose steeds langer in leven blijven, komt er meer aandacht voor de 
late en langdurige effecten van kanker en de behandeling op het welbevinden of de gezondheid 
gerelateerde kwaliteit van leven van (ex-)kankerpatiënten. Gezondheid gerelateerde kwaliteit 
van leven omvat het fysieke, emotionele, sociale en cognitief functioneren van een patiënt. 
Daarnaast omvat het de ziekte- of behandeling gerelateerde symptomen en vertegenwoordigt 
het de subjectieve ervaring van de patiënt met kanker. Studies tonen aan dat sommige (ex-)
kankerpatiënten tot wel vijftien jaar na diagnose nog een verminderde kwaliteit van leven 
hebben in vergelijking met de algemene Nederlandse populatie. Daarnaast worden korte termijn 
effecten, zoals haaruitval, pijn en misselijkheid, lange termijn effecten zoals vermoeidheid, 
geheugen problemen en seksueel disfunctioneren en late effecten zoals tweede tumoren en 
hart- en vaatziekten geregeld gerapporteerd. De kennis op dit gebied is voornamelijk verzameld 




Doel van dit proefschrift
Er is nog weinig bekend over de invloed van kanker en de behandeling op de kwaliteit van 
leven van patiënten die een vorm van lymfeklierkanker hebben of hebben gehad. Doordat 
steeds meer mensen lang na diagnose nog in leven zijn en er steeds nieuwe behandelingen 
worden ontwikkeld, is het belangrijk dat zowel de verbeteringen in overleving als de mogelijke 
bijwerkingen en invloed op kwaliteit van leven van deze nieuwe behandelingen worden 
geëvalueerd. Daarom heb ik in dit proefschrift gekeken naar wat de invloed van kanker en 
de bijbehorende behandeling is op zowel de korte als lange termijn gezondheid gerelateerde 
kwaliteit van leven van patiënten met verschillende soorten van lymfeklierkanker.   
Het bestuderen van de korte en lange-termijn effecten van verschillende behandelingen geeft 
informatie over de medische en psychosociale behoeften van patiënten. Deze informatie draagt 
bij aan het evalueren van de functionele effectiviteit van de behandeling en helpt artsen en 
kankerpatiënten te informeren over de mogelijke late effecten van de specifieke behandeling 
die zij krijgen of hebben ontvangen. 
Gebruikte databases
Om de onderzoeksvraag te beantwoorden ben ik een longitudinaal population-based onderzoek 
gestart bij patiënten met HL of NHL die geregistreerd werden in de Eindhovense kankerregistratie 
tussen 1999 en 2010. De gegevens met betrekking tot kwaliteit van leven en lange termijn effecten 
zijn verzameld in PROFILES en de gedetailleerde behandelingsgegevens werden verkregen via 
PHAROS. PROFILES is wetenschappelijk onderzoek naar kwaliteit van leven bij mensen die kanker 
hebben of hebben gehad en PHAROS is een uitbreiding van de kankerregistratie waarin extra 
gegevens over de behandeling van patiënten met lymfeklierkanker worden verzameld. 
Gegevens over kwaliteit van leven werden ook verzameld van mensen zonder kanker uit 
de algemene Nederlandse bevolking om zo de gevolgen van kanker buiten het natuurlijke 
verouderingsproces en de invloed van bijkomende ziekten te bestuderen. Alle studies zijn 
uitgevoerd bij het Integraal kankercentrum Nederland (IKNL), locatie Eindhoven in samenwerking 
met Tilburg University en de tien ziekenhuizen in de regio. 
belangrijkste bevindingen van het proefschrift
Literatuuroverzicht
In dit proefschrift ben ik begonnen met een literatuurstudie waarbij ik de literatuur met 
betrekking tot de gezondheid gerelateerde kwaliteit van leven (KvL) van patiënten met een 
Hodgkin lymfoom (HL) en non-Hodgkin lymfoom (NHL) heb bestudeerd (Hoofdstuk 2). Het doel 
was om te identificeren welke domeinen van kwaliteit van leven het meest zijn aangedaan in 
deze patiëntengroepen. Daarnaast werd de invloed van klinische (zoals behandeling en stadium 
van de ziekte) en sociaal demografische kenmerken op de kwaliteit van leven onderzocht. 
Tevens heb ik de methodologische sterke punten en beperkingen van de geïncludeerde studies 
bekeken. Vierentwintig artikelen die voldeden aan de vooraf gedefinieerde inclusiecriteria 
werden geïdentificeerd, veertien gericht op HL en tien op NHL. Deze werden beoordeeld op 
basis van een lijst met kwaliteitscriteria. De tekortkomingen van deze studies waren voornamelijk 
het ontbreken van een prospectieve opzet en het ontbreken van informatie over de non-
respondenten. Uit de literatuur kwam naar voren dat verschillende domeinen van kwaliteit van 
leven zijn aangedaan, zelfs nog jaren na diagnose. In vergelijking met een normatieve populatie, 
rapporteerden HL patiënten de meeste problemen in fysiek, sociaal en cognitief functioneren, 
algemene gezondheid, vermoeidheid en financiële problemen. NHL patiënten rapporteerden 
de meeste problemen in het fysieke functioneren, verlies van eetlust, vitaliteit en financiële 
problemen. Daarnaast rapporteerden HL patiënten die ouder waren en/of vrouw zijn meer 
beperkingen. Voor NHL waren de resultaten minder duidelijk, omdat er weinig studies werden 
uitgevoerd. Bovendien waren deze studies vooral gericht op alle NHL subtypes gecombineerd 
in plaats van op subtypes van NHL.
De invloed van kanker en bijbehorende behandeling
Uit het literatuuronderzoek bleek dat er nog nauwelijks onderzoek was gedaan naar subtypen 
van NHL. Daarom voerden we drie studies uit naar het effect van behandeling op de kwaliteit van 
leven van patiënten met de meest voorkomende subtypen van NHL, namelijk diffuus grootcellig 
B lymfoom (DLBCL), folliculair lymfoom (FL) en chronische lymfatische leukemie/klein lymfocytair 
lymfoom (CLL/SLL). De Eindhovense kankerregistratie werd gebruikt om alle patiënten met 
DLBCL, FL en CLL/SLL die in de periode 2004-2010 werden gediagnosticeerd te selecteren en 
respectievelijk 256 (84%), 148 (82%) en 136 (78%) van hen participeerden in het onderzoek.
Patiënten met DLBCL die elke twee weken de immuno-chemotherapie rituximab, cyclofosfamide, 
doxorubicine, vincristine en prednison (R-CHOP14) ontvingen, rapporteerden meer neuropathie 
(zoals tintelingen in handen en voeten) en meer vermoeidheid in vergelijking met patiënten 
die dezelfde immuno-chemotherapie elke drie weken ontvingen (R-CHOP21). Daarnaast 
rapporteerden patiënten behandeld met R-CHOP21 ook een betere algemene gezondheid 
en kwaliteit van leven dan patiënten behandeld met R-CHOP14. Tot voor kort werd gedacht 
dat behandeling met R-CHOP14 tot een betere totale overleving leidde dan R-CHOP21, 
maar recentelijk toonden twee studies geen verschil aan in totale overleving tussen beiden 
behandelingen. Daarom wordt R-CHOP21 nu als standaard eerstelijns behandeling gegeven. Op 
basis van onze bevindingen met betrekking tot kwaliteit van leven en symptomen is R-CHOP21 
ook de voorkeursbehandeling (Hoofdstuk 3). 
In Hoofdstuk 4 observeerden we dat patiënten met FL (N=148) die immuno-chemotherapie 
ondergingen een slechtere gezondheid gerelateerde kwaliteit van leven rapporteerden in 
vergelijking met een normpopulatie van dezelfde leeftijd en geslacht. Patiënten die ‘wait 
and see’ volgden of radiotherapie ondergingen rapporteerden een vergelijkbare gezondheid 
gerelateerde kwaliteit van leven in vergelijking met de normpopulatie, met uitzondering van 
vermoeidheid. Daarnaast rapporteerden patiënten die immuno-chemotherapie ontvingen meer 
vermoeidheid ten opzichte van patiënten die radiotherapie ondergingen. Een kwart tot de helft 
van de patiënten met FL rapporteerden aanhoudende zorgen over hun toekomstige gezondheid, 
waren aanhoudend vermoeid en waren beperkt in het uitoefenen van sociale bezigheden. 
Patiënten met CLL/SLL (N=136) die ooit werden behandeld voor hun kanker met chloorambucil 
of een andere (immuno-)chemotherapie ervoeren een slechtere kwaliteit van leven dan de 
algemene populatie, terwijl er geen verschillen werden waargenomen tussen CLL/SLL patiënten 
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die een ‘wait and  see’ beleid volgden en de normpopulatie. In tegenstelling tot onze hypothese 
rapporteerden patiënten die chloorambucil kregen de slechtste kwaliteit van leven. Daarnaast 
verwachtten we dat patiënten die een ‘wait and see’ beleid volgden zich meer zorgen zouden 
maken over hun gezondheid, omdat ze niet ‘actief’ behandeld worden tegen hun kanker, maar 
de resultaten toonden aan dat patiënten die chloorambucil kregen zich aanzienlijk meer zorgen 
maakten (Hoofdstuk 5).
Prevalentie van vermoeidheid, angst en depressieve klachten
Uit onderzoek is gebleken dat kankerpatiënten met solide tumoren (zoals borst-, darm- 
of prostaatkanker) vaak angst, depressieve klachten en vermoeidheid rapporteren. Deze 
klachten komen hoogstwaarschijnlijk ook bij kankerpatiënten met niet-solide tumoren (zoals 
lymfeklierkanker) voor, alleen is het onbekend wat de prevalentie hiervan is en of deze klachten 
over de tijd blijven bestaan. Daarom hebben we de prevalentie van deze symptomen over 
een periode van vier jaar onderzocht bij een groep patiënten met lymfeklierkanker. Angst 
en depressieve klachten werden door 17-24% van de patiënten met HL (N=180) en DLBCL 
(N=309) gerapporteerd in vergelijking met 11-14% in de normpopulatie van dezelfde leeftijd 
en geslacht. Over de meetperiode van vier jaar, rapporteerden 10% van de HL en DLBCL 
patiënten altijd angstige of depressieve klachten te hebben. Daarnaast rapporteerden 15% soms 
angstige of depressieve klachten te hebben. Bij patiënten met deze klachten was de globale 
gezondheidstoestand en kwaliteit van leven aanzienlijk lager en deze relatie was constant over 
de meetperiode (Hoofdstuk 6). 
In Hoofdstuk 7 werd de prevalentie van aanhoudende vermoeidheid bestudeerd bij NHL 
patiënten; 824 patiënten (80%) vulden de eerste vragenlijst in en 434 (53%) patiënten vulden 
een jaar later nogmaals de vragenlijst in. De resultaten lieten zien dat de meerderheid van 
de patiënten aanhoudende vermoeidheid rapporteerde tot 10 jaar na de diagnose. Zes van 
de tien patiënten rapporteerden een klinische relevante hogere vermoeidheidscore dan de 
normpopulatie. Ook de gezondheid gerelateerde kwaliteit van leven was slechter onder patiënten 
in vergelijking met een normpopulatie. Over een periode van een jaar rapporteerde 22-28% een 
achteruitgang en 19-23% een verbetering in vermoeidheid. Aanhoudende vermoeidheid werd 
door 44-54% van de patiënten gerapporteerd. 
De tevredenheid met informatievoorziening werd onderzocht in Hoofdstuk 8 bij 1.135 patiënten 
met NHL, HL of multiple myeloom (MM, een plasmacel tumor). Vijfenzestig procent van de 
patiënten met indolent NHL, 67% van agressief NHL, 74% van HL en 68% van de patiënten met 
MM waren tevreden over de hoeveelheid ontvangen informatie m.b.t. hun hematologische 
maligniteit en zorgtraject. Echter, ongeveer een derde van de patiënten was niet tevreden en ten 
minste een kwart had behoefte aan meer informatie. De onderwerpen die het meeste werden 
genoemd door patiënten die behoefte hadden aan meer informatie hadden betrekking op: late 
effecten van de ziekte en behandeling (37-50%), het beloop en de oorzaak van de ziekte (24-59%) 
en psychosociale nazorg (10-26%). Jonge leeftijd, een behandeling met chemo, een recentere 
diagnose, het gebruik van internet voor informatie, en de afwezigheid van andere ziekten waren 
de belangrijkste determinanten van een hoger waargenomen niveau van informatievoorziening. 
De variatie in waargenomen informatievoorziening en de aanzienlijke geobserveerde verschillen 
tussen ziekenhuizen suggereren dat er ruimte is voor verbetering.
In Hoofdstuk 9 werden de positieve en negatieve gevolgen van kanker onderzocht en vergeleken 
tussen Nederlandse (N=491) en Amerikaanse (N=738, uit North-Carolina) NHL patiënten. In 
vergelijking met de Amerikaanse patiënten scoorden de patiënten uit Nederland: 
- lager op de positieve gevolgen (altruïsme/empathie, gezondheidsbewustzijn, positieve 
zelf-evaluatie)
- hoger op de negatieve gevolgen (bezorgdheid over uiterlijk, bezorgdheid over veranderingen 
in het lichaam en bezorgdheid in het algemeen). 
Deze bevindingen bleven ook bestaan na het in acht nemen van de verschillen in sociaal-
demografische en klinische kenmerken tussen de twee onderzoeksgroepen. Cultuur lijkt invloed 
te hebben op de wijze waarop patiënten de gevolgen van kanker op het leven evalueren. 
De hogere scores op positieve invloeden van kanker die in de Amerikaanse groep werden 
waargenomen, worden misschien verklaard door de hogere mate van ‘verantwoordelijkheid 
voor jezelf’ die in Amerika geldt en/of de beschikbaarheid van goede nazorg in deze bepaalde 
Amerikaanse regio. 
toekomst: verbeteren van kwaliteit van leven en zorg door interventies
De aanzienlijke en continue stijging van de aantallen patiënten die lymfeklierkanker hebben 
of hebben gehad resulteert in toenemende gezondheidszorglasten in de oncologie. Om de 
zorg van deze groeiende groep kankerpatiënten die steeds nieuwe behandelingen ondergaan 
te verbeteren, is het herkennen en monitoren van specifieke klachten waar kankerpatiënten 
mee te maken krijgen zeer belangrijk. Met behulp van de kankerregistratie en PROFILES 
kunnen we dit ook in de toekomst blijven doen. Een ander belangrijk aspect is het aanbieden 
van informatie op maat. Uit onderzoek blijkt dat patiënten die goed geïnformeerd zijn over 
hun kanker, behandeling en nazorg meer kans hebben om hun behandeling te voltooien en 
minder angst ervaren. Het verstrekken van een persoonlijk nazorgplan voor iedere patiënt kan 
bijdragen aan betere informatievoorziening en daarbij de zorg voor lymfeklierkankerpatiënten 
mogelijk verbeteren. Deze persoonlijke nazorgplannen bestaan uit gedetailleerde informatie 
over de diagnose en behandeling van kanker, mogelijke lange-termijn en late effecten en de 
behandeling daarvan, aanbevelingen voor leefstijl en contactgegevens voor psychosociale 
hulp. Via de website www.kanker.nl kunnen patiënten na het aanmaken van een profiel ook 
informatie op maat krijgen. Deze website is een initiatief van de NFK (Nederlandse Federatie 
van kankerpatiëntenorganisaties) en is ontwikkeld in samenwerking met KWF en IKNL.
In de afgelopen decennia is de gezondheidszorg veranderd door een toename van kennis en 
technologie, waarbij steeds meer patiënten een actieve rol spelen in de behandelingskeuze en de 
verantwoordelijkheid nemen voor het ontvangen van goede (na)zorg, ook wel zelfmanagement 
genoemd. Het geven van feedback en informatie aan patiënten over hun zelf-gerapporteerde 
kwaliteit van leven en symptomen in vergelijking met resultaten van andere kankerpatiënten 
of vergeleken met een normatieve populatie zou kunnen bijdragen aan het verhogen van de 
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zelfmanagement van patiënten. Daarnaast kan het patiënten helpen om relevante onderwerpen 
te bespreken met de behandelend arts. Om te onderzoeken of patiënten daar behoefte aan 
hebben, voerde ik een pilotstudie uit. Van de 47 ondervraagde patiënten met lymfeklierkanker 
(respons 73%), gaf twee-derde aan dat ze graag feedback ontvangen op hun zelf gerapporteerde 
kwaliteit van leven en ziekte- en behandeling-gerelateerde symptomen. Vooral de mogelijkheid 
van het vergelijken van de eigen scores met de scores van andere patiënten met lymfeklierkanker 
werd als heel waardevol gezien: 80% van de patiënten zou dit graag willen. Om inzicht te krijgen 
over hoe zelfmanagement ondersteund kan worden in patiënten met lymfklierkanker zijn 
interventiestudies nodig. 
Om de zorg voor lymfeklierkankerpatiënten, in het bijzonder patiënten die meer dan vijf jaar 
geleden zijn gediagnosticeerd, verder te verbeteren is de nationale initiatiefgroep ‘BETER’ 
opgericht. Deze bestaat uit afgevaardigden van verschillende Nederlandse (academische) 
ziekenhuizen, waaronder hematologen, internisten, radiotherapeuten en epidemiologen. De 
groep heeft als doel de kwaliteit en de duur van de overleving bij patiënten met HL of NHL 
te verbeteren door ziekte en sterfte ten gevolge van late complicaties van de behandeling te 
verminderen. Door middel van het opzetten van poliklinieken in de academische ziekenhuizen zal 
er een gerichte zorg ontstaan voor overlevenden van HL of NHL, waardoor late effecten eerder 
worden herkend en beter worden behandeld. Andere doelstellingen zijn het informeren van 
patiënten over de lange termijn risico’s, adviseren van preventieve maatregelen en screening en 
het verbeteren van nazorg door het verstrekken van revalidatieprogramma’s. Het uitnodigingen 
van patiënten voor het ‘BETER’ initiatief kan een efficiënte oplossing zijn voor het verbeteren 
van de zorg en voor het aanpakken van blijvende lichamelijke en psychosociale behoeften. 
concluderende opmerkingen
Door de continue verbetering van behandelingen, de stijgende incidentie en de vergrijzing van 
de bevolking zal het aantal patiënten dat lymfeklierkanker heeft (gehad) sterk toenemen. Zowel 
patiënten met een Hodgkin als non-Hodgkin lymfoom ervaren fysieke en psychosociale problemen 
als gevolg van kanker en de behandeling, ook lang na voltooiing van de primaire behandeling. 
Bovendien wordt door ten minste een kwart van de lymfoompatiënten aanhoudende ziekte en/of 
behandeling gerelateerde symptomen gemeld, zoals neuropathie en een gevoel van lusteloosheid. 
Ongeveer de helft van de patiënten maakt zich zorgen over hun toekomstige gezondheid, 17-24% 
meldt angst of depressieve symptomen en 44-54% rapporteert aanhoudende vermoeidheid. 
Bewustwording en erkenning van de specifieke gezondheidsproblemen die lymfoompatiënten 
ervaren is belangrijk om optimale ondersteunende zorg te verlenen. Strategieën om deze zorg 
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het dan zover: mijn proefschrift is klaar. Mijn eerste werkdag op het IKZ in 2009 kan ik me nog 
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